Exploring peripheral blood mononuclear cells as the source of interleukin-6 in polymyalgia rheumatica by Bazzard, Hannah L
  
      
 
 
 
 
EXPLORING PERIPHERAL BLOOD MONONUCLEAR 
CELLS AS THE SOURCE OF INTERLEUKIN-6 IN 
POLYMYALGIA RHEUMATICA 
 
HANNAH LOUISE BAZZARD 
 
A thesis submitted in partial fulfilment of the requirements of the 
University of the West of England, Bristol, for the degree of Doctor of 
Philosophy 
 
Centre for Research in Bioscience (CRIB), Bristol UK 
 
 
 
  
Abstract 
Polymyalgia rheumatica (PMR) is a chronic inflammatory condition which affects the 
elderly, causing aching and stiffness of the neck, shoulders and pelvis, as well as more 
systemic manifestations such as fever, malaise and fatigue. PMR shares symptoms 
with rheumatoid arthritis (RA) and both are associated with significantly elevated 
circulating concentrations of interleukin-6 (IL-6), which is thought to play a key role in 
the pathogenesis of these diseases. In RA, IL-6 is derived from synovial cells in the 
joints. In PMR, however, the source of IL-6 is unknown. PMR patients do not exhibit 
the same joint involvement as in RA but they do have elevated circulating IL-6 
concentrations, thus, it was hypothesised that the source of IL-6 in PMR may be one of 
the circulating peripheral blood mononuclear cell (PBMC) types, which are all capable 
of producing IL-6.  
Blood samples were taken from untreated PMR patients, RA patients with active 
disease and healthy controls (HC) of similar age and gender. To account for known 
circadian variations in circulating IL-6, samples were taken at a standard time. IL-6 
was quantified in plasma and serum using cytometric bead array (CBA) and enzyme-
linked immunosorbent assay. The biological activity of the IL-6 was tested for the first 
time in PMR using a B cell proliferation assay. Using immunostaining and flow 
cytometry, constitutive intracellular IL-6 was measured in CD3+, CD14+, CD19+, 
CD123+ and CD11c+ PBMCs. Intracellular IL-6 was also determined following 
PBMC stimulation in vitro, to determine potential differences in cell responsiveness. 
Concentrations of secreted IL-6 in the culture supernatants of resting and stimulated 
PBMC were determined by CBA in parallel cultures. Other cytokines were also 
quantified in order to examine PMR and RA pathologies more broadly. Finally, the 
results of the cytokine assays were compared with patient reported severity of fatigue 
and the four different components of fatigue (emotional, living, physical and 
cognitive).  
Circulating IL-6 was significantly elevated above HC in both serum and plasma of 
PMR and RA patients, and this IL-6 was found to be biologically active. PBMC in all 
subjects constitutively produced low levels of intracellular IL-6 and very low 
concentrations of secreted IL-6 in parallel cultures. Overall, responses to in vitro 
stimulation were variable but no significant differences were observed between PMR, 
RA and HC samples. Secreted IL-6, in contrast, increased dramatically following 
stimulation of all cultures, suggesting intracellular staining may not reflect the 
secretory capability of these cells, but also confirming that there were no differences 
between PBMC responses of PMR, RA and HC groups. A significant correlation was 
observed between circulating IL-6 concentrations in PMR and RA patients, and 
physical fatigue, living fatigue and total fatigue. Broader cytokine analysis 
demonstrated that IL-6 alone was significantly elevated in PMR patients. 
Taken together, circulatory IL-6 in active PMR is found to be elevated in the absence 
of other inflammatory cytokines. It is biologically active and correlates strongly with 
physical and living aspects of fatigue. Circulating PBMCs are not the source of this 
elevated IL-6 in PMR patients, suggesting that neutrophils, vascular endothelium or 
muscle tissue may instead be involved.  
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1.1 Demographics and historical perspective of polymyalgia 
rheumatica and rheumatoid arthritis 
Immune-mediated inflammatory diseases are a set of chronic and debilitating 
conditions that are highly prevalent in the Western world (5%- 7% of population) and 
are grouped according to a characteristic imbalance of cytokines associated with the 
pathogenesis of inflammation (El-Gabalawy et al., 2010). Included in this group of 
inflammatory diseases are polymyalgia rheumatica (PMR) and rheumatoid arthritis 
(RA), both of which are characterised by chronic inflammation, and are strongly 
associated with significantly elevated levels of the pro-inflammatory cytokine, 
interleukin-6 (IL-6) (Arvidson et al., 1994, Roche et al., 1993). 
The symptoms of PMR were first described by Bruce in 1888, when he identified that 
the disease shared similarities with rheumatism, gout and rheumatoid arthritis, thus he 
labelled the disease ‘senile rheumatic gout’ (Bruce, 1888). Years later, studies by 
Barber described the symptoms of PMR in further detail, including key laboratory 
findings still used to diagnose PMR today, such as increased erythrocyte sedimentation 
rate (ESR) (Barber, 1957). The disease was then given its current name ‘polymyalgia 
rheumatica’, due to characteristic muscular pain, lack of arthritis, but clear association 
with the rheumatoid diseases.  PMR was once considered to be a manifestation of giant 
cell arteritis (GCA), also known as temporal arteritis, because around half of the 
patients with GCA also present with symptoms of PMR (Salvarani et al., 2004, 
Martinez-Taboada et al., 2008). GCA, however, is mainly associated with 
inflammation of the larger arteries and in particular the branches of the proximal aorta, 
sometimes causing blindness and stroke (Salvarani et al., 2008). Clinically it is often 
confused with PMR at initial presentation. 
PMR generally affects people over the age of 50, peaking around 60-70 years, with 1 
in 1,200 people developing the condition in the UK each year (National Health 
Service, 2013). It is characterised by morning aching and stiffness of the proximal 
muscles in the neck, shoulders and pelvis, as well as causing other systemic 
manifestations such as low-grade fever, weight loss, malaise and depression (Bird et 
al., 1979, Salvarani et al., 2004, Kaposi and Schmidt, 2006). Women have a fourfold 
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higher risk of developing the disease compared to men (Zimmermann-Gorska, 2008), 
which may be influenced by female sex hormones (prolactin and oestrogen) that are 
known to encourage immune-mediated inflammation (El-Gabalawy et al., 2010). 
RA patients, in contrast, have more localised symptoms, including swelling of the 
proximal interphalangeal (PIP), metacarpophalangeal (MCP) or wrist joints, and also 
the development of rheumatoid nodules (Arnett et al., 1988) (Figure 1.). The symptom 
of morning stiffness is shared between RA and PMR. Chronic synovitis (inflammation 
at the synovial sites) in RA results in the severe and permanent destruction of 
synovium, cartilage and bone, causing great pain and discomfort for sufferers (Kim 
and Kim, 2010).  
 
Figure 1: Hand of an elderly woman suffering from rheumatoid arthritis.  The proximal 
interphalangeal joints (green arrows) and metacarpophalangeal joints (blue arrows) have 
rheumatoid nodules (red arrows). Inflammation around these joints and the wrist can also be 
observed (Image courtesy of Science Photo Library 2013 Reprinted with Permission). 
 
Rheumatoid 
nodules 
Proximal 
interphalangeal 
joints 
Metacarpophalangeal 
joints 
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The prevalence of RA in the UK is higher than PMR and again it affects more women 
(1.16%) than men (0.44%) (Symmons et al., 2002). According to a report published by 
the National Audit Office (NAO) in 2009, rheumatoid arthritis costs the National 
Health Service (NHS) around £560 million per year and costs the economy a further 
£1.8 billion per year through absence from work and work-related disability (NAO, 
2009). Facts such as these show the economic importance for research to continue 
looking into the pathogenesis of these debilitating diseases and new methods to 
alleviate them.  
In addition to suffering from chronic pain, PMR and RA patients suffer from a specific 
type of fatigue which arguably has the most important impact on the individual’s 
quality of life (Hewlett et al., 2005). Fatigue has recently been estimated to be 
experienced by around 98% of RA patients at some point during the disease (Nicklin et 
al., 2010). In a study by Professor Hewlett and colleagues, patients described RA 
fatigue as ‘severe’, ‘dramatic’ and ‘overwhelming’, and often regarded the impact of 
fatigue as being comparable to pain (Hewlett et al., 2005).  
 
1.2 Diagnosis of PMR and RA 
Modern diagnosis of PMR and RA is based on criteria developed by researchers and 
clinicians who have examined the disease in great detail for a number of years. 
According to Salvarani and co-workers, there was a ‘lack of effort’ to standardise the 
diagnosis of PMR because for years it was believed to be part of the pathogenesis of 
GCA (Salvarani et al., 2004). Bird, Chuang, Healey and colleagues have, however, all 
suggested criteria for the diagnosis of PMR based on different inclusion and exclusion 
factors, and these have been widely adopted by physicians to help detect and treat 
PMR globally (Bird et al., 1979, Chuang et al., 1982, Healey et al., 1984).  
The Bird diagnostic criteria were developed from a collaboration of results and 
findings from eleven rheumatology units in the South and West of Great Britain (Bird 
et al., 1979). Seven key characteristics of PMR were selected, and it was determined 
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that if the patient was exhibiting three of the seven key symptoms then they would be 
diagnosed as having ‘probable PMR’ (Bird et al., 1979). As only three features are 
required to be present out of seven for a PMR diagnosis, the Bird criteria have a more 
practical application within a clinical setting as they are more broadly inclusive, 
compared to those which require all the criteria to be satisfied in order to make a 
diagnosis, e.g. the Healey criteria (Semanta and Kendall, 2002). The Bird criteria were 
thus selected for use in this study to recruit patients with PMR (Table 1).  
Table 1:  Bird Criteria for initial diagnosis of PMR (Bird et al., 1979). 
Bird criterion Clinical description of symptom* 
1. Bilateral shoulder pain/stiffness 
2. Duration of symptoms <2 weeks** 
3. Initial ESR >40 mm/h 
4. Morning stiffness duration >1 h 
5. Age >65 years 
6. Depression and/or weight loss 
7. Bilateral upper arm tenderness 
 
*Three or more features are required to make a positive diagnosis. 
**Time taken for symptoms to become fully apparent. 
The American College of Rheumatology (ACR) have described a list of criteria for RA 
diagnosis which is widely used, and was thus selected for use in the diagnosis and 
recruitment of RA patients in this study (Arnett et al., 1988) (Table 2). The ACR 
criteria follow similar principles to the Bird criteria, with four out of seven key criteria 
needing to be fulfilled in order to diagnose the patient with RA. These criteria are 
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based on physical symptoms, laboratory findings and also radiographic images (Arnett 
et al., 1988). 
Table 2: ACR Classification criteria for initial diagnosis of RA (Arnett et al., 1988). 
ACR criterion Clinical description of symptom
‡
 
1. Morning stiffness duration (≥1 hour)*** 
2. Swelling (soft tissue) of three or more joints***† 
3. Swelling (soft tissue) of hand joints (PIP, MCP, or wrist)*** † 
4. Symmetrical swelling (soft tissue)***† 
5. Subcutaneous nodules† 
6. Serum rheumatoid factor (RF) 
7. Erosions and/or periarticular osteopenia in hand  
or wrist joints seen on radiograph 
 
‡
A classification as RA requires that four of the seven criteria be fulfilled. 
***Must have been continuously present for 6 weeks or longer. 
†Must be observed by a physician. 
In addition to elevated serum levels of IL-6, PMR is also characterised by an 
exaggerated acute phase response (APR) (Alvarez-Rodriguez et al., 2010).  In order to 
assess the intensity of an APR, C-reactive protein (CRP) levels and ESR are both 
measured in patient blood samples. An elevated CRP and an increase in ESR above 40 
mm/h are generally regarded as indicative of PMR (Zimmerman-Gorska, 2008). It is 
not uncommon for PMR patients, however, to exhibit a low ESR and low CRP levels 
and still have active disease based on the Bird criteria. According to Brooks and 
McGee, 13% of all patients who have all the typical features of PMR also have a 
normal ESR (Brooks and McGee, 1997). Therefore it has been suggested that CD8+ T 
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cell numbers or IL-6 levels could be measured as an alternative method of assessing 
the acute phase response (Dasgupta et al., 2006), although this has not been routinely 
adopted. A conclusive diagnosis of PMR is usually made if there is a rapid response to 
low dose glucocorticoids (GC), despite this not being included in the Bird criteria. 
Patients with ‘pure’ PMR usually experience a rapid clinical response (>70%) in under 
a week to 10-20 mg prednisone per day and laboratory inflammatory markers (such as 
ESR and CRP) return back to normal reference range within four weeks (Dasgupta, 
2010, Gonzalez-Gay et al., 2010).  
The diagnosis of PMR and RA is not always straightforward, particularly as the Bird 
criteria are very inclusive and PMR diagnostic criteria are similar to the ACR criteria 
for the diagnosis of RA. In order to aid the differential diagnosis of PMR and RA and 
to allow the clinician to get deeper insight into the type and the extent of the symptoms 
experienced by the patient, questionnaires have been developed to measure other 
aspects of these diseases. These measurements are based particularly on the level of 
pain and fatigue the patient experiences. The Health Assessment Questionnaire 
(HAQ), Disease Activity Score (DAS) and Bristol Rheumatoid Arthritis Fatigue Multi-
Dimensional Questionnaire (BRAF-MDQ) are all different forms of such 
questionnaire and were adopted in this study to aid the diagnosis of PMR and RA and 
allow further insight into the nature and severity of the patient’ symptoms. 
The HAQ (Appendix A) is a method of assessing patient-reported outcomes based on 
five patient-focused components, namely: pain, disability, the effects of medication, 
the cost of care, and mortality (Bruce and Fries, 2005).  The DAS (Appendix A) was 
devised in order to measure inflammatory activity in RA, and combines clinical and 
laboratory-based information to create a score which can be used to measure patients’ 
response to therapy (Fransen and van Riel, 2005). As the patients in this study are 
required to have active disease when the sample is taken, use of the DAS ensures that 
the patient fulfils this criterion.  
The BRAF-MDQ has recently been devised by Nicklin and colleagues as a method of 
measuring fatigue in RA, but it can also be used to measure fatigue in PMR (Nicklin et 
al., 2010). Standardised numerical rating scales (NRS) and visual analogue scales 
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(VAS) are incorporated into the BRAF-MDQ, which tests fatigue severity, effects of 
fatigue, and also the patient’s perceived ability to cope with fatigue on a daily basis 
(Appendix A) (Nicklin et al., 2010). The development of the BRAF-MDQ allows 
clinicians or researchers to understand the fatigue experience as a whole, as well as 
focusing on the individual aspects of fatigue, which may be caused by different factors 
or require different treatment options (Hewlett et al., 2011). As fatigue is such a major 
feature of RA and PMR, tools such as this are an important aid for the invaluable 
treatment and support of PMR patients and also for future research. 
 
1.3 Treatment of PMR and RA 
GCs such as prednisolone are predominantly used in the treatment of PMR and RA. 
Despite providing relief from symptoms, however, GCs do not correct the underlying 
mechanisms causing these diseases (Martinez-Taboada et al., 2008). For the majority 
of PMR patients, GC treatment is required for around 1-2 years, yet patients who 
suffer from ‘a more chronic, relapsing course’ often require lower doses of steroid 
treatment for 5 years or more (Salvarani et al., 2007). The prednisolone dose should be 
reduced or ‘tapered’ gradually over time to avoid or reduce the detrimental side-effects 
associated with prolonged steroid use (Dasgupta, 2010). Too rapid a reduction, 
however, often results in relapse of PMR (Zimmerman-Gorska, 2008). 
The adverse side-effects associated with long-term steroid use include chronic 
conditions such as diabetes and osteoporosis. A study of PMR by Gabriel and 
colleagues demonstrated that 65% of their 124 patients treated with corticosteroids 
alone developed at least one secondary condition (Gabriel et al., 1997). Symptoms of 
potential co-morbidities such as osteoporosis and diabetes are therefore monitored 
closely and prophylactic treatment for them may be given alongside GC treatment. 
Alendronic acid, calcium, vitamin D supplementation and bisphosphates, for example, 
may be given to help prevent the development of osteoporosis (Zimmerman- Gorska, 
2008). Furthermore, there are a number of RA patients who do not respond to GC 
treatment at all, for reasons which are currently unclear (Kirwan, J., personal 
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communication, 2011). A recent study by Clarke and colleagues has suggested, 
however, that there may be a link between the cytokine profile of the patient and their 
responsiveness to GC treatment (Clarke et al., 2011).  
Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen are 
often the first choice for the treatment of PMR. If there is no improvement in PMR 
symptoms within 2-4 weeks then steroidal treatment is recommended (Salvarani et al., 
2004). It has been suggested that PMR patients with the ‘pure’ form only experience 
short and mild beneficial effects from NSAIDs (Gonzalez-Gay et al., 2010), making 
them superfluous. They may, however, have a role in keeping patients in remission 
after GC therapy has been stopped (Gonzalez-Gay et al., 2010). A study by Gabriel 
and colleagues demonstrated that even low doses and short duration of combined 
corticosteroid and NSAID treatment caused a higher incidence of adverse events in 
PMR patients, such as gastrointestinal bleeding and hypertension (Gabriel et al., 
1997), for this reason NSAIDs are not recommended during GC therapy.  
It is has been well established that cytokines such as IL-1β, TNFα, IL-6 and IL-8 play 
a role in the pathogenesis of inflammatory disease, and recently there has been a more 
targeted therapeutic approach which centres around the blockade of particular 
cytokines or cytokine receptors in order to reduce the signs and symptoms of these 
diseases (Houssiau et al., 1988, Luqmani, 2007).  The most well-known example is the 
use of TNFα-antagonists such as the monoclonal antibody Infliximab which is used in 
the treatment of RA (Blumenauer et al., 2002). 
Tocilizumab, a monoclonal antibody which blocks the IL-6 receptor, has also been 
approved for use in RA patients in the UK (Ohsugi and Kishimoto, 2008). Research by 
Emery and colleagues was highly significant to this approval, as results from their 
study showed that the use of Tocilizumab (plus methotrexate) could accomplish swift 
and continuous improvements in the symptoms of RA in patients who failed to 
respond to TNFα blockers (Emery et al., 2008). Hagihara and colleagues demonstrated 
that Tocilizumab can also ameliorate the symptoms of PMR (Hagihara et al., 2010), 
however, the results presented are from one patient only and serious side-effects have 
been reported elsewhere (Campbell et al., 2011). Tocilizumab therapy is not currently 
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approved by the Food and Drug Administration for the treatment of PMR, as it can 
cause serious infections of the respiratory tract, nasopharynx, skin and soft tissue and 
gastrointestinal tract (Campbell et al., 2011).  
A more recent study by Macchioni and colleagues contradicts this; two newly 
diagnosed PMR patients were treated with Tocilizumab and it was determined that 
Tocilizumab is an ‘effective and safe’ way to treat PMR (Macchioni et al., 2013). This 
is despite having to administer GC therapy to one of the patients alongside the 
Tocilizumab after the second infusion due to a lack of clinical response (Macchioni et 
al., 2013). Further trials and larger studies are underway to see if Tocilizumab could be 
an effective and safe therapy for PMR patients, and to determine whether the benefits 
outweigh the side effects. 
 
1.4 Pathogenesis of RA 
The pathogenesis of RA is complex. The interaction of both environmental factors, 
such as drinking alcohol and smoking, and genetic factors is thought to increase 
susceptibility to the disease, by activating the series of immunological events which 
lead to the onset of RA (Silman et al., 1996, Klareskog et al., 2006). It is suspected 
that there is a genetic predisposition for both RA and PMR, as the geographical 
distribution of the diseases are well defined, with Scandinavia and other parts of 
Northern Europe having the highest incidence of PMR (Cimmino, 1997). Patients with 
RA and PMR have been found to share an association with a serotype known as HLA-
DR4 (i.e. a characteristic set of antigens found on leukocytes and other cells). A 
similar sequence polymorphism encoded by the second hypervariable region of the 
allele HLA-DRB1 has been discovered in PMR and GCA patients (Weyand et al., 
1994). The exact role of these alleles is yet to be elucidated despite the association of 
HLA-DR4 with RA being discovered more than 25 years ago (Stastny et al., 1988). 
The immunological events that are triggered in RA include the recognition of 
citrullinated antigens by self-reactive T cells, causing them to ‘attack’ joint tissue 
Chapter 1- Introduction 
 
11 
 
(Boissier, 2011). This brings about an overwhelming inflammatory response, resulting 
in severe and permanent destruction of synovial tissue, cartilage and bone (Kim and 
Kim, 2010). The breakdown of the inflammatory process causes major imbalances in 
cytokine systems (Boissier, 2011), resulting in an increase in the production of many 
of the pro-inflammatory cytokines such as IL-6, IL-1β, TNFα and IL-8 (Perry et al., 
2009). These are abundant in the affected tissues of RA patients (Feldmann et al., 
1996) along with the more recently identified, IL-17 (Chabaud et al., 1999). IL-6 in 
particular is known to be significantly elevated in the synovial fluid (Hirano et al., 
1988, Guerne et al., 1989) and plasma (Perry et al., 2009) of RA patients, whilst a 
preliminary study suggests circulating IL-1β, TNFα, and IL-4 may also be significantly 
elevated in a subset of RA patients (Clarke et al., 2011). Clarke and colleagues also 
observed a potential link between patients with the latter cytokine profile and non-
responsiveness to GC therapy in a small scale study (Clarke et al., 2011).  
 
1.5 Cytokines involved in the pathophysiology of RA 
It is well established that IL-6 is strongly associated with both RA and PMR, and its 
exact function and role in the disease pathogenesis is outlined in the following section. 
Other cytokines which have been strongly implicated in RA disease pathology are 
discussed here, as well as some cytokines whose involvement in RA disease pathology 
is still speculative.   
1.5.1 TNFα 
TNFα is produced by many cell types including macrophages (Clavel et al., 2008), 
endothelial cells (Ranta et al., 1999), fibroblasts (Fahey et al., 1995) and synovial-
derived T cells (Steiner et al., 1999). It has a broad range of biological activities and 
plays a fundamental role in RA, by bringing about synovitis and inducing the network 
of other inflammatory cytokines that are seen in RA (Figure 2) (Vasanthi et al., 2007). 
The blocking or neutralising of TNFα reduces joint inflammation in RA (Perdriger, 
2009). TNFα is raised particularly in the synovium of RA patients (Steiner et al., 1999) 
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and as a result, has been shown to be raised in the serum/plasma of RA patients 
compared to healthy controls in most but not all studies (Espersen et al., 1991, Cutolo 
et al., 2006, Perry et al., 2009, Szodoray et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The complex cytokine network involved in RA disease pathogenesis. Th1 and Th17 T 
cell subsets have a role in promoting inflammatory cytokine production in macrophages and 
synovial cells. Activated macrophages and fibroblasts in the synovial lining produce inflammatory 
cytokines that can activate themselves or nearby cells (Firestein, 2003). Diagram adapted from 
Firestein (2003) and Boissier (2011). Key:- APC: Antigen presenting cell; MHC: Major 
histocompatibility complex; TCR: T-cell receptor, NK cell; Natural killer cell. 
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1.5.2 IL-1β 
IL-1β is also secreted by a variety of cells including monocytes and macrophages 
(Figure 2) (Ward et al., 2010). IL-1β is raised in the serum and plasma of RA patients 
(Szodoray et al., 2006, Perry et al., 2009). Furthermore, concentrations of IL-1β in the 
plasma and synovial fluid of RA patients strongly correlate with various measures of 
the disease, such as the length and extent of morning stiffness and the level of pain 
experienced by the patient (Kay and Calbrese, 2004). Blocking this cytokine also 
dramatically reduces these symptoms (Kay and Calbrese, 2004), thus strongly 
implicating IL-1β in the pathogenesis of RA.    
1.5.3 IL-8 
IL-8 is produced by a range of cell types and plays a key role in recruiting and 
activating immune cells such as neutrophils at the site of inflammation (Harada et al., 
1994). Plasma IL-8 is significantly raised in RA patients compared to normal healthy 
controls (Perry et al., 2009). 
1.5.4 IL-17 
IL-17 (or IL17A as it is otherwise known) is a cytokine derived from a relatively 
newly discovered subset of T cells known as Th17 cells, and is induced by high 
concentrations of IL-6 in the presence of TGFβ (Harrington et al., 2005, Kimura and 
Kishimoto, 2010). IL-17 is expressed at high levels in the synovial fluid of RA patients 
(Chabaud et al., 1999). The principal function of IL-17 is thought to be in the defence 
against pathogens in the mucosal or epithelial lining (Jin and Dong, 2013) and also in 
the removal of extracellular (Ishigame et al., 2009) and intracellular (Hamada et al., 
2008) pathogens following infection. IL-17, however, has a crucial role in the 
pathogenesis of RA by strongly inducing many of the pro-inflammatory cytokines, 
such as IL-8 and IL-6 (Figure 2) (Hwang et al., 2004), whilst also being directly 
involved in the destruction of joint tissue (Chabaud et al., 2001). Specifically, IL-17 
causes degradation of cartilage by increasing the breakdown of proteoglycan and 
decreasing proteoglycan synthesis, as well as destroying type I collagen (Chabaud et 
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al., 2001). It has been suggested that neutrophils are also a critical source of IL-17 in 
the effector phase of RA, although the trigger for this secretion is still unclear 
(Katayama et al., 2013). Despite its localised action, high serum concentrations have 
previously been measured in RA patients compared to healthy controls (Wallis et al., 
2011). Studies have shown that treatment with anti-IL17 monoclonal antibodies can 
reduce RA symptoms, such as joint inflammation and destruction, both in mouse 
models and in human trials (Lubberts et al., 2004, Genovesse et al., 2010), thus 
confirming a crucial role for this cytokine in the pathophysiology of RA. 
1.5.5 IL-4 
IL-4 is produced predominantly by Th2 cells, as well as basophils and mast cells, and 
has various proinflammatory and anti-inflammatory functions within the immune 
system (Gessner et al., 2005). IL-4 is a powerful activator of B cells, it mediates the 
differentiation of naïve helper T cells into Th2 cells (Figure 2), it is a potent 
suppressor of IFNγ-producing CD4+ Th1 cells, and also induces class II major 
histocompatibility complex (MHC) expression on macrophages and DCs (Nelms et al., 
1999, Ohmura et al., 2005). In terms of having a potentially anti-inflammatory role in 
RA, the proliferation of synoviocytes has been shown to be suppressed by IL-4, as it 
inhibits the initial phases of the cell cycle (Dechanet et al., 1993). Moreover, a study 
by Wallis and co-workers suggests that IL-4 significantly reduces the production of IL-
17 in healthy subjects (Wallis et al., 2011) and therefore may down-regulate RA.  
Ohmura and colleagues, in contrast, suggest that IL-4 may actually promote RA, 
perhaps because of its ability to activate B cells (Ohmura et al., 2005), which produce 
RF, anti-citrullinated antibodies and a range of pro-inflammatory cytokines involved in 
RA pathogenesis (Silverman and Carson, 2003). Ohmura and colleagues demonstrated 
that IL-4 is vital for the full development of RA disease in mouse models; however it 
was not directly involved in the effector phase of the disease (Ohmura et al., 2005).  
According to Wallis and colleagues, some individuals possess an inherited gene 
polymorphism in the coding region of the IL-4 receptor that would normally function 
to suppress or control the immune responses of Th17 cells, and hence the amount of 
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IL-17 produced (Wallis et al., 2011). With this genetic polymorphism in its receptor, 
IL-4 cannot function to suppress Th17 cells as it would normally (Wallis et al., 2011).  
A recent study has confirmed the association between genetic variants of the IL-4 
receptor and the progression rate of joint damage in RA patients (Krabben et al., 
2013). Furthermore, despite IL-4 being capable of down-regulating IL-17 secretion by 
Th17 cells, Cooney and colleagues have shown that Th17 cells which have been 
subjected to ‘multiple rounds of stimulation’ (as would be happening in RA), are no 
longer affected by IL-4 and cannot signal through the IL-4 receptor (Cooney et al., 
2011).  
Overall then, IL-4 may have both anti-inflammatory and pro-inflammatory roles in 
RA. IL-4 suppresses synoviocyte proliferation and IL-17 production by Th17 cells. 
Yet, a genetic polymorphism in the IL-4 receptor in some individuals and the 
desensitisation of Th17 cells to IL-4 signalling may inhibit the anti-inflammatory 
activities of IL-4 and promote a more sinister role for IL-4 in RA disease pathogenesis. 
1.5.6 IL-2 
IL-2, produced mainly by CD4+ T cells, predominantly exerts its effects on T cells, 
inducing rapid expansion, proliferation and differentiation (Gaffen and Liu, 2004). 
Early research suggests that IL-2 production from synovial and peripheral blood 
lymphocytes is diminished in RA patients compared to healthy controls (Combe et al., 
1985). Other studies have also demonstrated that plasma IL-2 concentrations are 
decreased in RA patients compared to healthy controls (Kitas et al., 1988, Espersen et 
al., 1991). Espersen and colleagues hypothesise that this may be due to RA patients 
having greater concentrations of the IL-2 receptor in serum and synovial fluid (Symons 
et al., 1988, Espersen et al., 1991). More recently, normal lymphocytes have been 
shown to produce decreased amounts of IL-2 in the presence of RA synovial fluid as 
well as having a decreased response to IL-2; again attributed to the presence of an 
inhibitor of IL-2 in RA patient synovial fluid (Miossec et al., 2005). In contrast, it has 
been suggested that IL-2 is significantly elevated in the synovium particularly in the 
early stages of RA, compared to patients with ‘established RA’ (Raza et al., 2005). 
Thus, the role of IL-2 in RA disease pathogenesis is unclear. 
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1.5.7 IL-12p70 
IL-12p70 is the biologically active form of IL-12 (Feinberg et al., 2004). Phagocytic 
cells (especially DCs), are the main producers of IL-12, with B cells also capable of 
IL-12 secretion (Trinchieri, 1995). The major function of IL-12 is to induce IFNγ 
production from CD4+ T cells and to favour the Th1 response in the early stages of 
selection, promoting the production and proliferation of Th1 cells (Trinchieri, 1995). 
Th1 cells secrete IFNγ and TNFα in order to activate macrophages and cytotoxic T 
cells to destroy intracellular pathogens, as well as stimulating B cells to produce 
appropriate antibodies (Alberts et al., 2002). 
Kim and co-workers measured serum and synovial fluid levels of IL-12p70 in 152 RA 
patients (as well as 69 OA patients) and 50 healthy controls (Kim et al., 2000). A sub-
group of 64 RA patients had detectable serum concentrations of IL-12p70, whereas 
only 5 healthy controls had detectable serum concentrations of the cytokine (P<0.001). 
When measuring synovial fluid IL-12p70, the number of RA patients with detectable 
IL-12p70 was again significantly higher than healthy controls (Kim et al., 2000). In the 
study by Kim and colleagues, patients with elevated concentrations of IL-12p70 also 
had raised levels of IL-2, IL-6 and TNF (Kim et al., 2000). It has also been reported 
that serum concentrations of IL-12p40 (one of the subunits of IL-12p70) are 
significantly elevated in RA compared to healthy controls (Szodoray et al., 2006). This 
combined evidence indicates a role for IL-12 in RA disease pathogenesis. 
1.5.8 IL-10 
IL-10 is generally considered as having an anti-inflammatory function in the immune 
system, by inhibiting the production of pro-inflammatory cytokines IL-1β, TNFα and 
IL-8 by macrophages and leukocytes (Fiorentino et al., 1991, Cassatella et al., 1993). 
In RA it has been shown that IL-10 also has an anti-inflammatory role by down-
regulating production of IL-1β and TNF by synovial fluid mononuclear cells (Isomaki 
et al., 1996). Studies have shown that concentrations of IL-10 are raised in RA patients 
compared to healthy controls (Perry et al., 2009, Szodoray et al., 2006), possibly to 
suppress rising concentrations of potentially damaging pro-inflammatory cytokines. 
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1.5.9 Other cytokines involved in RA 
IL-23 is produced by macrophages, dendritic cells (DCs) and natural killer (NK) cells 
and was once thought to promote Th17 cell expansion and IL-17 secretion (Aggarwal 
et al., 2003). Studies have since shown that IL-23 alone does not promote these 
activities (Betteli et al., 2006). The generation of IL-17-secreting pathogenic Th17 
cells does, however, require stimulation from IL-23 along with IL-6 and TGF-β1 in 
order to produce TGF-β3, which then (along with IL-6) further drives the development 
of pathogenic Th17 cells (Jin and Dong, 2013). IL-23 is also thought to stabilise the 
Th17 phenotype, stopping the conversion of Th17 cells to a Th1 phenotype (Taherian 
et al., 2014). An increased expression of IL-23p19 mRNA has been observed in RA 
synovial fibroblasts, as well as an increase in serum IL-23 (Kim et al., 2007) indicating 
a role for this cytokine in RA disease development. 
The cytokine IL-18, which is closely related to IL-1α and IL-1β, is raised in the serum 
of RA patients and is thought to play a pathophysiological role in RA by inducing 
various pro-inflammatory cytokines (Figure 2) (Bresnihan et al., 2002). Recently, a 
gene polymorphism in the IL-18 gene was confirmed as a risk factor for RA (Wen et 
al., 2014). The recently discovered cytokine IL-32 has also been found to be highly-
expressed in the synovium in RA (but not osteoarthritis or healthy controls) after 
synovial tissue biopsies were performed on these patients (Joosten et al., 2006). IL-32 
is also thought to promote secretion of IL-6, IL-1, TNFα and IL-17, acting upon the 
monocytes, dendritic cells, macrophages and T cells (Figure 2) (Xu et al., 2013). IL-
26 has also been identified as a crucial mediator of rheumatoid arthritis as another 
initiator of this typical inflammatory cytokine cascade (Corvaisier et al., 2012). IL-26 
is constitutively produced by synoviocytes and stimulates monocytes to produce 
inflammatory cytokines, however it also favours the generation of pathogenic Th17 
cells (Corvaisier et al.,2012), making it yet another cytokine involved in this complex 
dysfunction of the immune system.  
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1.6 Cytokines involved in PMR 
Whilst cytokine profiles for RA have been well studied, those for PMR have not. Only 
a handful of studies have looked at elements of the circulating PMR cytokine profile, 
the results of which are discussed here. 
Studies have shown that IL-10 concentrations in the serum of PMR patients are raised 
and correlate negatively with the severity of symptoms, indicating an ameliorative role 
for IL-10 much like in RA (Straub et al., 1999, Alvarez-Rodriguez et al., 2010). In two 
studies, serum concentrations of IL-12p70 were suppressed in PMR compared to 
healthy controls (Szodoray et al., 2006, Alvarez-Rodriguez et al., 2010). Alvarez-
Rodriguez and co-workers also showed that levels of the inflammatory cytokines IL-
1β and TNFα in the serum of PMR patients were not elevated above healthy controls 
(Alvarez-Rodriguez et al., 2010), indicating that RA and PMR pathogenesis are very 
different, despite sharing clinical symptoms and raised circulating IL-6. Similarly, 
cytokines such as IL-17, IL-8, IL-1β, IL-4 and TNFα, which are all elevated in RA and 
most likely to be produced in the synovium, may not be elevated in PMR, which does 
not appear to have similar levels of joint involvement. Recently, however, Samson and 
colleagues showed that Th17 cell numbers are increased in PMR and GCA patients, 
indicating a potential role for IL-17 in the development of these diseases (Samson et 
al., 2012). A conflicting report by van der Geest and colleagues proposes that there are 
no clear alterations in Th subsets or regulatory T cells in PMR patients and thus IL-17 
may not be elevated at all (van der Geest et al., 2012).  
Evidently, the circulating cytokine profile of PMR patients is not well studied, and 
requires further research in order to address this lack of knowledge of the cytokines 
involved in PMR pathogenesis. Hence, one of the aims of this study is to characterise 
the serum/plasma cytokine profile of PMR patients and directly compare this with RA 
patients and healthy controls.  
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1.7 The crucial role of interleukin-6 in RA and PMR 
The cytokine interleukin-6 (IL-6) has long been highlighted as a major contributor to 
the pathophysiology of both PMR and RA, by promoting synovitis and joint 
destruction in RA as well as controlling many of the systemic symptoms of both PMR 
and RA (Srirangan and Choy, 2010). Originally, IL-6 was known as B cell stimulatory 
factor. It was identified as a T cell line-derived interleukin which stimulated B cell 
differentiation and maturation (Andersson and Matsuda, 1989). Since then, however, 
its pleiotropic capabilities have been identified and its name changed to interleukin-6 
(IL-6). IL-6 can be synthesised by a range of different cell types, such as neutrophils 
and eosinophils (Melani et al., 1993), fibroblasts (Cichy et al., 1996), synoviocytes 
(Guerne et al., 1989), endothelial cells (Dasgupta and Panayi, 1990), monocytes 
(Roche et al., 1993), macrophages (Martin and Dorf, 1991), T cells (Andersson and 
Matsuda, 1989), B cells (Barr et al., 2012), DCs (Jego et al., 2003, Leech et al. 2013) 
and myoblast cells (De Rossi et al., 2000), amongst others. 
One of the key roles of IL-6 is to stimulate the acute phase response during the early 
stages of inflammation by inducing the expression of the acute phase genes (Kishimoto 
et al., 1995). This systemic response involves the onset of fever, leukocytosis, and the 
synthesis of acute-phase proteins by hepatocytes in the liver (Heinrich et al., 1990). IL-
6 is also thought to play a possible role in the shift from acute to chronic inflammation, 
by changing the nature of the leukocyte infiltrate at the site of inflammation from 
neutrophils to monocytes (i.e. the mononuclear shift) (Gabay, 2006). Under normal 
circumstances, the action of IL-6 is thought to resolve inflammation by removing 
neutrophils from the inflammatory site and encouraging the recruitment of monocytes 
and macrophages in order to accomplish an effective and complete immune response 
(Gabay, 2006). IL-6 also has the potential to exert an anti-inflammatory effect. This is 
demonstrated by studies looking at the increased production of IL-6 in interstitial 
muscle during exercise, where IL-6 is considered to suppress TNFα production by 
negative feedback and thus dampen the inflammatory response (Starkie et al., 2003, 
Rosendal et al., 2005). Furthermore, IL-6 has recently been suggested to have a crucial 
role in anti-viral immunity by limiting pathological inflammation in the lung following 
exposure to influenza (Lauder et al., 2013).  
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IL-6 signals principally through the membrane-bound IL-6 receptor which is present 
on hepatocytes, neutrophils, monocytes, macrophages and some lymphocytes (Rose-
John et al., 2006). IL-6 signalling, however, also requires two sub-units of a signal 
transducing receptor component called glycoprotein130 (gp130), which is ubiquitously 
expressed (Taga and Kishimoto, 1997). This method of signalling is known as the 
classical signalling pathway (Dayer and Choy, 2010) (Figure3a).  
IL-6, unlike most other cytokines, is also capable of signalling through a soluble form 
of the IL-6 receptor, which is thought to be released by naïve and memory CD4 T cells 
(Briso et al., 2008) through proteolytic cleavage of the membrane bound IL-6 receptor 
protein (Jones et al., 2001) or by alternative mRNA splicing (Horiuchi et al., 1994). 
Consequently, IL-6 and the soluble IL-6 receptor form a complex which is then able to 
bind to gp130 (present on most cells) in order to stimulate several types of cells which 
would not ordinarily be responsive to IL-6 alone (Rose-John et al., 2006). For 
example, endothelial cells (Romano et al.,1997), fibroblasts (Sporri et al., 1999) and 
synoviocytes (Dayer and Choy, 2010) do not express the IL-6 receptor, but do express 
gp130 and are thus able to respond to IL-6 when it is bound to the soluble IL-6 
receptor. This alternative method of signalling is known as ‘trans-signalling’ (Rose-
John et al., 2006) (Figure 3b). 
A soluble form of gp130 also exists and acts as a natural inhibitor to the IL-6/sIL-6R 
complex thus blocking trans-signalling (Jostock et al., 2001) (Figure 3c). 
Concentrations of circulating sgp130 are relatively high in human blood (Jones et al., 
2001). In a study by Jostock and colleagues it was found that sgp130 only inhibited IL-
6 when it was associated with its soluble receptor, and did not inhibit IL-6 alone, nor 
did it interfere with bound IL-6 on the surface of cells (Jostock et al., 2001) and thus 
sgp130 provides a method of removing excess circulating IL-6 in order to stop 
inflammation.  
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 Figure 3: IL-6 signalling: classical and alternative pathways. (a) Classical signalling. IL-6 binds to 
the membrane-bound IL-6 receptor, in conjunction with two gp130 molecules. Once bound, 
transcription factors are activated and gene expression changes. (b) Trans-signalling. CD4+ T 
cells synthesise the soluble IL-6 receptor (sIL-6R). IL-6 binds the sIL-6R to form a complex, 
which then binds to ubiquitously expressed membrane bound gp130. (c) Soluble gp130 is a natural 
antagonist to IL-6 which binds the IL-6/sIL-6R complex and selectively inhibits the trans-
signalling process.  (Diagram adapted from Rose-John et al., 2006. Reprinted with permission). 
 
(c) 
(a) (b) 
Classical Signalling Trans-Signalling 
Inhibition of trans-
signalling by a molar 
excess of sgp130 
Signal Signal 
No Signal Signal 
IL-6 
gp130 gp130 
sgp130 sgp130 
IL-6R 
Generation of 
the sIL-6R 
Chapter 1- Introduction 
 
22 
 
When these tightly-controlled immunological responses break down, the function of 
IL-6 becomes ‘more sinister’ (Jones, 2005). There is growing evidence to suggest that 
this pleiotropic cytokine plays a crucial role in the development of inflammatory 
diseases such as PMR and RA, as well as being linked to certain cancers associated 
with chronic inflammation, such as colon cancer (Grivennikov and Karin, 2011). IL-6 
is raised significantly in the serum/plasma of RA and PMR patients, and also in the 
synovial fluid of RA patients (but not PMR) (Houssiau et al., 1988, Hirano et al., 
1988, Madhok et al., 1993 and Perry et al., 2009). Serum levels of IL-6 have been 
shown to reach up to 234 pg/ml in RA patients (Arvidson et al., 1994, Robak et al., 
1998), and up to 400 pg/ml in PMR patients (Kirwan, J., personal communication, 
2011), although published values of up to approximately 54 pg/ml in PMR are quoted 
(Cutolo et al., 2006). This compares to mean IL-6 concentrations of <5 pg/ml in the 
serum and plasma of healthy individuals (Arvidson et al., 1994, Robak et al., 1998, 
Straub et al., 2000).  
The concentrations of IL-6 measured in the serum and plasma of PMR and RA patients 
thus varies dramatically within the literature but similar trends are apparent, in that IL-
6 concentrations are consistently significantly elevated in PMR and RA patients above 
that of healthy controls. One issue is that there is no standardised way of measuring 
cytokines, making meaningful comparisons between laboratories very difficult. 
Furthermore, some studies measure serum IL-6 concentrations (Arvidson et al., 1994, 
Robak et al., 1998, Straub et al., 2000, Alvarez-Rodriguez et al., 2010), whilst others 
measure plasma concentrations (Roche et al., 1993, Perry et al., 2009). As plasma and 
serum have different constituents this may affect cytokine measurement. Thus one of 
the aims of this study is to determine whether a correlation exists between plasma and 
serum concentrations of IL-6 in PMR patients, RA patients and healthy controls.   
In both RA and PMR, IL-6 levels fall rapidly in response to treatment with 
glucocorticoids (GC) (Cutolo et al., 2006, Martinez-Taboada et al., 2008) and the 
amelioration of patient symptoms strongly correlates with this decline in serum IL-6, 
confirming a special role for IL-6 in the pathogenesis of PMR and RA (Arvidson et al., 
1994). Similarly, when IL-6 signalling mechanisms in RA (and PMR in some cases) 
are blocked by drugs such as Tocilizumab, the patient goes into remission, again 
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demonstrating IL-6 is a major contributor to disease pathogenesis of RA. Whilst the 
biological activity of synovium-derived IL-6 in RA has been confirmed using an IL-6-
dependent cell line, known as B9 cells (Guerne et al., 1989), the biological activity of 
raised circulating IL-6 in PMR has not yet been confirmed. Thus a further aim for this 
study is to confirm the biological activity of circulating IL-6 in PMR patients- in order 
to establish whether it is capable of causing the symptoms associated with the disease. 
 
1.8 Circadian variation in IL-6 and RA and PMR symptoms 
Early morning joint stiffness in RA patients was described over 50 years ago by Scott 
who noticed a diurnal variation of grip strength, as well as the usual stiffening of the 
joints and general immobility experienced by RA patients (Scott, 1960). This was later 
attributed to circadian alterations in immune and inflammatory responses (Harkness et 
al., 1982). A distinct circadian variation in serum IL-6 levels in RA patients was 
initially identified by Arvidson and colleagues in 1994, and later confirmed by 
Crofford and colleagues in 1997 who explored the relationship between these 
fluctuating levels of IL-6 and changing concentrations of adrenocorticotrophic 
hormone (ACTH) and cortisol in the plasma of RA patients (Arvidson et al., 1994, 
Crofford et al., 1997). In more recent years, circadian variation in specific RA 
symptoms such as pain and fatigue has been directly linked to the fluctuation in levels 
of IL-6 in the blood during different times of the day, with a peak early in the morning 
(07:15am) (Perry et al., 2009). No other cytokines that were tested in this study 
(TNFα, IL-1β, IL-8, IL-4, IL-5, IL-13, IL-10 or IFNγ) were found to fluctuate in the 
plasma throughout the day in this manner (Perry et al., 2009). 
Knowledge of circadian fluctuations in IL-6 levels has some benefit for the patient. It 
has since been shown that the timing of therapeutic drug application can be optimised 
to better alleviate early morning stiffness, specifically 02:00am delivery has been 
found to not only improve symptoms, but it also improves responsiveness to lower GC 
doses (Spies et al., 2010, Clarke et al., 2011). Additionally, lack of controlling for this 
circadian variation in IL-6 may also explain differences in cytokine results from 
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different studies, and a move towards standardisation of cytokine measurement should 
include standardising the timing of sampling. Hence, in the present study, all 
participant blood samples were taken at a fixed specific time in the day (between 9-
11am), soon after the peak in circulating IL-6 concentration, but still at a convenient 
time for participants.   
 
1.9 IL-6 and fatigue 
In the last ten years the clinical importance of fatigue in RA and PMR has become 
better recognised. The recent development of the BRAF-MDQ has allowed clinicians 
to gain a more comprehensive understanding of the individual aspects of fatigue 
particularly in patients with RA, but also other inflammatory diseases such as PMR 
(Nicklin et al., 2010). The BRAF-MDQ assesses the different dimensions of fatigue, 
such as physical fatigue, the experience of day-to-day living with fatigue, cognitive 
fatigue (i.e. the ability to concentrate with fatigue), emotional fatigue, as well as the 
overall impact of fatigue (Appendix A) (Hewlett et al., 2011).  
IL-6 has been implicated as a major cause of fatigue, mainly because of the link 
between fluctuating IL-6 concentrations in the circulation and the changing severity of 
fatigue symptoms in RA. Two studies in particular have confirmed a link between IL-6 
and fatigue in RA (Davis et al, 2008 and Helal et al, 2012), the latter using the BRAF-
MDQ in order to assess fatigue. The author of the latter paper, however, looked only at 
the correlation between IL-6 and overall fatigue, and did not consider that there may be 
correlation between IL-6 and the individual aspects of fatigue. A study by Späth-
Schwalbe and colleagues strongly implicates IL-6 in causing the key symptoms 
associated with fatigue, as low-dose IL-6 was administered to a group of healthy male 
subjects who reported fatigue, inactivity and an inability to concentrate for long 
periods of time (compared to those who were given a placebo) (Späth-Schwalbe et al., 
1998). Other studies have highlighted pro-inflammatory cytokines (such as TNFα and 
IL-1) as a cause of the fatigue experienced by cancer patients (Bower et al., 2002, 
Bower et al., 2013 and Fung et al., 2013).  
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IL-6 and other pro-inflammatory cytokines are capable of stimulating the 
hypothalamo-pituitary-adrenal (HPA) axis, which is thought to be linked to the 
development of fatigue (Tsigos and Chrousos, 2002 and Sriringan and Choy, 2010). 
The exact mechanisms involved, however, are yet to be elucidated.  Further research 
into the association between IL-6 and fatigue in RA and PMR is essential to work out 
exactly how IL-6 is causing fatigue in these diseases and how to reduce this chronic 
and debilitating symptom. Hence, one of the aims of this study is to determine whether 
there is correlation between circulating IL-6 concentrations in PMR and RA patients 
and overall fatigue, as well as the individual aspects of fatigue, as categorised by the 
BRAF-MDQ, which has not previously been examined. 
 
1.10 Potential sources of IL-6 in RA and PMR 
In RA, the synovium is the likely source of IL-6, after cells from the synovial fluid of 
RA patients were found to express IL-6 mRNA (Hirano et al., 1988). Guerne and co-
workers substantiated this theory by detecting higher concentrations of IL-6 in the 
synovial fluids of RA patients than osteoarthritis (OA) patients, and confirming the 
biological activity of this synovial-derived IL-6, demonstrating that synoviocytes were 
in fact a potent source of IL-6 in RA (Guerne et al., 1989). Since then, IL-6 levels of 
around 5000 pg/ml have been measured in the synovial fluid of the knee in patients 
with active RA (Perry et al., 2009). By measuring levels of IL-6 in the synovium and 
in the plasma in parallel, it was hypothesised by Perry and colleagues that in RA, IL-6 
is produced initially in the joints, but subsequently diffuses across the synovial 
membrane into the plasma with a constant rate of transport across the membrane (Perry 
et al., 2009). This explains why IL-6 concentrations in the serum are much higher in 
RA patients (up to 234 pg/ml) than in healthy controls (<5 pg/ml) (Arvidson et al., 
1994, Robak et al., 1998, Straub et al., 2000).  
In PMR patients, serum IL-6 levels have been measured at up to 400 pg/ml (Kirwan, 
J., personal communication 2011), despite limited joint inflammation. PMR is largely 
a muscular and systemic inflammatory disease, and there is little evidence of joint or 
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vascular involvement. This suggests that the source of IL-6 in PMR is unlikely to be 
the synovium as in RA, but may be derived from peripheral blood mononuclear cells 
(PBMC) (which includes T cells, B cells, monocytes and DCs). The principal aim of 
this study is to individually explore the PBMCs as potential sources of elevated 
circulating IL-6 in PMR. 
 
1.11 Peripheral sources of IL-6 
Only two studies have explored IL-6 production in the PBMC of PMR patients, both 
focusing on the monocytes (Roche et al., 1993, Alvarez-Rodriguez et al., 2010) and/or 
the T cells (Roche et al., 1993). This section examines the strength of the evidence that 
suggests that monocytes and T cells are (or are not) the source of IL-6 in PMR, as well 
as providing evidence that one of the other PBMCs may be a potential source. 
1.11.1 Monocytes 
Two studies have looked specifically at circulating monocytes as a potential source of 
elevated circulating concentrations of IL-6 in PMR. Firstly, Roche and colleagues used 
the polymerase chain reaction (PCR) to demonstrate that peripheral blood derived 
CD14+ monocytes express IL-6 specific mRNA (Roche et al., 1993). Based on this, 
the authors conclude that monocytes are the source of IL-6 in PMR. Yet, no difference 
was observed between PMR patients and controls, and although the monocytes 
expressed IL-6 mRNA, the authors did not prove that the monocytes can actually 
secrete IL-6, and thus have no conclusive evidence that the monocytes are the major 
source of IL-6 in PMR.   
In contrast, a more recent study by Alvarez-Rodriguez and co-workers concluded that 
monocytes are not the source of raised circulating IL-6 in PMR. The authors used 
intracellular antibody staining and flow cytometry to demonstrate that circulating 
CD14+ monocytes in PMR patients did not produce greater amounts of pro-
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inflammatory cytokines (including IL-6) than circulating monocytes in healthy 
controls (Alvarez-Rodriguez et al., 2010). They hypothesise that the increased 
concentrations of IL-6 in PMR are instead produced by another subset of blood cells or 
at a specific site of inflammation, possibly in the tissue (Alvarez- Rodriguez et al., 
2010). Alvarez-Rodriguez and co-workers used intracellular staining and flow 
cytometry techniques in order to look at monocytes at a single cell level, however, they 
only presented half of the data which was available to them. The authors only took into 
account the percentage of monocytes which were stained positively for IL-6, and did 
not take into consideration the mean fluorescence intensity (MFI) of IL-6 antibody 
staining. This would have indicated the quantity of IL-6 within the monocytes, and not 
just the percentage of cells containing it. Furthermore almost 100% of control cells 
were stimulated making observation of increases during disease unlikely. Thus these 
assays need repeating, measuring both the percentage of IL-6 positive cells and the 
MFI of IL-6 antibody staining. 
1.11.2 T cells 
A clear role for T cells has already been highlighted in the pathogenesis of RA in the 
synovium, however, there is limited research on the role of T cells in the pathogenesis 
of PMR. It has been suggested that T cells could be a potential source of this elevated 
IL-6, as memory CD3+ T cell numbers are increased during active PMR (Dejaco et al, 
2010) and a subset of T cells are able to produce IL-6 (Andersson and Matsuda, 1989). 
Various studies have looked at CD8+ T cells in PMR, with conflicting outcomes. 
Some say there is a significant reduction in the number of CD8+ T cells in active PMR 
(Dasgupta et al., 1989, Boiardi et al., 1996) whereas others suggest that CD8+ T cells 
are not reduced in active PMR (Pountain et al., 1993, Martinez-Toboada et al., 2001). 
Roche and colleagues claim that CD4+ T cells do not contribute to IL-6 production in 
PMR as they could not detect IL-6 mRNA in unstimulated or stimulated cells, instead 
they concluded that CD14+ monocytes are the ‘exclusive source’ of IL-6 in PMR 
(Roche et al., 1993). Again, the presence or absence of IL-6 mRNA is not conclusive 
evidence as to whether cells are capable of producing IL-6, and the stimulant used here 
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(immobilised anti-CD3 antibody) may not provide an accurate reflection of the 
situation in vivo.  
In a recent study, Samson and colleagues (2012) provide evidence that patients with 
PMR have reduced numbers of Treg and Th1 cells and significantly increased numbers 
of Th17 cells compared to controls (Samson et al., 2012). This suggests that chronic 
inflammation may be induced or initiated through the release of IL-17 from Th17 cells, 
triggering the production of IL-6 from other cell types. This study does not, however, 
provide evidence as to whether T cells contribute to the production of IL-6 and this 
finding is strongly contested by others (van der Geest et al., 2012). Further research is 
required to confirm if T cells are a potential source of IL-6 in PMR.   
1.11.3 B cells 
B cells are capable of IL-6 secretion. Using experimental autoimmune 
encephalomyelitis (EAE) mouse models, Barr and colleagues showed that when IL-6-
secreting B cells are depleted, autoimmune disease ameliorates- indicating that IL-6 
production may be a major pathogenic function of B cells in diseases such as EAE and 
multiple sclerosis (MS) (Barr et al., 2012). Whether this extends to diseases such as 
PMR (which has a very different pathogenesis to MS) is unknown, however this 
evidence suggests that B cells are capable of producing IL-6 in large enough quantities 
to drive autoimmune disease pathogenesis. 
It has been shown that Human Immunodefiency Virus (HIV) can induce spontaneous 
secretion of IL-6 from peripheral B cells, in the presence of IL-4 (Boue et al., 1992). 
The direct involvement of HIV remains unclear but this increased production of IL-6 
leads to the large-scale B cell malfunction which HIV patients’ exhibit. This suggests 
that an infectious agent, such as a virus, could be involved in the pathogenesis of 
autoimmune diseases such as PMR, perhaps suggesting that a malfunctioning B-cell 
subset could be the source of spontaneous, elevated concentrations of IL-6 in the 
serum. Others have also proposed that a link may exist between infection and the onset 
of PMR (Perfetto et al., 2005). With evidence to suggest that B cells are capable of, 
and are known to produce excessive levels of IL-6 in patients with known infectious 
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diseases, and with such a crucial role in the onset of RA, it is plausible that B 
lymphocytes could be the source of elevated concentrations of IL-6 in PMR.  
1.11.4 Dendritic cells 
DCs may also be a possible source of IL-6 in PMR. There are two principal subsets of 
DC in humans; plasmacytoid DCs (pDCs) and myeloid DCs (mDCs). pDC are a ‘rare’ 
type of immature DC, with a capacity to produce large amounts of TNF-α and IFN-α 
(Lande et al., 2004, Cavanagh et al., 2005). Myeloid DCs are considered important 
antigen-presenting cells needed for triggering primary T cell responses (Morelli et al., 
2001). mDCs are present in normal peripheral blood and RA patients but are found to 
be significantly elevated in the synovium of RA patients (Thomas et al., 1999). It is 
thought that the number of DCs correlates directly (pDCs) or inversely (mDCs) with 
the severity of RA disease depending on the subtype. pDCs (subtype CD123
+
)
 
have an 
ameliorative effect on RA symptoms (Jongbloed et al., 2009) whereas circulating 
mDCs (subtype CD11c
+
) contribute to RA activity (Richez et al., 2009). A recent 
study by Leech and co-workers has shown that in models of EAE, early T cell 
activation was driven by IL-6 which was exclusively derived from DCs (Leech et al., 
2013). Nonetheless, overall no studies to date have examined DCs as the source of IL-
6 in PMR. It is also possible that viral infection could be the DC activating factor as 
viral infection can induce release of IL-6 from DCs (Jego et al., 2003). 
1.11.5 Endothelium 
Activated endothelial cells are capable of producing significant amounts of IL-6 
(Dasgupta and Panayi, 1990). Furthermore, IL-6 mRNA has been detected in human 
dermal microvascular endothelial cells after 24 hours stimulation with LPS and TNFα 
(Hettmansperger et al., 1992). In a study by Loppnow and colleagues, following 
incubation with LPS or IL-1β, in vitro endothelial cells produced IL-6 for an extended 
period of at least 144 hours- which may have had an effect on local immune and 
inflammatory responses (Loppnow et al., 1989). Thus, endothelial cells are a potential 
source of elevated concentrations of IL-6 in PMR, but will not be tested in this study 
due to the invasive and difficult process of taking a blood vessel biopsy. 
Chapter 1- Introduction 
 
30 
 
 
1.12 Potential sources of IL-6 in the tissue 
Generally PMR patients are not thought to suffer severely from synovitis (Kyle et al., 
1990). There is limited evidence, however, to suggest that a tissue component such as 
the synovium, muscle or ligaments could be the source of IL-6 in PMR. Two studies 
have suggested that a synovitis component is not only present in PMR but is a major 
feature; causing many of the musculoskeletal symptoms that PMR patients present 
(Meliconi et al., 1996, Frediani et al., 2002). Meliconi and colleagues state that in their 
study, ‘synovitis was present in 10 of 12 (83%) untreated PMR patients’, whilst 
Frediani and colleagues claim that synovitis was present in at least one site in 100% of 
PMR patients following their sonographic study (Meliconi et al., 1996, Frediani et al., 
2002). Bursitis (inflammation of the bursae) is also considered by some to contribute 
to the pain and discomfort felt in the shoulders and other proximal extremities of PMR 
patients (Salvarani et al., 1997). In two PMR case studies, radio-labelled glucose 
(18FDG) was found to accumulate in specific locations within the joints, particularly 
the ligament attachment sites, leading the authors to believe that inflammation of the 
ligament attachment sites may be an important element of PMR (Kotani et al., 2011).  
PMR, however, has significantly less evidence of joint inflammation than RA, despite 
having equivalent circulating IL-6 levels, making this an unlikely source of IL-6 in 
PMR. 
Kreiner and co-workers suggest that there may also be a muscle component involved 
in PMR (Kreiner et al., 2010). Increased interstitial levels of inflammatory cytokines 
IL-6, IL-8, IL-1β were measured in symptomatic muscles of 20 glucocorticoid-naïve 
PMR patients compared to 20 healthy controls, by microdialysis (Kreiner et al., 2010). 
The authors suggest that cytokines may be released locally, causing muscle pain in 
very specific areas where inflammatory cytokine production is high (Kreiner et al., 
2010). The study did not, however, perform internal controls for affected muscle and 
unaffected muscle within individuals. In addition, others have found that human 
myoblast cells constitutively express IL-6 mRNA and secrete IL-6 (De Rossi et al., 
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2000). Overall, the evidence does not point towards muscular or joint involvement in 
PMR.  
 
1.13 Methodologies  
1.13.1 Measuring circulating IL-6 
Previous studies have shown that circulating IL-6 is raised in PMR patients compared 
to healthy controls using different methods, including enzyme-linked immunosorbent 
assays (ELISAs) (Roche et al., 1993, Straub et al., 2000, Cutolo et al., 2006) or 
cytometric bead array (CBA) (Alvarez- Rodriguez et al., 2010). Circulating 
concentrations of IL-6 have also been measured in either plasma or serum, depending 
on the study. In order to determine how comparable the results are from these different 
methods of cytokine measurement and in these different blood components, in the 
present study both plasma and serum IL-6 were measured by ELISA and CBA. To my 
knowledge, no previous study has confirmed the biological activity of the raised 
circulating IL-6 in PMR. Hence, this was also tested using a cell-line based bioassay, 
with a cell-line known as B9 cells. This cell line is dependent on biologically active 
IL-6 for metabolism and growth (Helle et al., 1988), and was thus able to establish the 
biological activity of the circulating IL-6 present in participant samples. 
1.13.2 Measuring fatigue vs IL-6 
As previous studies have shown evidence for a relationship between IL-6 and fatigue 
in RA (Davis et al., 2008, Helal et al., 2012), this study set out to determine if a 
correlation exists between circulating IL-6 concentrations (measured by CBA) and 
fatigue (measured using the recently-devised BRAF-MDQ) in PMR. For the first time, 
the correlation coefficients between circulating IL-6 concentrations and individual 
aspects of fatigue (as determined by the BRAF-MDQ) were determined in order to 
establish if IL-6 is associated with specific aspects of fatigue in PMR and RA. 
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1.13.3 Measuring intracellular IL-6 production in PBMCs  
Previous studies have looked at IL-6 production in one or two PBMC types, for 
example the monocytes (Roche et al., 1993, Alvarez-Rodriguez et al., 2010) or the T 
cells (Roche et al., 1993) and only one of these studies looked at intracellular IL-6 
production at a single cell level (Alvarez-Rodriguez et al., 2010). Neither of these 
studies managed to locate the source of the elevated circulating IL-6 in PMR. Thus, in 
order to advance on these studies, the source of raised circulating IL-6 in PMR was 
explored within the five main PBMC types (T cells, monocytes, B cells, pDC and 
mDC), using intracellular staining and flow cytometry.  
 
The study by Alvarez-Rodriguez and colleagues looked at IL-6 production in 
monocytes using similar techniques, however, the authors only presented data showing 
the percentage of IL-6 producing cells and not the intensity of IL-6 staining within 
each cell type, i.e. the MFI (Alvarez-Rodriguez et al., 2010). It is currently unclear 
whether the elevated concentrations of IL-6 may be coming from a large number of 
one cell type producing a small quantity of IL-6, or whether a small number of one cell 
type were producing an abnormally large quantity of IL-6. Thus, in order to account 
for both of these possible outcomes, both the percentage of IL-6-producing cells in 
each cell type and the intensity of the staining within all five cell types (MFI) were 
taken into consideration in the present study. Constitutive IL-6 secretion was measured 
in unstimulated PBMC, whereas the potential for these cells to secrete IL-6 was tested 
using a specific cell stimulant. 
1.13.4 Measuring secreted IL-6 by PBMCs 
A single method will not normally provide sufficient evidence to form a positive or 
negative conclusion, thus the aim was to accumulate data collected using different 
methods to strengthen the enquiry. Hence, as well as measuring circulating IL-6 
concentrations in the plasma and serum, and measuring IL-6 production in individual 
PBMC types, the PBMC culture supernatants were collected after 24 hours in culture 
with or without additional stimulation, and secretory IL-6 measured using CBA. This 
gave an insight into whether large quantities of IL-6 were being secreted into the 
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extracellular matrix by the PBMC of PMR patients compared to the PBMC of healthy 
control and RA participants. If secretory IL-6 concentrations were significantly greater 
in PMR culture supernatants, it would confirm that one of the PBMC types within that 
culture were the source of spontaneous secretions of IL-6.  
Secretory IL-6 from PBMCs of PMR patients has been measured in other studies, 
however, specific stimuli were used which were capable of activating only individual 
PBMC types. Roche and colleagues collected PBMC culture supernatants (isolated 
from PMR, GCA and HC blood samples) at 24, 48 and 72 hours post stimulation with 
immobilised anti-CD3 antibody (Roche et al., 1993). The concentration of secreted IL-
6 in PMR supernatants was not significantly different from the concentration of 
secreted IL-6 in the healthy control supernatants at each time point (Roche et al., 
1993). This contradicts their argument that the monocytes are the source of elevated 
IL-6 in PMR. The authors defend this finding by suggesting that the monocytes were 
not properly activated by the T cell specific stimuli (Roche et al., 1993). Therefore this 
requires re-testing with a stimulant specific for monocytes and the other cell types 
present in the cultures.  
E. coli derived LPS is commonly used as a potent monocyte stimulator. LPS from 
other organisms can stimulate human B cells (Vaughan et al., 2010), however this has 
never been reported for E. coli LPS. Alvarez-Rodriguez and colleagues found that after 
24 hours stimulation with LPS there was no significant difference between secreted IL-
6 concentrations from PBMC in PMR patients and controls (Alvarez-Rodriguez et al., 
2010). They do, however suggest that there is ‘a tendency’ for the PBMC in PMR 
patients to produce larger concentrations of IL-6, despite it not being statistically 
significant (Alvarez-Rodriguez et al., 2010). Previously, they suggest that monocytes 
are not the source of raised IL-6 in PMR, which implies that another PBMC type may 
be responsible for this ‘tendency’ to secrete high IL-6 concentrations in PMR patients.  
 
Thus, these issues need resolving. The PBMC in this study were therefore cultured 
with stimulants capable of activating monocytes, lymphocytes and DCs in order to 
determine if any of these PBMC types are responsible for the elevated circulatory IL-6 
reported in PMR patients.  
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1.13.5 Looking at the circulating cytokine profile of PMR patients 
Aside from IL-6, the other cytokines involved in PMR disease pathogenesis are not 
well characterised. Using CBA analysis, ten cytokines were measured in the serum and 
plasma of PMR patients, RA patients and healthy controls, in order to confirm which 
cytokines might be raised alongside IL-6 in PMR, and thus gain a deeper 
understanding of the pathology of the disease. Secreted cytokines in the PBMC culture 
supernatants were also measured using CBA, alongside IL-6. 
 
1.14 Strengths of the study 
1.14.1 Appropriate controls 
Studies have shown that age (O’Mahony et al., 1998) may impact on clinical levels of 
IL-6 and thus is controlled for in this study. According to O’Mahony and colleagues, 
in a group of older subjects (62 years and above- mean age 73) there were significant 
increases in cytokine production in T cells compared with the younger subjects (20-40 
years- mean age 29), in particular IL-6 and TNFα (O’Mahoney et al., 1998). It has also 
been reported that serum concentrations of IL-6 (and sIL-6r in women) increase 
naturally with age, and older individuals are often in a constant low-grade 
proinflammatory state, thought to be related to the increased risk of cardiovascular 
disease (Bruunsgard et al., 2003, Ferruci et al., 2005). It is now generally accepted that 
immunosenescence occurs as individuals get older, with ‘immune alterations’ evident 
even in apparently healthy 55-70 year olds (Hodkinson et al., 2006). Thus it was 
deemed necessary to age-match the healthy controls to the diseased patients as closely 
as possible in order to observe differences that were not related to immunosenescence. 
Various studies have suggested a link exists between sex hormones such as oestrogen, 
progesterone and dehydroepiandrosterone and cytokine secretion by PBMCs, resulting 
in differential secretory cytokine profiles in men and women (Verthelyi and Klinman, 
2000, Asai et al., 2001), so where possible gender-matched controls were obtained in 
this study.  
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One of the major strengths of this study is the inclusion not only of healthy controls of 
a similar age and gender distribution, but also the inclusion of a second disease control. 
There were initial concerns that circulating IL-6 in PMR patients might alter the 
biological activity of circulating PBMCs, confounding the interpretation of 
investigation results. In order to make allowances for this, patients with active RA 
were also included in this study as a comparator, as RA patients have similarly raised 
concentrations of circulating IL-6. Therefore, RA patients served as a control for any 
underlying general response of the PBMC to circulating IL-6, meaning that any 
differences in IL-6 production observed in PMR patients were specific to PMR disease 
pathogenesis and most likely due to abnormally functioning PBMCs. This additional 
control vastly increases the power of the enquiry. 
The inclusion of a positive control cell line allowed the efficacy of the IL-6 antibody 
staining method to be validated, and was tested alongside each participant. 
1.14.2 Timing of sampling 
Knowing that IL-6 is strongly associated with a circadian fluctuation throughout the 
day, strict timing of blood sampling was adhered to, in order to control for this natural 
variation. The peak time for circulating IL-6 concentrations is 7:15am (Perry et al., 
2009). Participant blood samples were taken between 9am and 11am, thus IL-6 
concentrations would still be high, whilst the timing convenient for participants to visit 
the clinic to donate their sample. 
1.14.3 Blinding of study samples 
The study was performed blinded, with the disease status of the participant not 
revealed until after preliminary data analysis, meaning that the investigator could not 
form a biased interpretation of the data that best fitted the hypotheses. Thus, the power 
and reliability of the enquiry was further increased. 
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1.14.4 Optimisation of laboratory techniques 
Prior to testing on study participant blood samples, the blood separation technique and 
in vitro stimulation methods were optimised on healthy donor blood samples at UWE, 
Bristol. Antibodies used for the detection of both surface markers and intracellular IL-
6 were titrated in order to determine the optimal concentrations (i.e. the equivalence 
point, where both antibody and antigen are at an optimal concentration). The IL-6 
antibody was titrated on a positive control cell line (Jurkat T cells), known for its 
ability to constitutively produce IL-6. Several cell stimulants were tested on healthy 
PBMC from blood donors at UWE, in order to determine which could stimulate IL-6 
production in all five PBMC types. In their study, Roche and colleagues used a T-cell 
specific stimulus (immobilised anti-CD3 antibody), which was thought to indirectly 
activate the monocytes (Roche et al., 1993). Here, the T cell mitogens 
phytohemagglutinin (PHA) (Baran et al., 2001) or phorbol 12-myristate 13-acetate 
(PMA) and ionomycin (Touraine et al., 1977) were tested, alongside LPS and IFNγ 
(Hobbs et al., 1991, Verhasselt et al., 1997, Bueno et al., 2001) in order to try and 
activate the different PBMC types. The stimulation techniques which provided an all-
round stimulation of all five PBMC types were selected for use in the assays. 
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1.15 Hypotheses 
Several hypotheses were formed prior to carrying out the study, and are as follows: 
                                                                                                              
1) The concentration of IL-6 will be significantly raised in the serum and 
plasma of PMR and RA patients compared to healthy controls of a similar 
age and gender distribution. 
 
2) IL-6 concentrations in stored serum and plasma will demonstrate a positive 
correlation, but the values will not be exactly equivalent. 
3) The IL-6 measured in the serum/plasma of PMR and RA patients will be 
biologically active, confirming a role for IL-6 in the pathogenesis of these 
diseases. 
4) Using rigorously controlled timing of sampling, and the latest fatigue 
scoring system (BRAF-MDQ) there will be a strong correlation between all 
aspects of fatigue and IL-6 concentration in the plasma and serum of PMR 
and RA patients. 
5) Within PBMC cultures, one of the PBMC subsets will be identified as the 
cellular source of IL-6 in patients with PMR but not RA (which is believed 
to be synovial-derived) nor healthy controls of a similar age and gender 
distribution. 
 
 
Chapter 1- Introduction 
 
38 
 
 
1.16 Aims and objectives 
Based on these hypotheses, the specific aims and objectives of this study were as 
follows: 
 
1) To confirm that IL-6 is elevated in the serum and plasma of PMR and RA 
patients compared to healthy age-matched controls, using cytometric bead 
array (CBA) and sandwich ELISAs. The samples will be taken at a fixed 
specific time of day (9-11am) to control for circadian variation in circulating 
IL-6 levels, and thus to provide an accurate and consistent method of 
measuring IL-6. 
 
2) To determine if a correlation exists between IL-6 concentrations in the serum 
and plasma, in order to determine whether these can be used interchangeably to 
measure cytokine concentrations in the blood, despite the difference in the 
method of extraction from the blood and the difference in composition. 
 
3) To determine whether the elevated IL-6 in PMR is biologically active and thus 
capable of causing the symptoms described by PMR patients, using the IL-6-
dependent hybridoma cell-line, B9 cells. 
 
4) To determine if there is a correlation between fatigue and IL-6 concentrations 
in the blood using the latest BRAF-MDQ assessment questionnaire to assess 
different aspects of fatigue in each subject. As the samples will be taken at a 
fixed specific time of day (9-11am), this not only controls for circadian 
variation in circulating IL-6, but may also control for changes in PMR and RA 
symptoms such as fatigue, and thus makes it possible to examine more robustly 
whether there is a correlation between the circulating IL-6 concentration and 
fatigue. 
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5) To identify the cellular source of elevated circulating IL-6 within the PBMC of 
PMR patients using immunostaining of cell surface markers and intracellular 
IL-6, and flow cytometry techniques. RA patients and healthy controls will be 
tested alongside PMR patients to show specificity to PMR. Both constitutive 
and inducible IL-6 will be measured in five different cell types within the 
PBMC (T cells, monocytes, B cells, pDCs and mDCs), in order to observe 
differential cellular responses between control and disease groups and to 
determine the cellular potential for IL-6 production. Intracellular staining will 
be correlated with IL-6 secretion in PBMC cultures. 
 
 
Additionally, this study aims to address the lack of knowledge of the cytokines 
involved in PMR pathogenesis, by characterising the serum/plasma cytokine profile 
for PMR, and comparing it to the serum/plasma cytokine profile of RA patients and 
healthy control patients.  
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1.18 Summary 
IL-6 is significantly raised in the bloodstream of PMR patients, implicating it as a 
major contributor to the pathogenesis of the disease. The significance of this finding is, 
however, still uncertain, with many questions and theories still requiring answers. Why 
is IL-6 raised in the circulation of PMR patients? Is this IL-6 biologically active, thus 
capable of causing the symptoms of PMR? If IL-6 is involved, then which symptoms 
is it specifically involved with and how? Does IL-6 work alone to cause these 
symptoms, or are there other cytokines which are involved? And perhaps the most 
crucial question of all; where does this IL-6 come from?  
Despite being the subject of many years of research, the cellular source of IL-6 in 
PMR and the causative agent of its release are yet to be identified. A few isolated 
studies have shown limited evidence for the existence of a tissue component; however, 
collectively there is more evidence to suggest that there may be a peripheral source of 
IL-6 in PMR. This is demonstrated by the excess serum and plasma IL-6 
concentrations (Roche et al., 1993, Straub et al., 2000, Cutolo et al., 2006, Alvarez-
Rodriguez et al., 2010) and secretion of high levels of IL-6 in PBMC cultures (Roche 
et al., 1993). Studies have suggested that this IL-6 may (Roche et al., 1993) or may not 
(Alvarez-Rodriguez et al., 2010) be monocyte derived, but none have examined the 
other PBMC cell types. Weaknesses and discrepancies in these two studies have been 
discussed throughout this section. Here, evidence has been provided which 
demonstrates that IL-6 may be monocyte, dendritic cell, T cell or B cell derived. 
Hence, the principle aim of this study is to locate the source of IL-6 within these cell 
types. Subsequently, the cause of the dysfunction could potentially be unravelled and 
alternative targets for therapeutic intervention could be identified, reducing the need 
for harmful steroids. 
Overall, this study aims to advance our current understanding of PMR, answering the 
questions posed in a systematic and exhaustive manner, in order to explore the overall 
immunopathology underlying polymyalgia rheumatica. 
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In this chapter the experimental procedures used to test the hypotheses are described in 
detail. First of all, the procedures used to screen and recruit participants and collect 
samples are outlined, along with the ethical practices put in place to maintain patient 
confidentiality and to abide by the rules of the Human Tissue Act (2004). Following 
this, the laboratory procedures are described in detail, including techniques used to 
culture cell lines and primary cells, the methods used to transport, separate and store 
blood samples, methods used to measure cytokines in serum, plasma and PBMC 
culture supernatants (CBA and/or ELISA), methods used to test the bioactivity of IL-6 
in patient plasma samples (B9 cell proliferation assay) and the methods used for the 
detection and measurement of IL-6 at a single cell level within the PBMCs (using 
intracellular antibody staining and flow cytometry). Each of these methods required 
some level of optimisation, the methods for which are described prior to the 
description of each laboratory procedure. Finally, statistical methods are described at 
the end of the chapter. 
 
2.1 Collection of blood samples 
2.1.1 Recruitment and screening of study participants 
Study participants were recruited at the University Bristol Hospitals, NHS Foundation 
Trust (UBHT), Rheumatology Centre. Those people with signs and symptoms of 
active PMR and RA and who fulfilled the inclusion criteria but not the exclusion 
criteria (Table 3 and 4) were provided with an information sheet about the study 
(Appendix B). Patients were given 24 hours to decide whether they would like to take 
part. Arrangements were then made to bring them back to the clinic the following day 
to complete the necessary screening and consent forms and provide a blood sample 
(Appendix A and B). Control participants were also recruited within the hospital 
setting. A blood test was used to confirm if control participants were suitable for the 
study, alongside the inclusion and exclusion criteria (Table 5).  
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Table 3: PMR patient screening: inclusion and exclusion criteria. 
Inclusion criteria: 
 Is the patient above 55 but below 85 years old? 
 Does the patient meet 3 or more of the Bird criteria? 
 
Bird Criteria (Bird at al., 1979): 
 Bilateral shoulder pain/stiffness 
 Duration of symptoms <2 weeks 
 Initial ESR >40 mm/h (PV>1.72, CRP>5) 
 Stiffness >1 hour 
 Age >65 years 
 Depression and/or weight loss 
 Bilateral upper arm tenderness 
 
 Currently active disease (CRP≥5, PV≥1.72 or ESR≥29)? 
 
Exclusion criteria: 
 On glucocorticoids (oral or parenteral) or biologic treatment in the last month? 
 Inflammatory diseases such as inflammatory bowel disease, colitis, asthma? 
 Giant cell arteritis? 
 Other auto-immune diseases? 
 Cancer? 
 Infections, treatment with antibiotics within the past 6 weeks? 
 Significant renal disease (creatinine >150 μmol/L and/or eGFR < 30 ml/min)? 
 Significant hepatic impairment? 
 Participation in a clinical trial within the past 30 days? 
 Pregnancy and lactation? 
 Working shift employee? 
 Jet lag? 
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Table 4: RA patient screening: inclusion and exclusion criteria. 
Inclusion criteria: 
 Is the patient above 55 but below 85 years old? 
 Does the patient meet 4 or more of the ACR criteria? 
 
           ACR Criteria (Arnett et al., 1988): 
 Morning stiffness (≥1 hour) 
 Swelling (soft tissue) of three or more joints 
 Swelling (soft tissue) of hand joints (PIP, MCP, or wrist) 
 Symmetrical swelling (soft tissue) 
 Subcutaneous nodules 
 Serum rheumatoid factor 
 Erosions and/or periarticular osteopenia in hand or wrist joints seen on  
radiograph 
 
 Currently active disease (CRP≥5, PV≥1.72 or ESR≥29)? 
 Are there at least 3 tender AND swollen joints? 
 Is morning stiffness ≥ 45 minutes? 
 
Exclusion criteria: 
 On glucocorticoids (oral or parenteral) or biologic treatment in the last month? 
 Inflammatory diseases such as inflammatory bowel disease, colitis, asthma? 
 Co-existent giant cell arteritis? 
 Other auto-immune diseases? 
 Cancer? 
 Infections, treatment with antibiotics within the past 6 weeks? 
 Significant renal disease (creatinine >150 μmol/L and/or eGFR < 30 ml/min)? 
 Significant hepatic impairment? 
 Participation in a clinical trial within the past 30 days? 
 Pregnancy and lactation?                                                          
 Working shift employee? 
 Jet lag? 
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Table 5: Healthy control screening: inclusion and exclusion criteria. 
 
Inclusion criteria: 
 Is the participant above 55 but below 85 years old? 
 Is there any inflammatory rheumatological illness? 
 Is CRP < 5? 
 Is PV < 1.75? 
 
Exclusion criteria: 
 On glucocorticoids (oral or parenteral) or biologic treatment in the last month? 
 Inflammatory diseases such as inflammatory bowel disease, colitis, asthma? 
 Giant cell arteritis? 
 Other auto-immune diseases? 
 Cancer? 
 Infections, treatment with antibiotics within the past 6 weeks? 
 Significant renal disease (creatinine >150 μmol/L and/or eGFR < 30 ml/min)? 
 Significant hepatic impairment? 
 Participation in a clinical trial within the past 30 days? 
 Pregnancy and lactation?                                                          
 Working shift employee? 
 Jet lag? 
 
 
2.1.2 Sample collection and ethical approval 
At the rheumatology clinic at UBHT, approximately 35 ml peripheral blood (PB) was 
taken from adults recently diagnosed with either PMR (n=7) or RA (n=6) who fitted 
the criteria outlined in the previous section. PB samples (approximately 35ml) were 
also taken from participants of a similar age and gender distribution (n=7) who did not 
have an inflammatory condition. C-reactive protein (CRP) and plasma viscosity (PV) 
levels were tested routinely at UBHT for PMR and RA patients in order to confirm the 
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diagnosis. A separate 5 ml blood sample was collected from healthy control subjects in 
order to similarly measure their CRP levels and thus confirm a lack of inflammatory 
disease.  
To account for the fact that pronounced circadian variation of IL-6 occurs in both RA 
and PMR patients (Crofford et al., 1997, Perry et al., 2009), all blood samples were 
taken between 09:00am and 11:00am when IL-6 levels were still high. By rigorously 
controlling the timing of sampling, this allowed direct comparison of patient samples 
and provided a more accurate and consistent way of measuring IL-6 concentrations in 
the blood. Furthermore, as low intensity exercise has been reported to elevate cytokine 
IL-6 levels (Rosendal et al., 2005), participants were encouraged to arrive by pre-paid 
taxi when donating blood for the study. 
The collection of PB complied with the relevant guidelines and institutional and ethical 
practices, as approved by the NRES Committee South West - Frenchay (formerly 
South West 5) (reference number 11/H0107/5) and local Research and Development 
department at UBHT (reference number ME/2011/3679). The samples were made 
anonymous by the research doctor at the clinic by the use of a coding system, prior to 
being transported to UWE by the researcher. This allowed unbiased blind testing of 
samples and ensured patient confidentiality.   
To generate patient serum, an extra 4 ml of blood was collected into a plastic tube 
coated in ‘silica act clot activator’ (BD Biosciences). This was left at room temperature 
to clot for a minimum of one hour. The tube was then placed in a centrifuge 
(Capricorn, Hampshire) for ten minutes at 1600 g to ensure the complete separation of 
the serum from the rest of the blood. The top layer of serum was then removed using a 
plastic Pasteur pipette and stored in 1 or 2 aliquots of approximately 1ml in Eppendorf 
tubes. These aliquots were then frozen at -80°C within the hour (where possible). The 
remaining blood components were destroyed. 
Simultaneously, 35 ml of blood was taken separately in glass tubes containing the 
anticoagulant sodium heparin (BD Biosciences) for transport to UWE. PBMC and 
plasma were separated as detailed below. In accordance with the Human Tissue Act, 
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cells were in culture for no longer than one week, and all remaining sample 
constituents were destroyed at the end of the study. All samples taken to UWE were 
recorded in an electronic tissue ‘ledger’ in order to log the whereabouts of the human 
tissue sample at all times. 
In order to optimise dual staining for surface markers and intracellular IL-6, 10-35 ml 
samples of peripheral blood (PB) were also taken from healthy donors at UWE. The 
collection of PB complied with guidelines and ethical practices set in place by UWE, 
as approved by the ethics committee and under the existing NRES approval. In 
compliance with the Human Tissue Act, the blood donors remained anonymous to the 
researcher, and again an electronic tissue ‘ledger’ was used to log the whereabouts of 
the human tissue sample at all times. Samples were rendered acellular (destroyed by 
autoclaving) within 5 days of extraction. 
 
2.2 Materials 
Unless otherwise stated, all chemicals and reagents were supplied by Sigma Aldrich 
(Dorset, UK), all plastics by Corning (The Netherlands) and all antibodies are listed in 
Table 6. 
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Table 6: List of monoclonal antibodies used in the flow cytometry assays. CD: cluster of 
differentiation, FITC: Fluorescein isothiocyanate, FL: fluorescence, PE: Phycoerythrin. 
Monoclonal 
Antibodies (mAbs) 
 
Clone 
 
Conjugate 
Detection 
channel (FL) 
 
Provider 
 
Anti-human CD3 
 
UCHT1 
 
PE 
 
FL2 
 
Ebioscience, San 
Diego. 
 
Anti-human CD14 
 
61D3 
 
PE 
 
FL2 
 
Ebioscience, San 
Diego. 
 
Anti-human CD19 
 
HIB19 
 
PE 
 
FL2 
 
Ebioscience, San 
Diego. 
 
Anti-human CD123 
 
6H6 
 
PE 
 
FL2 
 
Ebioscience, San 
Diego. 
 
Anti-human CD11c 
 
3.9 
 
PE 
 
FL2 
 
Ebioscience, San 
Diego 
 
Mouse IgG1 k 
Isotype control 
 
P3.6.2.8.1 
 
PE 
 
FL2 
 
Ebioscience, San 
Diego. 
 
Anti-human CD45 
 
- 
 
FITC 
 
FL1 
 
Dako, Cambridge. 
 
Anti-human IL-6 
 
MQ2-13A5 
 
FITC 
 
FL1 
 
BD Biosciences, 
Oxford. 
 
Rat IgG1 k isotype 
control 
 
R3-34 
 
FITC 
 
FL1 
 
BD Biosciences, 
Oxford. 
 
Fixable viability dye 
-  
Efluor780 
 
FL4 
 
Ebioscience, San 
Diego. 
 
2.3 Cell culture, cell lines, primary cells and growth conditions 
2.3.1 Culture and maintenance of B9 cells 
B9 cells (ECCAC no.12121201) were maintained according to instructions provided 
by Leiniz-Institut Deutsche Sammlung Mikroorganism und Zellkulturen GmbH 
(DSMZ) (Brunswick, Germany) at purchase. B9 cells are a murine hybridoma B cell 
line, which are dependent on IL-6 for proliferation (Diamant et al., 1994). Cells were 
cultured at 5% CO2 at 37°C in RPMI 1640 supplemented with: 2 mM L-glutamine 
(Lonza), 50 µM 2-mercaptoethanol, 50 pg/ml recombinant human IL-6 and 20% foetal 
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bovine serum (FBS) (PAA). Cells were cultured in 24-well plates for approximately 
two to three days before being counted and re-seeded at 0.5 x10
6 
cells/ml in complete 
media. Human recombinant IL-6 was added at 50 pg/ml every 1-2 days for the first 
week after the initial seeding to account for the higher metabolic rate of the cells 
(DSMZ, 2013), then every 2-3 days subsequently. B9 cells were starved of IL-6 for 48 
hours before the cell proliferation assays, where approximately 5000 cells were added 
to each well of a 96-well plate. 
2.3.2 Culture and maintenance of Mono Mac 6 cells 
Mono Mac 6 (DSMZ cat no.ACC124), a human cell line which has many similar 
characteristics to mature blood monocytes (Ziegler-Heitbrock et al., 1994), were 
routinely grown in 5% CO2 at 37°C in RPMI 1640 supplemented with: 2 mM L-
glutamine (Lonza); 200 U/ml penicillin; 200 µg/ml streptomycin (Invitrogen); 1 mM 
sodium pyruvate (Lonza); 1% non-essential amino acids (Lonza) and 10% heat-
inactivated FBS (PAA). Cells were cultured in T75 tissue culture flasks for 
approximately three to four days before being counted and re-seeded at 2x10
5 
cells in 
20 ml complete media (as detailed above), or adjusted to 1x10
6 
cells in 1 ml complete 
media and cultured overnight in non-stick polypropylene round-bottom tubes (BD 
Falcon). These cells were used in the flow cytometry assays as a positive control due 
to their reported ability to produce IL-6 when stimulated (Neustock et al., 1993). 
2.3.3 Culture and maintenance of Jurkat cells 
Jurkat E6.1 (ECCAC no.88042803), a human leukemic T cell lymphoblast cell line, 
were maintained at 5% CO2 at 37°C in RPMI 1640 supplemented with: 2 mM L-
glutamine (Lonza), 200 U/ml penicillin, 200 µg/ml streptomycin (Invitrogen), and 
10% foetal bovine serum (PAA). Cells were cultured in T75 tissue culture flasks for 
approximately two to three days before being counted and re-seeded at 2 x10
6  
cells in 
20 ml complete media. When needed cells were adjusted to 1x10
6 
cells in 1ml 
complete media and cultured overnight in non-stick polypropylene round-bottom tubes 
for use in the flow cytometry assays as a positive control due to their ability to 
constitutively produce IL-6 (Khalaf et al., 2010). 
Chapter 2- Materials and Methods 
 
50 
 
2.3.4 Isolation and culture of PBMCs  
Within 0.5 to 2 hours after sample collection, the PBMCs were separated from whole 
blood on Histopaque-1077® by density gradient centrifugation (Hettich Universal 320, 
USA) for 30 minutes at 400 g, room temperature (Hofman et al., 1982). Slow 
acceleration and slow deceleration were used in order to aid the gentle separation of 
the different blood components. 
The overlying plasma (Figure 4) was removed using a Pasteur pipette and separated 
into aliquots. A minimum of four 2 ml cryovials (depending on the amount of plasma 
in the sample) were collected and stored at -80°C until ready for testing by IL-6 
sandwich ELISA, CBA analysis and in the cell proliferation assays. Using a Pasteur 
pipette, the buffy coat layer of PBMC (Figure 4) was then transferred to a sterile 50 ml 
conical centrifuge tube.  
The buffy coat layer was diluted in 40 ml RPMI 1640 and centrifuged at 400 g for 5 
minutes at room temperature with moderate acceleration and deceleration to prevent 
the PBMC from getting stuck to the bottom of the tube. The supernatant was then 
discarded and the cells washed again in 40 ml RPMI 1640 and centrifuged at 400 g for 
5 minutes at room temperature with moderate acceleration and deceleration. The 
supernatant was discarded and PBMC were re-suspended in 1 ml of complete RPMI 
1640 containing 100 U/ml penicillin and 0.1 mg/ml streptomycin (Invitrogen), 4 mM 
L-glutamine (Lonza) and 10 mM HEPES (Lonza). The cells were counted using a 
haemocytometer and viable cells were resuspended in complete media at a final 
concentration of 1x10
6 
cells/ml ready for culture. When in culture, PBMCs were 
maintained at 5% CO2, at 37°C. 
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Figure 4: Separated blood following density gradient centrifugation on Histopaque 1077. The 
PBMCs required for flow cytometric analysis were extracted from the buffy coat layer (grey) 
beneath the layer of plasma (yellow).  
 
2.4 Cytometric Bead Array (CBA) analysis of cytokines in plasma, 
serum and culture supernatant samples   
The cytometric bead array (CBA) human inflammatory cytokines kit and 
Th1/Th2/Th17 cytokines kit (BD Biosciences) were used in order to quantify a range 
of different cytokines including IL-6, IL-8, IL-10, TNF, IL-1β, IL-17, IFNγ, IL-2, IL-
4, and IL-12p70 in plasma, serum and culture supernatant samples taken from the 
study participants, which had been frozen at -80°C for use in these assays.  
2.4.1 Principles of CBA 
CBA is a method of measuring particular analytes within a sample, using capture 
beads with unique fluorescence intensity characterisitics (BD Biosciences, 2010). Each 
bead was labelled with a different intensity of fluorochrome, designed to be resolved in 
Plasma 
Buffy coat layer 
(PBMCs) 
Red blood cells and 
granulocytes 
Histopaque 1077® 
Centrifuge tube 
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the red channel (FL4), and then coated in capture antibodies specific to one cytokine 
(Figure 5). The participant sample was added, and cytokines with the correct 
specificity bound to antibodies coating the beads. Antibodies conjugated to a different 
fluorochrome, PE (resolved in channel FL2), were used to label the captured sample, 
forming sandwich complexes (antibody+antigen+antibody) (BD Biosciences, 2010). 
The brightness of the PE corresponded to the quantity of cytokine in the sample. 
 
 
Figure 5: The principles of cytometric bead array (CBA). Beads with discrete fluorescence 
characteristics were coated in different capture antibodies. Cytokines in the sample with the 
correct specificity bound to the capture antibody. Captured cytokines were detected using 
antibody conjugated to fluorochrome (PE). Samples were then analysed using flow cytometry 
techniques. (Courtesy and © Becton, Dickinson and Company Reprinted with Permission)  
 
The data was analysed using a flow cytometer, with either 6 or 7 bead arrays 
simultaneously resolved in channel FL4 (Figure 6a) and the fluorescence intensity 
corresponding to the amount of bound cytokine resolved in channel FL2 (Figure 6b). 
Five-polynomial standard curves were constructed, using a range of known 
concentrations of each cytokine, allowing the quantification of cytokines in participant 
samples. 
Two different kits were used to measure the 10 cytokines of interest, with each kit 
measuring 6 or 7 cytokines simultaneously, though 3 of the cytokines were measured 
in both kits. The kits were used according to manufacturer’s instructions (BD 
Biosciences) and are now described in detail.  
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          (a)                                                      (b) 
      
Figure 6: Typical CBA plot from an inflammatory cytokine kit (BD Biosciences). Plot (a) 
demonstrates the negative control in which no sample and thus no cytokines were added. Plot (b) 
demonstrates an example of a stimulated PBMC culture supernatant sample with varying levels of 
cytokines.  Each bead corresponds to a different cytokine. 
 
2.4.2 Methods for CBA using the inflammatory cytokine kit 
All lyophilized standards were transferred to a 25 ml centrifuge tube and reconstituted 
together in 2 ml assay diluent (a buffered protein solution provided in kit by BD 
Biosciences). The tube was gently agitated and then left to equilibrate for 15 minutes at 
room temperature before being gently mixed using a pipette. A set of serial 2-fold 
dilutions were then set up by adding 300 μl of the top standard to 300 μl assay diluent, 
gently mixing with a Gilson pipette and then removing 300 μl, which was then added 
to the next tube containing 300 μl assay diluent. Doubling dilutions continued until 
standards ranged from 5000 pg/ml to 2.5 pg/ml. A negative control containing only 
assay diluent was also prepared to serve as the 0 pg/ml standard. 
To mix the cytokine capture beads, each tube containing the capture bead suspensions 
was vortexed vigorously for 3 to 5 seconds before use. Aliquots of 10 μl of each bead 
FL-2- PE FL-2- PE 
FL-4- unknown fluorochrome 
(resolved in red channel) 
FL-4- unknown fluorochrome 
(resolved in red channel) 
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mixture (per assay tube) were added to a single tube (for example, 30 assay tubes x 10 
μl = 300 μl of each bead mixture). The tube containing all the aliquots was then mixed 
thoroughly by vortexing vigorously for 10 seconds. 
The mixed capture beads were then centrifuged at 200 g for 2.5 minutes, and the 
supernatant carefully aspirated and discarded using a pipette. The mixed capture bead 
pellet was resuspended in ‘serum enhancement buffer’ (equal to the volume of liquid 
previously discarded) and vortexed thoroughly for 10 seconds to ensure that the pellet 
was thoroughly resuspended. The serum enhancement buffer was a protein solution 
provided by BD Biosciences which had the function of blocking endogenous human 
anti-mouse antibodies in the patient samples of plasma and serum that could 
potentially react with antibodies used in the assay, giving false-positive results. The 
mixed capture beads were then incubated for 30 minutes at RT, protected from the 
light to reduce fluorescence quenching.   
The capture beads were mixed using the vortex and 50 µl of the bead suspension was 
added to all assay tubes. Next, 50 µl of the human inflammatory cytokine standard 
dilutions and negative control (assay diluent only) were added to the appropriate 
standard tubes. The unknown samples were added at a volume of 50 µl to the 
remaining tubes. The samples were incubated for 1.5 hours at RT, and protected from 
light. 
Following the incubation, 1 ml of wash buffer (a PBS solution containing protein 
detergent, BD Biosciences) was added to each assay tube which were then centrifuged 
at 200 g for 2.5 minutes. The supernatant was carefully aspirated and discarded, 
leaving approximately 100 µl liquid in each assay tube. To this, 50 µl human 
inflammatory cytokine PE detection reagent was added. The tubes were then gently 
agitated to resuspend the pellet. The assay tubes were incubated for a further 1.5 hours 
at RT, protected from light, again to reduce quenching.  
At this point, 1 ml of wash buffer was added to each assay tube and the tubes were 
centrifuged at 200 g for 2.5 minutes. The supernatant was then carefully aspirated and 
discarded from each assay tube. The bead pellet was resuspended in 200 μl 1% 
Chapter 2- Materials and Methods 
 
55 
 
paraformaldehyde to kill any harmful bacteria or viruses that may be present in the 
biological samples, making them safe to analyse by flow cytometry. The samples were 
incubated at RT for 10 minutes. Following this, 800 μl wash buffer was added to each 
tube to dilute the paraformaldehyde, and the tubes were centrifuged at 200 g for 2.5 
minutes. The supernatant was discarded appropriately and the pellet resuspended once 
more in 300 µl of wash buffer per assay tube, ready for acquisition. 
Samples were acquired on an Accuri C6 flow cytometer, set to collect 2100 events on 
a medium flow rate to reduce the chance of missing dimly stained particles (BD 
Biosciences, 2010). Results were analysed using FCAP Array software (SoftFlow Inc., 
Hungary). Five parameter logistic (5PL) standard curves were constructed as 
recommended by BD Biosciences and cytokine concentrations were extrapolated 
accordingly. The theoretical limits of detection for the kits were as follows; IL-6: 2.5 
pg/ml, IL-8: 3.6 pg/ml, IL-10: 4.5 pg/ml, IL-4: 4.9 pg/ml, TNFα: 3.8 pg/ml, IFNγ: 3.7 
pg/ml, IL-2: 2.6 pg/ml, IL-12p70: 1.9 pg/ml, IL-17A: 18.9 pg/ml and IL-1β: 7.2 pg/ml. 
2.4.3 Methods for CBA using the Th1/Th2/Th17 cytokine kit 
The same methods were used as for the inflammatory cytokines except for the 
following difference: 
 When plasma/serum or supernatant samples were added to the bead mixture, 50 
μl human Th1/Th2/Th17 cytokine PE detection reagent was also added at the 
same time. These tubes were then incubated for 3 hours at RT, protected from 
light to reduce fluorescence quenching. 
 Following this, the samples were washed, fixed and analysed as previously 
described for the inflammatory cytokines kit. 
CBA was used to assess cytokine concentrations in serum, plasma, and PBMC culture 
supernatants. Due to the cost of the kits and limited volumes of sample, the CBA was 
run twice for the plasma samples (2x inflammatory cytokines kit and 2x Th1/Th2/Th17 
cytokines kit) and only once for the serum and culture supernatants using each kit. As 
both kits measured TNF, IL-6 and IL-10, these three cytokines were measured four 
times in the plasma, and twice in the serum and culture supernatants. A geometric 
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mean was taken (of either two repeats or four repeats) which took into account the fact 
that the sensitivities of both kits differed slightly. Each value was logged (to the base 
10), the mean calculated and then inverse LOG10 was applied to the values.  
 
2.5 Using sandwich enzyme-linked immunosorbent assays (ELISAs) 
to measure secreted analytes in serum, plasma and PBMC culture 
supernatants 
The human IL-6 sandwich enzyme-linked immunosorbent assays (ELISAs) (R&D 
Systems) were performed in order to quantify the amount of IL-6 in the plasma, serum 
and PBMC culture supernatants from study participants 1-19 and the pilot sample. The 
kit was used according to the manufacturer’s instructions (R&D systems), with a few 
minor alterations which are detailed below.  
A 96-well Maxisorp® immunoplate (Nunc) was coated in 100 µl mouse anti-human 
capture antibody (2.0 µg/ml) diluted in PBS without carrier protein. Plates were sealed 
with adhesive strips (R&D systems) and incubated at 4⁰C for a minimum of 48 hours 
for optimal binding. The plate was washed three times with 300-400 µl of wash buffer 
(0.05% Tween 20 in PBS) per well for each wash and incubated for 30 seconds per 
wash, in order to remove excess unbound antibody. Plates were blotted dry between 
each wash to ensure that any wash buffer or unbound antibody had been removed from 
the wells.  
Following the wash step, 200 µl of reagent diluent (1% BSA in PBS) was then added 
to each well for one hour to block non-specific antibody binding prior to the samples 
being added. Standards and sample dilutions were prepared in reagent diluent during 
this time. Plasma and serum were not diluted as IL-6 levels were expected to be low 
and thus within range. Stimulated PBMC supernatants required a dilution of 1 in 20 in 
reagent diluent in order to fit within the limits of detection. The plate was thoroughly 
washed again three times with wash buffer (300-400 μl per well) and the samples were 
added to appropriate wells at 100 μl per well (Figure 7). The plate was then incubated 
overnight at 4°C to allow the antigen to bind with the immobilised capture antibody. 
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The following day the plate was washed 3 times, again with 300-400 μl of wash buffer 
per well and per wash, to remove excess unbound sample. The detection antibody, 
biotinylated goat anti-human IL-6, was then diluted to a working concentration of 50 
ng/ml in reagent diluent and added to the plate (100 μl per well). The plate was 
incubated at room temperature (RT) for 2 hours, to allow the secondary antibody to 
bind to the captured IL-6 antigen.  
The plate was then washed again three times using 300-400 μl per well of wash buffer 
for each wash to remove any excess unbound detection antibody, and 100 µl of 
streptavidin conjugated horseradish-peroxidase (SHRP) was added to each well for 30 
minutes at RT, avoiding exposure to quenching light (Figure 7). The plate was then 
washed once more with wash buffer (300-400 μl per well for each wash) and 100 µl of 
substrate solution (H2O2 and the chromogen Tetramethylbenzidine) was added to each 
well. The oxidation reaction between the SHRP and TMB (in the presence of H2O2) 
formed a blue product (Figure 7). The plate was incubated for a further 40 minutes in 
the dark at RT to allow the enzymatic colour reaction to develop. The reaction was 
stopped by the addition of 50µl 2NH2SO4 which turned the blue to yellow.  
The optical density (OD) of the substrate colour change was determined at 450 nm on 
an Anthos HT11 plate reader (Anthos Labtech, Salzburg Austria). A reading at 540 
nm was taken and then subtracted from the reading at 450 nm to correct for optical 
imperfections in the plate (R&D Systems, 2013). A four polynomial standard curve 
was generated on GraphPad Prism software, which Herman and colleagues suggest 
provides ‘more precise and less biased’ estimates for samples measured by sandwich 
ELISA than the 4-parameter logistic model (Herman et al., 2008). The amount of IL-6 
in the samples was quantified by extrapolating values from the graph based on the OD 
of the sample, giving a final concentration of IL-6 in pg/ml.  
Each sample was tested in triplicate, except for the serum ELISAs which were tested in 
duplicate due to the limited volume of sample. Plasma ELISAs were independently 
repeated three times, whilst serum was independently repeated twice, again due to 
limited volumes of the samples. Mean values of these repeats were taken for 
subsequent analysis. 
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Figure 7: The main stages involved in the sandwich ELISA used to quantify IL-6 in the plasma and serum.  (a) A 96-well plate is coated with IL-6 capture 
antibody (Ab) diluted in PBS. Following a wash, the sample or standards are added and IL-6 present in the sample binds to immobilised capture Ab. 
Materials that do not bind are washed away. (b) IL-6 detection Ab (conjugated to enzyme SHRP) is added, which binds to the captured IL-6.  Detection Ab 
that did not bind is washed away. (c) Addition of the substrate solution (TMB and H202) results in the development of a blue colour. Colour development is 
proportional to the quantity of IL-6 present. The addition of H2SO4 prevents any further reaction and turns the blue colour to yellow. The absorbance is 
measured at 450 nm. (Courtesy and © R&D Systems Reprinted with Permission) 
a) c) b) 
Key: 
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2.6 Testing the bioactivity of IL-6 in study participant plasma samples 
using the MTS cell proliferation assay 
Whilst immunoassays such as CBA and ELISA are useful for the detection of 
cytokines in plasma and serum, they only indicate the presence of ‘immunologically 
reactive’ molecules, and not necessarily ‘biologically active’ molecules (Mire-Sluis 
and Thorpe, 1998). B cell proliferation assays have previously been conducted using 
IL-6-dependent B9 cells in order to detect IL-6 production in synoviocytes in RA 
patients, confirming the biological activity of the IL-6 present in the joints of these 
patients (Guerne et al., 1989, de Bendetti et al., 1991, Rosenbaum et al., 1992). The 
biological activity of elevated circulating IL-6 in PMR, however, has not previously 
been tested. 
Thus, in order to test the biological activity of the IL-6 present in the study participant 
plasma samples, the ability to stimulate proliferation of the IL-6 dependent murine 
hybridoma cell line, B9 (Helle et al., 1988) was measured using CellTiter96® 
Aqueous One Solution (Promega). This colorimetric assay was centred around the 
bioreduction of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) by viable B9 cells into a coloured soluble formazan 
product which could be quantified by measuring the absorbance of the culture medium 
at 450 nm (Promega, 2012). The extent of the colour change was directly proportional 
to the amount of living cells in culture, and the amount of living cells in culture was 
directly proportional to the concentration of IL-6 in the samples.  
A negative control of RPMI 1640 media containing 2 mM L-glutamine (Lonza) and 50 
μM 2-ME was added to the first column (50 μl per well) and top row of a flat-
bottomed 96-well plate (Nunc). The recombinant IL-6 was serially diluted (10-fold 
dilutions) in RPMI 1640 (containing 2 Mm L-glutamine and 50 μM 2-ME), from 
50000 pg/ml to 0.5 pg/ml in Eppendorf tubes. The standards were then added in 
duplicate wells across the bottom two rows of the plate (Nunc) at 50 μl per well. 
The plasma samples (from study participants 1-19) to be measured were heat 
inactivated in order to deactivate complement pathways, by placing the samples in a 
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water bath at 56°C for 35 minutes (Madhok et al., 1993).  Exactly 48 μl of each 
sample was added to the wells of a 96-well Maxisorp® immunoplate (Nunc). The 
samples were added in triplicate, with the first two wells also containing 2 µl of RPMI 
1640, and the third well also containing 2 μl of the monoclonal anti-human interleukin 
6 neutralising antibody (at a final concentration of 50 ng/ml). This was in order to 
subtract the levels of background stimulation, caused by other factors present in the 
plasma samples. The plate was equilibrated at 37°C in a humidified 5% CO2 
atmosphere for one hour so that the antibody had time to bind and neutralise the IL-6 
in the sample, while the cells were harvested for use in the assay (Soman et al., 2009). 
The B9 cells were washed twice in RPMI 1640 (containing 2 mM L-glutamine and 50 
mM 2-ME) by centrifugation (Hettich Universal 320, USA) at 400 g for 5 minutes per 
wash. The cell number and viability were determined by trypan blue exclusion and 
cells were resuspended at a final concentration of 1x10
5 
cells/ml viable cells in RPMI 
1640 with supplements but no IL-6 or FCS. Following this, 50 µl of the cell 
suspension (approximately 5000 cells) was dispensed into all wells of the plate, to 
make a final volume of 100 µl per well. The plate was then incubated for 72 hours at 
37°C in a humidified 5% CO2 atmosphere (Madhok et al., 1993). 
The CellTiter96® Aqueous One Solution (Promega) was thawed in a water bath at 
37°C for ten minutes. The plate was then collected and cells were mixed gently using a 
pipette in order to disrupt any clumps of cells. Precisely 20 μl of the MTS stock was 
pipetted into each well of the 96-well assay plate containing the samples and standards. 
This was then incubated for 4 hours in a humidified, 5% CO2 incubator.  
A multichannel pipette was used to gently mix the samples three times to ensure 
homogeneity of the colour and the absorbance was then read at 450 nm using an 
Anthos HT11 plate reader (Anthos Labtech, Salzburg Austria). The absorbance of the 
standards at 450 nm was plotted against the concentration of the recombinant IL-6 
present and a four-parameter regression curve fitted. The unknown concentrations of 
biologically active IL-6 in the plasma samples were then interpolated from this 
standard curve. The mean value of the 2 duplicate wells was calculated for each 
sample, and the value from the well containing IL-6 neutralising antibody subtracted to 
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account for the fact that other cytokines and growth factors may be present in the 
plasma samples. Three independent repeats of the assay were carried out.  
Titration of the neutralising antibody was performed prior to the assays to determine 
the optimal concentration required to neutralise the concentrations of IL-6 expected in 
the participant samples. For this, a range of concentrations of recombinant IL-6 
(0.00025-25 ng/ml) were incubated with a range of concentrations of the IL-6 
neutralising antibody ((0.000-50 µg/ml). The inhibitory effects of the IL-6 neutralising 
antibody were observed and the concentration which reduced B9 cell growth for the 
longest and broadest range was chosen as the concentration to use in the B9 cell 
proliferation assays.   
 
2.7 Fatigue analysis 
At the time of blood sample extraction, patients and healthy controls were asked to 
complete the BRAF-MDQ, in order to assess levels of fatigue, a prominent feature of 
both RA and PMR. Each participant scored themselves on four individual aspects of 
fatigue, namely physical fatigue, fatigue associated with day-to-day living, cognitive 
fatigue, and emotional fatigue. These scores were then added together to give an 
overall fatigue score (Appendix A).  
The scores for the individual aspects of fatigue and the overall fatigue scores were then 
plotted against the concentration of IL-6 measured in the plasma and serum by CBA to 
determine if there was any significant correlation between them. The correlation 
between various clinical measures of PMR and RA disease (such as CRP and PV 
levels) and the overall and individual aspects of fatigue was also investigated.  
In order to determine whether other pro-inflammatory cytokines may be involved in 
fatigue, the correlation coefficients between plasma and serum concentrations of 
cytokines measured by CBA and the fatigue scores were also generated.  
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2.8 Preparation of PBMC and positive control cell line for 
immunostaining and flow cytometry 
2.8.1 PBMC overnight culture 
To prevent the known attachment of monocytes to plastic in culture, 1 ml PBMC 
volumes (containing 1x10
6
 cells) were cultured in sterile round-bottom polypropylene 
tubes (BD Falcon) (Kelley et al., 1987). Cells were then stimulated as described below 
or they were cultured without stimulation in 5% CO2 at 37°C, to see if the patients’ 
cells constitutively produced IL-6. In one tube, 50% of cells were heat-killed in a water 
bath (65°C for 1 minute, followed by 1 minute on ice) to function as a positive control 
for the viability dye, used later to exclude dead cells from the analysis.  
2.8.2 Stimulation of PBMCs 
Prior to testing patient samples, a range of stimulants were explored using PBMC 
isolated from healthy control blood from donors at UWE, Bristol. Phorbol 12-
myristate 13-acetate (PMA) and Ionomycin (used simultaneously) and 
phytohemagglutin (PHA) were tested for their ability to stimulate the populations 
within the PBMC to produce IL-6, using the same isolation and culture methods 
described previously. PMA and Ionomycin together make a potent T cell mitogen 
(Touraine et al., 1977), and were used at final concentrations of 10 and 100 ng/ml 
respectively. PHA, also considered to stimulate T cells and monocytes to their full 
cytokine-producing capacities (Baran et al., 2001), was used at a final concentration of 
2.5 μg/ml. Lipopolysaccharide (LPS) from Escherichia coli serotype 0111:B4 and 
interferon gamma (IFNγ) were eventually selected to stimulate the PBMCs in the flow 
cytometry assays, due to their ability to promote both cell surface marker up-regulation 
and IL-6 production, in most or all cell types in healthy participants. 
Lipopolysaccharide (LPS) was added to the appropriate tubes at a concentration of 1 
μg/ml for the full 24 hours of culture. IFNγ was added to these same tubes for the final 
four hours of culture at a concentration of 100 ng/ml. Monensin (GolgiStop®, BD 
Biosciences) was also added to all tubes at 4 μM for the final four hours of culture to 
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prevent Golgi export of cytokines and thus to enable intracellular detection of IL-6 
(Pala et al., 2000). When added to PBMC cultures overnight, monensin had a toxic 
effect on the cells. Cells were also stimulated with LPS and IFNγ as above, but in the 
absence of monensin, to allow the concentration of secretory cytokines in the culture 
supernatant to be measured.  
2.8.3 Positive control cell lines 
Two cell lines were investigated as potential positive controls for the intracellular IL-6 
staining; Mono Mac 6 (MM6) cells and Jurkat T cells. Initially, during assay 
optimisation, MM6 cells were stimulated with PHA at 10 µg/ml for 24 hours and 
stained for intracellular IL-6 alongside the PBMC. MM6 cells have many similar 
characterisitics to mature blood monocytes and reportedly produce potent amounts of 
IL-6 both constitutively and following stimulation for 24 hours with PHA (Neustock et 
al., 1993). Results, however, were found to be extremely variable between assays 
(n=8) for reasons which were not fully determined, but may relate to the age of the 
cells and the high passage number. Infection, incubator CO2 levels and temperature 
were investigated and consequently ruled out. As a result of this inconsistency, Jurkat 
cells were similarly tested and then chosen as the positive control for the IL-6 antibody 
staining to be run alongside the PBMC in each assay. The Jurkat cells were left 
unstimulated as they were known to constitutively produce IL-6 (Khalaf et al., 2010).  
 
2.9 Immunohistochemistry and flow cytometric analysis of PBMC 
preparations 
After 24 hours of incubation, samples were examined by intracellular staining for the 
presence of IL-6. At this point, the tubes containing cells which had not been treated 
with monensin were spun down in a centrifuge (DADE Immufuge 569) at 650 g for 2 
minutes in order to pellet the cells. The culture supernatants were collected and stored 
in cryovials at -80°C until ready for testing by cytometric bead array (CBA) and 
sandwich ELISA.      
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2.9.1 Staining the non-viable cells 
PBMCs were washed twice in cold phosphate buffered saline (PBS) and re-suspended 
in 1 ml PBS ready for staining with the viability dye, eFluor780. Subsequently, 1 μl of 
the dye was added to each tube, except the control tubes with single stains (for colour 
compensation). The tubes were then incubated at 4°C for 30 minutes to allow the dye 
to bind, protected from light in order to prevent the fluorophore from quenching. 
2.9.2 Cell surface marker staining  
Following a wash in 1 ml PBS to remove excess dye, cells were resuspended in PBS 
containing 10% BSA for 15 minutes (5% CO2, 37⁰C) in order to block non-specific Fc 
antibody (Ab) binding. Cells were washed and stained with mouse monoclonal PE- 
conjugated Abs against the cell surface markers (Davenport et al., 2003) including 
CD3, CD14, CD19, CD123 or CD11c or isotype control, diluted in PBS (containing 
1% BSA and 1% sodium azide) and incubated for 45 mins at 4°C in the dark.  
During optimisation of the assay a range of dilutions were made for each antibody to 
determine the concentration required for optimal staining (1.5:10- 1.25:100). The final 
antibody concentrations chosen for use in the flow cytometry assays were as follows: 
anti-human CD3: 5 µl, anti-human CD14: 5 µl, anti-human CD19: 10 µl, anti-human 
CD123: 5 µl and anti-human CD11c: 2.5 µl (per 100 µl cell suspension, containing 
1x10
6
 cells). 
Stained samples were washed twice with cold PBS to remove excess antibody, then 
fixed with 1% paraformaldehyde (PFA) for 20 minutes at 4°C.  
2.9.3 Intracellular IL-6 staining 
Cell membranes were permeabilised by treatment with saponin (0.1% in PBS) for 30 
minutes at room temperature. Permeabilised cells were washed and stained with FITC-
conjugated anti-human IL-6 antibody or matching isotype control antibody diluted in 
0.1% saponin in cold PBS for 60 minutes at 4°C. The cells were washed twice in the 
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permeabilisation buffer to allow any internal unbound antibody to wash out of the 
cells, and then re-suspended in PBS containing 0.5% BSA for flow cytometric 
analysis. 
2.9.4 Flow cytometric analysis 
Cells were analysed on an Accuri C6 flow cytometer set to collect 10,000 events. 
PBMCs were gated based on forward scatter and side scatter properties. FITC labelled 
cell signals were resolved on channel FL1. PE labelled signals were resolved on 
channel FL2, and the viability dye, Efluor780 was resolved on channel FL4. 
2.9.5 Gating strategy used to determine IL-6 positive and negative PBMC 
populations 
Initial gating was based on excluding obvious dead cells and cell debris (Figure 8a). 
The viability dye, Efluor780, was used to stain dead cells within the gated population 
which had the potential to interfere with staining compensation. Cells stained with the 
dye were excluded from analysis (Figure 8b) as it is thought that dead cells are 
associated with ‘non-specific and erratic antibody binding’ (Pembroke et al., 2013) 
which may compromise the results. 
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Figure 8: Gating strategy used to exclude dead cells and cell debris from analysis. Plot (a) 
demonstrates a forward and side scatter plot of a PBMC sample. Dead cells and cell debris with 
very low FSC-A values (<~400,000) were not included in the collection gate and thus were not 
included in the analysis. 10,000 events were collected within the gate. Plot (b) demonstrates an 
example of positive control PBMCs (approx. 50% heat-killed), dyed with Efluor780. This allowed 
dead cells to be located within the gated population, which were subsequently excluded from 
further analysis. 
Fluorescence compensation was then carried out using the brightest FITC and PE 
single stains as controls (CD3-PE and CD45-FITC) (Figure 9) to correct for 
‘fluorescence spillover’ between channels (Maecker and Trotter, 2006). 
           
Figure 9: Compensated single stains for (a) CD3-PE and (b) CD45-FITC. Single staining is shown 
with minimal (<1%) spill over into the regions highlighted (orange stripes)- achieved by 
subtracting a percentage of the fluorescence which is showing up in the neighbouring channel.  
(a) 
(a) 
(b) 
(b) 
Forward scatter 
Side scatter Cell count 
Cell viability- Efluor 780 
No FITC CD45- FITC 
CD3- PE No PE 
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Quadrants to determine the percentage cell type and level of IL-6 staining above 
background were set based on the position of the FITC and PE isotype controls, 
leaving 1% in neighbouring quandrants as standard to enable detection of minor 
changes in fluorescence (Figure 10). Isotype controls are antibodies of identical class 
or isotype of immunoglobulin as the antibodies under study, however, these antibodies 
are generated against an antigen that is not present on the cells used in the study, thus 
act as a negative control for background or nonspecific staining (Hulspas et al., 2009). 
 
 
Figure 10: Setting of quadrants using isotype controls. 
 
Fluorescence minus one (FMO) controls were used to confirm the suitability of the 
gates set using the isotype control antibodies, as isotype controls have recently been 
questioned as suitable control measures. FMO controls are separate samples which are 
stained with all of the antibodies used in the assay, minus one (Hulspas et al., 2009). In 
this case, cells were labelled with PE conjugated antibodies and the viability dye, 
excluding the FITC-conjugated antibody, and then vice versa (FITC and Efluor780, 
but not PE). As samples are stained with all fluorochromes (minus one), they show the 
PE isotype control 
FITC isotype control 
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amount of fluorescence spill over from other channels in the particular channel of 
interest (Maecker and Trotter, 2006). Minimal spill over (<1%) was observed between 
fluorochromes using FMO controls (highlighted) and accorded with gates set using 
isotype controls (Figure 11a and b). Figure 11a demonstrates minimal spill-over 
(0.7%) into the FL1 channel when looking at PBMC stained with PE conjugated anti-
CD3 antibodies (detected in FL2 channel) and the Efluor780 viability dye (detected in 
the FL4 channel). Figure 11b demonstrates minimal spill-over (0.2%) into the FL2 
channel when looking at PBMC stained with FITC conjugated anti-CD45 antibodies 
(detected in the FL1 channel) and the Efluor780 viability dye (detected in the FL4 
channel). 
 
(a)                                                         (b) 
               
Figure 11: Setting gates using ‘fluorescence minus one’ (FMO) controls.  
 
2.9.6 Staining and acquisition of samples 
After gating was set on negative controls, the quantity of IL-6 in each cell type (CD3+, 
CD14+, CD19+, CD123+ or CD11c+) was observed by looking at the percentage of 
cells which were positive for IL-6 and the median fluorescence intensity (MFI) of the 
No FITC CD45- FITC + Efluor780 viability dye 
CD3- PE + Efluor780 viability dye 
No PE 
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IL-6 staining. As MFI measures the intensity of IL-6 staining within each cell 
population, and thus the relative amount of IL-6, it may be more important than 
looking at the percentage of positive cells, in terms of finding the cell type responsible 
for spontaneous production of IL-6 in PMR patients. MFI data for PMR has not been 
previously reported.  
Cells which appeared in the top two quadrants (Figure 12a) were cells which were 
stained for the cell surface marker, and cells in the two right hand quadrants were 
considered to be cells stained for intracellular IL-6 (Figure 12b). Therefore, any cells 
in the top right-hand quadrant were considered to be the cell type of interest, stained 
for intracellular IL-6 (Figure 12c). 
In total, twenty samples were tested, including one pilot sample which was not 
included in the flow cytometry results due to slight variations in the permeabilisation 
method and discrepancies with the timing of sampling. For each participant, the 
PBMCs were isolated and resuspended ready for culture within 3 hours of the sample 
being taken. All cells, including the positive control Jurkat cells, were cultured for 24 
hours, with or without stimulation. The staining process was started immediately after 
this 24 hour culture period, and all cells were fixed within 3 hours of starting this 
process. Data was acquired on the flow cytometer within 24 hours of fixation. Controls 
were run alongside each sample and the gates and the quadrants were set specifically 
for each individual participant in order to account for slight differences in temperature 
or timings that may have affected the results. 
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Figure 12:  IL-6 production in CD3+ T cells from a healthy individual.  
 
2.9.7  Calculating the absolute numbers of specific PBMC types producing IL-6 
in each subject 
The absolute number of each cell type which were producing IL-6 in each subject was 
also calculated, using the percentage of each cell type that were positive for IL-6 in a 
(a) 
(c) 
(b) 
CD3- PE 
IL-6- FITC 
IL-6- FITC 
IL-6- FITC 
CD3- PE 
CD3- PE 
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resting state (measured using flow cytometry) and the total white cell counts (WCCs) 
performed on PMR and RA patient blood samples in the hospital laboratories at 
UBHT. The PMR WCCs were performed during the same week as the flow cytometry 
assays, whereas the RA WCCs were performed at different times (date not provided). 
The WCCs were not performed on the healthy control samples so normal reference 
ranges for healthy adults have been provided (Table 12). 
Firstly, the total percentages of the five PBMC cell types in each subject were added 
together. The percentage of each cell type was then divided by the total percentage of 
all the cell types and multiplied by one hundred to give the proportion of each cell type 
in each patient. This proportion (represented as a percentage) was then multiplied by 
the total white cell count, to give the total amount of each cell type in each subject 
(Table 13). 
The absolute number of each cell type which were positive for IL-6 was then 
calculated by multiplying the percentage of IL-6 positive cells (calculated previously 
using flow cytometry) by the total number of each cell type in each subject. These 
values were then compared to normal reference ranges. Unpaired T tests were used to 
determine if there were any significant differences between the number of IL-6 
positive cells in PMR patients, RA patients and healthy control patients, for each cell 
type.    
 
2.10 Statistical analysis 
2.10.1 Statistical analysis plan 
Where samples were found to be normally distributed (i.e. Gaussian), unpaired T tests 
were employed to detect whether the means of the different disease groups or healthy 
control group were significantly different. PMR or RA patient groups were compared 
with relevant controls, i.e. RA vs HC, PMR vs HC, and finally PMR vs RA. P-values 
of 0.05 or below were considered to be significant. When exploratory T-tests were 
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used to look for potential differences between groups (when null hypothesis not 
previously applied), the Bonferroni test was used to correct for multiple comparisons, 
i.e. the defined significance threshold (0.05) was divided by number of comparisons, 
and that value accepted as the significance threshold (Bland, 1995). If independent 
repeats gave similar patterns but very different values, the geometric mean of the data 
was taken in order to normalise the data. 
When looking for correlation or a relationship between sets of data, the two sets of 
data were plotted against each other in a scatter plot and the Pearson correlation 
coefficient (r), R-squared value (r
2
) and P-value (p) were determined. To confirm the 
correlation and judge whether results from different methods sufficiently agree, Bland-
Altman plots were employed. In some cases, where determining Pearson correlation 
coefficients was not suitable, Spearman’s rank correlation coefficients were 
determined, then judged whether significant at a 5% probability level using pre-
determined critical values.  
When these statistical tests were not appropriate, descriptive statistics were used to 
provide a simple summary of the overall pattern of the results. 
2.10.2 Geometric mean 
To work out the geometric mean, each value from each independent repeat was logged 
(to the base 10) and the mean of these values was calculated. The inverse LOG(10) was 
then applied to this value to give the geometric mean. If the initial values were 0 or 
were negative values, an arbitrary number was added to all scores before the initial log 
stage, then subtracted again from the final value.  
2.10.3 Bland-Altman plots 
The methods used to test clinical samples were compared using Bland-Altman plots. 
Here, the mean of the two values measured (x axis) was plotted against the difference 
between the two values measured (y axis). The level of agreement in methods could be 
visualised by determining the level of scatter about zero (zero being that there was no 
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difference between values measured by the two methods). The direction of scatter gave 
an indication of bias in favour of one of the methods. By applying a regression line 
with 95% confidence bands the bias could be detected if it was not obvious by initial 
visualisation. 
2.10.4 Graphical representation 
Graphical representation and the majority of statistical analysis were performed in 
Microsoft Excel 2007/2010 and GraphPad Prism 5. CBA data was analysed using 
FCAP Array software (SoftFlow Inc., Hungary). 
In order to present the growth kinetics of the B9 cells for the IL-6 bioactivity assays, 4-
parameter log regression standard curves were constructed using GraphPad Prism 5. 
For the IL-6 ELISA standard curve, a 4-polynomial curve was constructed using the 
same software. 
All values quoted represent mean ± standard error of the mean (SEM) of the sample 
unless stated otherwise.    
Chapter 3 - Results 
74 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
 
 
 
 
 
 
 
 
 
 
  
Chapter 3 - Results 
75 
 
 
The results section is presented in the same order as the aims and objectives (Section 
1.16), so as to address each one systematically. Where appropriate, results from the 
pre-optimisation assays are presented before the results of the clinical investigation. 
 
3.1 IL-6 and the pathogenesis of PMR and RA 
 
3.1.1 Participant demographics 
The clinical data and demographics of the 20 study participants are set out in Table 7. 
 
Table 7: Demographics of the PMR and RA patients and healthy controls. 
 PMR patients 
(n=7) 
RA patients 
(n=6) 
Healthy controls 
(n=7) 
No. of 
females/males 
6/1 4/2 5/2 
Age, mean (range) 
years 
75 (65-88) 67 (55-75) 63 (59-71) 
CRP, mean (range) 
mg/dL 
33.4 (11-102) 13.5 (4-29) 2 (1-5) 
Total white blood 
cell count (10
3
/µL) 
7.9 (5.4-9.4) 7.6 (7.0- 10.5) - 
 
3.1.2 IL-6 in the plasma and serum measured by CBA (refer to Aim 1 in Section 
1.16) 
Various studies have established that systemic IL-6 is raised in the plasma or serum of 
PMR (Cutolo et al., 2006) and RA (Arvidson et al., 1994) patients compared to 
healthy controls. In order to confirm this, the concentration of IL-6 was measured in 
the plasma of 7 PMR patients and 6 RA patients alongside 7 healthy controls of a 
similar age. 
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Figure 13: The concentration of IL-6 measured by CBA in the plasma and serum of RA and PMR 
patients alongside healthy control participants of a similar age. The concentration of IL-6 was 
measured in (a) the plasma and (b) the serum of each study participant using CBA. Each data 
point represents the geometric mean of cytokine concentration for each study participant (n=2 
repeats for serum and n=4 repeats for plasma). The solid red line represents the mean of the 
patient or control group. The dotted red line represents the lower threshold limit of the CBA kit. 
*P< 0.05 **P< 0.01 NS=P> 0.05 
(a) 
(b) 
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As hypothesised, IL-6 concentrations were significantly elevated in the plasma of 
PMR (P< 0.01) and RA (P< 0.05) patients compared to healthy controls of a similar 
age (Figure 13a) when measured using CBA. The mean plasma concentration of IL-6 
in PMR patients was 12.8 pg/ml (range: 3.3-24.1 pg/ml), compared to 17.5 pg/ml 
(range: <2.5-41.2 pg/ml) in RA patients. In contrast, the concentration of IL-6 in all 
healthy controls fell below the sensitivity threshold for the assay (<2.5 pg/ml). There 
was no significant difference between the means of the plasma IL-6 concentration in 
PMR patients and RA patients. 
To determine if there was a difference in the result when using patient plasma or 
serum, the concentration of IL-6 in the serum of study participants (extracted in the 
clinic) was also measured by CBA. Again, the concentration of IL-6 was significantly 
raised in the serum of PMR (P< 0.05) and RA (P< 0.05) patients compared to healthy 
controls of a similar age (Figure 13b). The mean serum concentration of IL-6 in PMR 
patients was 15.1 pg/ml (<2.5-35.2 pg/ml), compared to 25.7 pg/ml (<2.5-56.5 pg/ml) 
in RA patients, and again all healthy controls fell under the sensitivity threshold for the 
assay (<2.5 pg/ml). As for plasma, there was no significant difference between the 
mean of the serum IL-6 concentration in PMR patients and RA patients. 
 
3.1.3 The correlation between IL-6 measured in the plasma and serum by CBA 
(refer to Aim 2 in Section 1.16) 
The correlation between IL-6 measured in the plasma and serum (by CBA) was 
examined (Figure 14) in order to observe whether these different methods of sample 
preparation produced comparable results. The concentration of IL-6 in the plasma and 
serum of study participants correlated well, with a high correlation coefficient (r) of 
0.961 and a P-value of less than 0.0001 (***). The angle of the regression line, 
however, is >45° demonstrating that serum-derived IL-6 concentrations were 
consistently higher than those derived from patient plasma samples. 
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Figure 14: The correlation between IL-6 measured in the plasma and serum of RA and PMR 
patients. Each data point represents the geometric mean of each study participant of n= 2 repeats 
for serum and n=4 repeats for plasma. The correlation coefficient, r = 0.961, ***P< 0.0001. 
 
Bland and Altman also provide a method of comparing clinical measurement, in order 
to judge whether results from different methods sufficiently concur, as the use of 
correlation can hide disagreement, especially at the lower end of the data (Bland and 
Altman, 1986). Figure 15 demonstrates the Bland Altman method of comparison of 
the plasma and serum values measured by CBA.  
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Figure 15: Bland Altman plot comparing IL-6 concentrations measured in the plasma and serum 
of RA and PMR patients and healthy controls of a similar age. Each data point represents one 
participant. 
 
By initial observation it can be seen that at low concentrations of IL-6 there is close 
agreement, i.e. the difference between the means is close to zero. All the values, 
however, are below zero suggesting a minimal amount of bias towards the serum 
measurements at the lower end. In contrast, at the higher end (above a mean IL-6 value 
of 20 pg/ml) there is more variation, and a clear bias towards the serum. This indicates 
that although the correlation coefficient was high (0.961) for the two sets of data, the 
IL-6 concentrations measured in the serum are higher than the IL-6 concentrations 
measured in the plasma i.e. the variation is much greater than the correlation graph 
suggests. The angle of the regression line also indicates a strong bias towards high 
serum measurements at high concentrations (Figure 15). Thus, based on this statistical 
method of comparison, the two methods could not be used interchangeably as they 
were not considered to sufficiently agree. In the rest of the study both serum and 
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plasma were assessed, so that comparisons could be made with values seen in the 
literature, where values for either plasma or serum are specifically cited.   
3.1.4 IL-6 measured in the plasma and serum by ELISA 
Plasma and serum IL-6 concentrations were also measured by sandwich ELISA prior 
to being measured by CBA, in order to determine the range of IL-6 expected from the 
samples and the dilution factor required and to observe how similar these results were 
to the results from the CBA assays (Figure 16). Similar trends to those seen in the 
CBA assay were observed, with both the mean plasma and serum IL-6 values higher 
for PMR and RA patients than healthy controls. The mean IL-6 concentration in the 
plasma measured at 4.9 pg/ml (range: <4.7- 11.6) for healthy controls, 9.1 pg/ml 
(range: <4.7- 28.3) for RA patients and 10.8 pg/ml (range: <4.7- 19.6) for PMR 
patients. The mean serum IL-6 concentrations were 5.9 pg/ml (range: <4.7- 21.9) for 
healthy controls, 8.6 pg/ml (range: <4.7- 24.2) for RA patients and 12.4 pg/ml (range: 
<4.7- 28.8) for PMR patients. The lower threshold of sensitivity for the assay was 4.7 
pg/ml (i.e. the lowest standard). 
The actual values measured in the ELISA were lower in RA and PMR patients than the 
values measured in the CBA; so that the difference between the mean concentration of 
IL-6 in PMR and RA patients compared to healthy controls was not statistically 
significant. In both the plasma and serum ELISAs there were two healthy control 
subjects with much higher IL-6 concentrations than would be expected for a healthy 
individual. It was not, however, the same two individuals with raised concentrations of 
IL-6 in the plasma and in the serum, indicating an inconsistency in the results. Also, 
when measuring IL-6 in the plasma and serum of each participant, a large amount of 
variability was observed between independent repeats (3 independent repeats for 
plasma and 2 independent repeats for serum) of these healthy controls with a high 
mean concentration of IL-6. This variability between repeats was not observed in the 
CBA, where all healthy controls had undetectable concentrations of IL-6 as expected 
in both the plasma and serum in all repeats. Consequently, cytokine concentrations 
were measured in the plasma and serum of each participant by CBA for all further 
analysis. 
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Figure 16: The concentration of IL-6 measured by ELISA in the plasma and serum of RA and 
PMR patients alongside healthy controls of a similar age. The concentration of IL-6 was measured 
in (a) the plasma and (b) the serum of each study participant using a sandwich ELISA. Each data 
point represents the mean of cytokine concentration for each study participant (n=3 repeats for 
plasma and n=2 repeats for serum). The solid red line represents the mean of the patient or 
control group. The dotted red line represents the lower threshold limit of the ELISA. *P< 0.05 
**P< 0.01 NS=P> 0.05 
(a) 
(b) 
Chapter 3 - Results 
82 
 
3.1.5. Determining the biological activity of circulating IL-6 in PMR and RA 
patients (refer to Aim 3 in Section 1.16) 
3.1.5.1 IL-6-dependent B9 cell proliferation in response to IL-6 
A B cell proliferation assay was conducted using IL-6-dependent B9 cells in order to 
test the bioactivity of the IL-6 previously detected in the plasma samples of the study 
participants. This colorimetric assay was centred around the bioreduction of MTS by 
B9 cells into a coloured formazan product which could be quantified by measuring the 
absorbance of culture medium at 450nm (Promega, 2013).  
 
 
Figure 17: The range of IL-6 over which B9 cell growth was stimulated. B9 cells were incubated 
for 72 hours with a range of concentrations of recombinant IL-6, before MTS was added and the 
absorbance measured. A four parameter linear regression curve was applied. The red dotted lines 
indicate the range of IL-6 concentrations between which the B9 cell growth was stimulated. Data 
points represent the mean±SE of triplicate wells. 
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The growth range of the B9 cells was observed in order to confirm whether the B9 
cells would be responsive to the levels of IL-6 present in the study participant samples.  
When a four parameter log regression curve was applied, it was possible to see that the 
B9 cells were responsive to IL-6 between approximately 6.5 pg/ml and 850 pg/ml 
(Figure 17). This range was considered to be sufficient to test the biological activity of 
IL-6 in the study participant plasma samples, which had previously been found to 
contain up to 41 pg/ml of IL-6 in the CBA assays.  
 
3.1.5.2 Titration of the anti-human IL-6 neutralising antibody 
In order to confirm the IL-6 specificity of B9 cell proliferation, IL-6 neutralising 
antibodies were added to the plasma samples and proliferation was measured in 
parallel with untreated samples. The measured growth of the B9 cells with the plasma 
sample in the presence of IL-6 neutralising antibody was subtracted from the total 
measured B9 cell growth with plasma sample, in order to give the concentration of IL-
6 which was actively causing the B9 cells to grow and proliferate. 
In order to determine the optimal concentration of IL-6 neutralising antibody to use in 
the IL-6 bioactivity assays, different concentrations of the neutralising antibody 
(0.000-50 µg/ml) were added to a range of concentrations of recombinant IL-6 
(0.00025-25 ng/ml) and then incubated with the IL-6-dependent B9 cells. The 
inhibitory effects of the neutralising antibody are illustrated in Figures 18 and 19. 
When the IL-6 neutralising antibody was applied at a concentration of 0.005 µg/ml and 
0.05 µg/ml, the growth of the B9 cells was not inhibited at any of the concentrations of 
recombinant IL-6 (Figure 18 and 19b). At a concentration of 0.5 µg/ml, the IL-6 
neutralising antibody inhibits B9 cell growth when incubated with IL-6 at a 
concentration of 0.25 ng/ml, but not at any of the other IL-6 concentrations (Figure 
19d). The neutralising antibody, however, had a potential stimulatory effect at the two 
highest IL-6 concentrations (2.5 and 25 ng/ml) (Figure 19d). 
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Figure 18: The B9 cell growth pattern when incubated with different concentrations of 
recombinant IL-6, in the presence of different concentrations of IL-6 neutralising antibody. Four 
parameter log regression curves were applied. Each point is the mean±SE of triplicate results. 
Representative experiment of 2 performed. Symbols represent means ± SE of duplicate wells. 
 
At a concentration of 5 µg/ml, the IL-6 neutralising antibody again had a clear 
inhibitory effect on B9 cell growth when stimulated with 0.25 µg/ml of IL-6 and a 
potentially stimulatory effect on the B9 cells when applied to the cells with 2.5 and 25 
ng/ml of recombinant IL-6 as previously (Figure 19e).  
At 50 µg/ml, the IL-6 neutralising antibody clearly inhibited B9 cell growth at 2.5 
ng/ml and 0.25 ng/ml (Figure 19f). Thus this concentration of IL-6 neutralising 
antibody was chosen as the optimal concentration as it inhibited B9 cell growth for the 
longest and broadest range (Figure 18 and 19f). 
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Figure 19: The effect of adding varying concentrations of IL-6 neutralising antibody to varying 
concentrations of recombinant IL-6 on the growth of the IL-6- dependent B9 cell line. The IL-6-
neutralising antibody was added to the recombinant IL-6 at a range of concentrations shown in 
(a) 0.000 µg/ml (b) 0.005 µg/ml (c) 0.05 µg/ml (d) 0.5 µg/ml (e) 5 µg/ml) (f) 50 µg/ml. The 
recombinant IL-6 was at a range of concentrations as shown on each individual bar chart on the x 
axis, in order to determine the concentration of neutralising antibody at which the B9 cell 
proliferation was inhibited at the longest and broadest range. Representative experiment of 2 
performed. The bars represent the mean±SE of duplicate wells. 
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3.1.5.3 Testing the biological activity of the IL-6 in the study participant samples 
In order to measure the bioactivity of IL-6 in the study participant plasma samples 
(SP1-19), the samples were incubated with and without the chosen concentration of IL-
6 neutralising monoclonal antibody (50 μg/ml), and then the B9 cells were added for 
72 hours. The proliferation of the B9 cells in response to incubation with study 
participant plasma samples was measured indirectly by measuring the absorbance of 
the samples at 450 nm in an MTS assay. 
Standard curves were constructed for each independent repeat and represent the growth 
of the B9 cells following incubation with known concentrations of recombinant IL-6 
(Figure 20). These standard curves illustrated in Figure 20, constructed using four 
parameter log regression, demonstrate the variability between the independent repeats 
of the assay. 
 
Figure 20:  The proliferation of B9 cells in response to standard concentrations of recombinant 
IL-6. The recombinant IL-6 was added to B9 cells at varying concentrations (x axis), 72 hours 
later the MTS assay was performed and the absorbance of wells measured at 450 nm. Data shown 
from three independent repeats, each performed in duplicate wells. Symbols represent mean ± SE. 
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The IL-6 present in the plasma samples was found to be biologically active, 
determined by the proliferation of B9 cells in the presence of sample, minus B9 cells in 
the presence of sample and neutralising antibody (Figure 21b). The concentration of 
this biologically active IL-6 was measured by interpolating values from the standard 
curves generated for each individual assay repeat. The mean concentration (±SE) of 
biologically active IL-6 in each subject sample is demonstrated in Figure 21b. 
Figure 21a demonstrates the IL-6 concentration measured in the plasma of study 
participants 1-19 by CBA. Despite slight differences in sensitivity between the assays, 
at initial observation the results appear to be very similar and thus both methods may 
be suitable for the measurement of IL-6 in human plasma, and the active IL-6 
measured by the MTS assay is most likely to be the same IL-6 measured in the 
samples by CBA.  
This ‘agreeability’ between assays was tested using the Bland-Altman principle 
(Figure 22) in order to confirm that the plasma IL-6 measured in both assays was the 
same. At the lower end of the scale, i.e. at concentrations of IL-6 <20 pg/ml, the 
measurements demonstrate some variation shown by the wide scatter, however, the 
points appear to be distributed randomly either side of zero suggesting that there is 
some broad agreement between the two assays. There are two major outliers, which 
suggests that there is some bias towards the MTS assay measurements at the higher 
end. This is, however, a biological system and thus some level of disagreement 
between assay measurements was expected, particularly at the higher end where the 
assays are not as sensitive. It was therefore accepted that the IL-6 measured in the 
plasma in the MTS assay was in fact the same IL-6 measured in the plasma by CBA, 
meaning that the IL-6 measured by CBA in PMR and RA patients was biologically 
active. 
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Figure 21: Biologically active IL-6 measured in study participant plasma samples. Graph (a) 
illustrates the geometric mean concentration of IL-6 in the plasma of study participants (1-19) as 
previously measured by CBA (n=4 repeats) showing the 95% confidence intervals. Graph (b) 
illustrates the mean concentration of IL-6 (±SE), measured in the same plasma samples using the 
B9 cell proliferation assay (n=3 repeats).  
(a) 
(b) 
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Figure 22: Bland Altman plot demonstrating the variation between the IL-6 concentration 
measured in participant plasma using CBA and the IL-6 concentration measured in participant 
plasma using the MTS B9 cell proliferation assay. Each data point represents one study 
participant. 
 
3.1.6 The relationship between IL-6 and fatigue in polymyalgia rheumatica and 
rheumatoid arthritis (refer to Aim 4 in Section 1.16) 
The results of the CBA assays were compared with patient reported levels of fatigue, 
an important symptom of PMR and RA. Two studies in particular have confirmed a 
link between circulating IL-6 and fatigue in RA (Davis et al, 2008 and Helal et al, 
2012). The aim of this part of the study was to confirm that this link between IL-6 and 
fatigue exists and to determine whether this link might also extend to PMR. Study 
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participants completed the BRAF-MDQ (Nicklin et al., 2010) at a fixed specific time 
of the day, i.e. 9am-11am when the blood sample was taken. Scores from the 
individual sections of the BRAF-MDQ were added and then a total score given. As 
previously described, IL-6 was measured in the serum and plasma of each subject by 
CBA (n=2 serum and n=4 plasma). The total fatigue scores and scores of the 
individual aspects of fatigue were directly compared in order to examine whether there 
was a correlation between IL-6 levels and fatigue in all participants. The results are 
illustrated below. 
 
3.1.6.1 Fatigue vs. plasma IL-6 
The concentration of IL-6 in the plasma of study participants was plotted against the 
total fatigue score for each patient. There was a significant correlation between the 
data, evidenced by the P-value, which was below 0.05 (*) and the high Pearson’s 
correlation coefficient, 0.487 (Figure 23a).  
The correlation between plasma IL-6 and the individual aspects of fatigue were also 
examined (Figure 23c-f). There was significant correlation between plasma IL-6 and 
the more somatic aspects of fatigue, i.e. physical fatigue and living fatigue, evidenced 
by high Pearson’s correlation coefficients (0.479 and 0.499 respectively) and low P-
values (0.033 and 0.025 respectively). There was, however, no significant correlation 
between plasma IL-6 and the more psychological aspects of fatigue, i.e. cognitive 
fatigue and emotional fatigue (P> 0.05). This suggests that the link between increased 
IL-6 in the blood and fatigue may be due to the physical effects that IL-6 has on the 
individual. 
Spearman’s rank correlation coefficients were also calculated in order to confirm the 
relationship between circulating IL-6 concentrations and fatigue. The distribution of 
points on the Pearson correlation graphs meant that calculating the Pearson correlation 
coefficients was not ideal, thus it was decided that ranking the data and using these 
‘ranks’ instead of actual values was a more suitable way of testing the strength of the 
correlation between the IL-6 concentrations and fatigue scores. Table 8 shows the 
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Spearman’s rank correlation coefficients for plasma IL-6 vs total fatigue, as well as 
plasma IL-6 vs each individual aspect of fatigue. In agreement with the Pearson’s 
correlation coefficients, it was confirmed that total fatigue and physical and living 
fatigue showed significant positive correlation with plasma IL-6 concentrations in the 
participants. Again, emotional and cognitive fatigue did not show any significant 
correlations with circulating IL-6 concentrations. 
   
Table 8: Spearman’s rank correlation coefficients calculated to test the strength of the 
relationship between IL-6 measured in participant plasma by CBA and the scores for the 
individual aspects of fatigue and total fatigue for the twenty study participants. The critical value 
at the 5% probability level was 0.378, thus anything higher than this value was taken to be 
significant. 
Plasma IL-6 concentration 
vs fatigue scores 
Spearman’s rank 
correlation coefficient 
Significant at 5% 
probability level? 
vs total fatigue score 0.543 Yes 
vs physical fatigue score 0.673 Yes 
vs living fatigue score 0.642 Yes 
vs cognitive fatigue score 0.187 No 
vs emotional fatigue score 0.334 No 
 
 
3.1.6.2 Other cytokines and fatigue 
The correlation between the other measured cytokines and total fatigue was also tested. 
No other measured cytokines displayed any significant correlation with fatigue. 
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Figure 23: The correlation between the total fatigue score or score for individual aspect of fatigue 
(generated by the BRAF-MDQ) vs. plasma and serum IL-6 concentrations. Each symbol 
represents one subject; triangles represent healthy controls, squares represent RA patients and 
circles represent PMR patients. IL-6 concentrations that fell below the sensitivity threshold for the 
CBA kit were taken as 2.5 pg/ml (the highest those values could possibly be). Pearson’s ‘r’ 
indicated on each graph. 
(a) 
(f) (e) 
(d) (c) 
(b) 
r= 0.487 
r= 0.479 r= 0.499 
r= 0.381 
r= 0.067 r= 0.311 
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3.1.6.3 Fatigue vs other clinical measures of PMR and RA 
The total fatigue score generated using the BRAF-MDQ was correlated with various 
clinical measures of disease activity, in order to observe whether a link existed 
between them. The CRP concentration was measured in the blood of all participants, as 
a measure of inflammation. This concentration was then plotted against the total 
fatigue score in order to determine whether a relationship existed between these two 
important measures of disease (Figure 24). Using Pearson’s correlation coefficient, no 
significant correlation was observed between these two diseases parameters, indicating 
that fatigue and the physiological mechanisms of inflammation occur as two unrelated 
disease events. However, when using rank order to test the relationship between these 
two disease measures, i.e. Spearman’s correlation coefficient, a significant positive 
correlation was evident (Table 9), indicating a relationship between CRP and fatigue 
in the participants. 
 
Figure 24. The correlation between the CRP levels measured in the blood and the total fatigue 
score generated by the BRAF-MDQ. No significant correlation was observed when testing using 
the Pearson’s correlation coefficient (r=0.404). Each symbol represents one subject. The black line 
represents the line of best fit.  
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Table 9: Spearman’s rank correlation coefficient to test the strength of the relationship between 
CRP score and total fatigue score. Significance at 5% probability level indicated.  
C-reactive protein score 
Spearman’s rank 
correlation coefficient 
Significant at 5% 
probability level? 
vs total fatigue score 0.661 Yes 
 
In order to test the quality of the IL-6 assays, plasma IL-6 concentrations were plotted 
against CRP levels measured in the blood in order to observe if a correlation existed. 
As CRP is produced by hepatocytes in response to increased circulating concentrations 
of IL-6, it was predicted that there would be a strong correlation. When measured 
using Pearson’s correlation coefficient, no significant correlation was observed when 
all participants were included in the analysis (Figure 25a); however there was one 
participant with an extremely high CRP measurement, indicating that this might be an 
anomaly. When excluded from the analysis the correlation was highly significant (P< 
0.0001) (Figure 25b) indicating that the results from the IL-6 assays were reliable- as 
CRP levels corresponded with circulating IL-6 levels. Also, when tested using 
Spearman’s rank correlation coefficient, a high rs value of 0.789 indicating a strong 
correlation between CRP and IL-6- this value was significant at the 0.5% probability 
level. 
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Figure 25: The relationship between CRP levels measured in the blood and plasma IL-6 
concentrations measured by CBA. No significant correlation was observed when using all 
participant data (a), however when participant 19 was omitted from the analysis (b), the 
correlation was highly significant. The black line represents the line of best fit. Each symbol 
represents one subject. 
(a) 
(b) 
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3.1.7 Summary 
Serum and plasma IL-6 concentrations in PMR and RA patients were found to be 
significantly elevated above healthy controls (P< 0.05), however IL-6 values were 
consistently higher in serum than plasma. Elevated plasma IL-6 in PMR and RA 
patients was found to be biologically active. 
A significant correlation was observed for the first time between the total fatigue score 
and IL-6 concentrations in the plasma of both PMR and RA patients (r= 0.487). Two 
individual aspects of fatigue, namely ‘physical fatigue’ and ‘living fatigue’ also 
correlated very well with IL-6 concentrations in the plasma of both PMR and RA 
patients whereas ‘cognitive fatigue’ and ‘emotional fatigue’ did not. The total fatigue 
scores and CRP levels displayed a significant correlation, as did circulating IL-6 
concentration with CRP levels, as expected. 
 
3.2 Exploring the cellular source of elevated IL-6 in PMR patients 
(refer to Aim 5 in Section 1.16) 
In order to identify the source of IL-6 in PMR patients, immunostaining and flow 
cytometry techniques were employed to detect IL-6 production by specific cell types in 
the blood. The percentage of cells which contained internal IL-6 was calculated for 
five PBMC types for each subject. The mean fluorescence intensity (MFI), a measure 
for the ‘intensity’ or concentration of the IL-6 staining within these cells, was also 
measured. Cell types included CD3+ T cells, CD14+ monocytes, CD19+ B cells, 
CD123+ pDCs and CD11c+ mDCs. 
3.2.1 Optimising the staining procedure  
Prior to measuring IL-6 within each cell type, optimisation assays were performed. 
This was to ensure that the optimal concentration of antibody was used (for 
identification of each cell type and intracellular IL-6), and also to find a suitable 
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stimulant which would activate each cell type. Other assays were performed to confirm 
the efficacy of the golgi-blocker (monensin, 4 μM) and permeabilisation buffer (0.1% 
saponin and 0.1% BSA in PBS) (data not included). The following section outlines the 
results obtained from the antibody titration and cell stimulant optimisation assays, 
tested on PBMC extracted from healthy blood, taken from donors at UWE, Bristol. 
3.2.1.1 Titrating the antibodies used for surface staining PBMC types 
The antibodies used for the identification of the different cell types were titrated on 
unstimulated PBMC from healthy donors, in order to find the dose at which the 
percentage of cells stained was at its peak, indicating the optimal concentration of 
antibody required for use in the following assays. Table 10 demonstrates the 
percentage of cells which were positively stained with antibodies against each of the 
five cell surface markers. The concentration which stained the highest percentage of 
each cell type was chosen as the optimal dose (highlighted).  
Table 10: Antibody titration for each of the cell surface markers. Highlighted boxes indicate the 
greatest percentage of positively stained cells, i.e. the optimal concentration of antibody to use. 
Ab= antibody. 
  Concentration of Ab (μl/100μl cell suspension 
containing 1x10
6
 cells) 
 
Ab 
Cell 
type 
1.25 2.5 5 10 15 
Percentage of positively stained cells (%) 
Anti-
human 
CD3 
CD3+ 44.6 54.6 58.7 55.5 49.4 
Anti-
human 
CD14  
CD14+ 6.2 5.6 6.4 5.9 5.0 
Anti-
human 
CD19 
CD19+ 4.3 1.7 4.4 5.0 3.7 
Anti-
human 
CD123 
CD123+ 7.5 13.1 15.2 13.2 13.7 
Anti-
human 
CD11c 
CD11c+ 3.3 4.3 3.6 3.1 3.1 
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3.2.1.2 Titration of the anti-human IL-6 antibody 
The Jurkat cell line constitutively produces IL-6 (Khalaf et al., 2010). Therefore the 
anti-human IL-6 antibody was titrated on the Jurkat cell line in order to find the 
optimal concentration for IL-6 detection in the PBMC. Cells were fixed and 
permeabilised prior to antibody staining in order to allow the antibody to bind 
intracellular IL-6. Figure 26a demonstrates the percentage of the Jurkat cells which 
were positively stained with the IL-6 antibody. Figure 26b demonstrates the mean 
fluorescence intensity of IL-6 staining in the Jurkat cell line at varying antibody 
concentrations. The optimal concentration was found to be 5 µl of antibody per 100 µl 
cell suspension containing 1x10
6
 cells, evidenced by the largest percentage of IL-6-
positive cells and greatest MFI of IL-6 staining at this concentration. 
3.2.1.3 Testing cell stimulants 
Prior to analysing study participant samples, various stimulants (PMA + Ionomycin, 
PHA, and LPS + IFNγ) were tested for their effectiveness in stimulating cellular 
responses and thus their ability to increase IL-6 production within all five PBMC cell 
types (CD3+, CD14+ CD19+, CD123+ and CD11c+) in blood from healthy donors. 
Isotype and FMO controls were used to set the gates. 
3.2.1.4 PMA and Ionomycin upregulated IL-6 production in CD3+ cells only 
Figure 27 (a-d) demonstrates four PBMC types stained with antibodies against each 
surface marker and intracellular IL-6, in both unstimulated and PMA- ionomycin 
stimulated cells. 
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Figure 26:  Titration of the anti-human IL-6 antibody on the Jurkat cell line. Graph (a) 
demonstrates the percentage of Jurkat cells which were positively stained for IL-6 and (b) 
demonstrates the mean fluorescence intensity of IL-6 staining within Jurkat cells. The Jurkat cells 
were fixed, permeabilised and then stained with 5 different concentrations of the antibody, in 100 
µl cell suspension containing 1x10
6
 cells. Mean±SE of n=3 repeats. 
(b) 
(a) 
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 Unstimulated PBMC 
CD3- PE 
CD19- PE 
CD14- PE 
IL-6- FITC 
IL-6- FITC 
IL-6- FITC 
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Figure 27: IL-6 production in PBMC subsets from a healthy individual following stimulation with 
PMA (10 ng/ml) and Ionomycin (100 ng/ml) for 24 hours. Plot (a) demonstrates the CD3+ T cells, 
(b) CD14+ monocytes, (c) CD19+ B cells, (d) CD123+ plasmacytoid DCs. 1x10
6 
cells were stained 
using PE-conjugated antibodies against surface markers and FITC-conjugated IL-6 antibodies 
against intracellular IL-6. Analysed by Accuri C6 flow cytometer set to collect 10,000 events. 
 
As expected, as a known T cell mitogen, PMA (with ionomycin) was successful in 
increasing the MFI of IL-6 staining in CD3+ T cells from 22,068 to 173,873 (Figure 
27a). There was, however, evidence of cell death and debris (circled in blue, Figure 
27a), which was not evident in the unstimulated culture, indicating that PMA is 
potentially detrimental to other cell types. In agreement with this, the monocyte 
population circled in red (Figure 27b) disappeared following stimulation with PMA 
and ionomycin, and cell death and debris were increased in this culture. The MFI of a 
small population of CD19+ B cells may have increased, indicating that some B cells 
may be activated by PMA and ionomycin in terms of IL-6 production (Figure 27c). 
There was, however, an overall decrease in the number of CD19+ B cells, indicating 
that this stimulation may be detrimental to surface expression of CD19. As with the 
CD14+ monocytes, the CD123+ pDC population disappeared following stimulation, 
suggesting that this method of stimulation is associated with cell death and/or a lack of 
cell surface expression of CD14, CD19 and CD123. Thus, this was considered not to 
be an ideal stimulatory technique for these assays. 
(d) 
  
CD123- PE 
IL-6- FITC 
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3.2.1.5 PHA did not induce IL-6 production in any of the PBMC 
PHA was next used to stimulate PBMC cultures (Figure 28) which were then stained 
for cells surface markers and intracellular IL-6. 
 
              
              
  
 
 
  
(a) 
(b) 
Unstimulated PBMC Stimulated PBMC 
 
IL-6- FITC 
IL-6- FITC 
CD3- PE 
CD14- PE 
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Figure 28: IL-6 production in PBMC subsets from a healthy individual following stimulation with 
PHA (2.5 µg/ml) for 24 hours. Plot (a) demonstrates the CD3+ T cells, (b) CD14+ monocytes, (c) 
CD19+ B cells, (d) CD123+ pDCs and (e) CD11c+ mDCs. 1x10
6 
cells were stained using PE-
conjugated antibodies against surface markers and FITC conjugated IL-6 antibodies against 
intracellular IL-6. Analysed by Accuri C6 flow cytometer set to collect 10,000 events. 
 
 
  
(c) 
(d) 
(e) 
   
 
IL-6- FITC 
IL-6- FITC 
IL-6- FITC 
CD19- PE 
CD123- PE 
CD11c- PE 
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PHA, also a known T cell mitogen, was tested for its ability to stimulate PBMC 
populations to increase IL-6 production as well as stimulating cell proliferation. A 
large, discrete CD3+ T cell population was observed in the unstimulated culture, 
however, following stimulation with PHA, the total amount of CD3+ T cells decreased 
by 37%, with only a small proportion of CD3+ cells demonstrating an increased MFI 
(i.e. an increase in IL-6 production) (Figure 28a). This indicated that PHA may have 
caused a reduction in the cell surface marker and did not successfully induce IL-6 
production in CD3+ T cells.  There was also some evidence of cell death and debris as 
demonstrated previously. 
Following stimulation with PHA, discrete populations of CD14+ monocytes and 
CD19+ B cells disappeared, with a very small proportion of CD14+ cells 
demonstrating an increase in MFI (Figure 28b and c). Nevertheless, with more cell 
death evident in these plots, it was difficult to say whether these were monocytes or 
cell debris. The MFI of IL-6 staining did not increase in CD123+ pDC or CD11c+ 
mDC (Figure 28d and e). Furthermore, the percentage of IL-6 positive cells was 
reduced in CD11c+ mDC following stimulation with PHA (Figure 28e). In 
conclusion, PHA was not an ideal stimulant for IL-6 production in any of the PBMC 
cell types, despite its reputation as a potent T cell mitogen.  
 
3.2.1.6 LPS and IFNγ induced IL-6 production in all PBMC 
When LPS and IFNγ were added to healthy PBMC cultures, the percentage of IL-6 
positive cells increased for every cell type (of the individual cell type, not the whole 
PBMC population), albeit a very minor increase for the CD14+ monocytes and 
CD123+ and CD11c+ dendritic cells (Figure 29b, d and e). The MFI, however, 
increased dramatically for all cell types (Figure 29a-e) indicating a large increase in 
IL-6 production by the cells involved, as well as an increase in the amount of each cell 
type producing IL-6. Thus, LPS and IFNγ were chosen as the stimulant for use in the 
assays, in order to test the IL-6 secreting potential of all 5 PBMC types. 
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Figure 29: IL-6 production in PBMC subsets from a healthy individual following stimulation with 
LPS (1µg/ml) for 24 hours and IFNγ (100 ng/ml) for the final 4 hours. Plot (a) CD3+ T cells, (b) 
CD14+ monocytes, (c) CD19+ B cells, (d) CD123+ pDCs (e) CD11c+ mDCs. 1x10
6 
cells were 
stained with PE-conjugated antibodies against surface markers and FITC-conjugated IL-6 
antibodies against intracellular IL-6. Analysed on Accuri C6 flow cytometer set to collect 10,000 
events. 
3.2.2 Measuring constitutive IL-6 production in PBMC 
3.2.2.1 The positive control cell line 
As Jurkat cells had previously been shown to produce high levels of IL-6, this cell line 
was stained for intracellular IL-6 alongside the samples as a positive control, in order 
to confirm that the intracellular IL-6 antibody staining techniques had been successful.  
(e) 
(d) 
  
  
CD123- PE 
CD11c- PE 
IL-6- FITC 
IL-6- FITC 
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The dotplot in Figure 30a demonstrates an example of unstained Jurkat cells with the 
gating used to exclude dead cells and cell debris. Histoplots shown in Figure 30 
demonstrate unstained Jurkat cells (b), Jurkat cells stained with the IL-6 antibody (d), 
and Jurkat cells stained with the matching isotype control (Rat IgG1k) (c). Intracellular 
IL-6 was measured in the Jurkat cell line alongside every assay confirming that the 
staining and permeabilisation techniques were effective. The results displayed some 
variability from assay to assay, however, IL-6 was always measured within the Jurkat 
cells with the percentage of IL-6 positive cells ranging from 31% to 92% (mean 69%) 
(Table 11).  
 
Table 11: The percentage of Jurkat cells which constitutively produced IL-6. Jurkat cells were 
used as a positive control for IL-6 staining for each sample (study participants 1-19). 
 
Study participant sample The percentage (%) of IL-6 positive cells 
SP1 53 
SP2 81 
SP3 92 
SP4 66 
SP5 66 
SP6 31 
SP7 46 
SP8 74 
SP9 72 
SP10 77 
SP11 79 
SP12 76 
SP13 35 
SP14 84 
SP15 90 
SP16 73 
SP17 47 
SP18 88 
SP19 77 
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Figure 30: Constitutive intracellular IL-6 measured in Jurkat cells. Plot (a) demonstrates the 
gating used to exclude dead cells and cell debris, visible in the bottom left hand corner and up the 
left hand side, and histoplots in (b),(c) and (d) demonstrate unstained Jurkats, Jurkats stained 
with the isotype control (Rat IgG1k) and Jurkats stained with the anti-human IL-6 antibody 
(respectively). The red marker is a second gate which was arbitrarily placed so that 2.5% of cells 
were positive when stained for the isotype control. Any fluorescence detected above this was taken 
as positive IL-6 staining. 
 
 
 
(a) Unstained cells (b) Unstained cells 
(c) Cells stained with 
isotype control 
(d) Cells stained with 
anti-IL-6 antibody 
Side scatter 
Forward scatter 
Cell count 
No FITC 
FITC isotype control IL-6 FITC 
Cell count Cell count 
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3.2.2.2 Measuring the percentage of PBMCs which constitutively produce IL-6 
In healthy control subjects, between 87% and 100% of all unstimulated CD14+ 
monocytes and CD123+ plasmacytoid dendritic cells were positively stained for 
intracellular IL-6 (Figure 31a). This suggests that in normal healthy people nearly all 
monocytes and pDCs constitutively produce IL-6 when in a resting state. Between 
61% and 90% of all CD11c+ myeloid dendritic cells were also found to be positive for 
intracellular IL-6. These cell types are all antigen presenting cells. 
The lymphocyte populations (T and B cells) in healthy control patients were found to 
be more heterogeneous in a resting state with subjects displaying variable percentages 
of these cell types with internal IL-6 (Figure 31a). Between 26% and 100% of CD19+ 
B cells were found to be positively stained for intracellular IL-6 in a resting state, 
whilst between 10% and 75% of CD3+ T cells were positively stained for intracellular 
IL-6. The CD3+ T cells have a biphasic distribution, with 3 subjects clustered at 
around 75%- 80% IL-6 positive, and the remaining subjects below 40%, whereas the 
CD19+ B cells are more normally distributed (Figure 31a). 
The percentage of IL-6 producing cells in RA and PMR patients was similarly 
measured (Figure 31b-c). Again, a high percentage (77%- 99%) of CD14+ monocytes 
was found to be positive for IL-6 in all RA subjects (Figure 31b). All RA subjects also 
had a high percentage of IL-6 positive CD123+ plasmacytoid dendritic cells (67%-
98%). CD11c+ myeloid dendritic cells and CD19+ B cells were more heterogeneous 
cell populations with subjects displaying more variable levels of IL-6 positive cells. 
The percentage of IL-6 positive CD11c+ mDCs in RA patients ranges from 40%-91%, 
and 18%- 94% for the CD19+ B cells. The majority of RA subjects had a low 
percentage of IL-6 positive CD3+ T cells (<27%), except for one subject (SP6) in 
which 96% of their CD3+ T cells were positive for IL-6 (Figure 31b). 
The PMR patients also had a high percentage of IL-6 producing antigen-presenting 
cells, with almost 100% of all CD14+ monocytes, CD11c+ dendritic cells and CD123+ 
dendritic cells positive for IL-6 except for one subject, SP8 (Figure 31c). Similarly to 
the HC and RA subjects, CD19+ B cells and CD3+ T cells were more varied in terms 
of the percentage of cells producing IL-6 (Figure 31c). CD19+ B cells had between 
16%- 100% of IL-6 positive cells whilst in CD3+ T cells, the percentage of IL-6 
positive cells varied between 5%- 94%, with a normal, evenly spread distribution 
(Figure 31c). 
Chapter 3 - Results 
110 
 
There were no statistically significant differences between the mean percentage of IL-6 
producing cells in RA, PMR and healthy controls for all cell types. It is therefore not 
obvious which of these five cell types (if any) are responsible for the over-production 
of IL-6 in PMR based on these results. What is clear is that all cell types in all subjects 
are capable of producing IL-6 in a resting state, some constitutively, with nearly 100% 
of all monocytes in all subjects (disease and controls) positive for IL-6, and a high 
percentage of the dendritic cells staining positive for IL-6 in all subjects. The 
percentage of lymphocytes, (CD3+ T cells and CD19+ B cells) which were positive for 
IL-6 was more varied between subjects; however there are no significant differences 
between the disease groups and healthy control group. 
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Figure 31: The percentage of each cell type within the PBMC containing constitutive intracellular 
IL-6. The cells were cultured for 24 hours prior to Ab staining. Values were determined by flow 
cytometry, with 10,000 events collected per participant. Graph (a) illustrates the percentage of IL-
6 positive cells in healthy controls (b) in RA patients and (c) in PMR patients. Each symbol 
represents one participant. 
Cell type 
% IL-6 positive cells 
(a) 
(b) 
(c) 
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3.2.2.3 Calculating the number of IL-6 producing cells in each cell type 
The actual number of IL-6 producing cells for each cell type was calculated in order to 
see if there were any significant differences between the disease groups and healthy 
control group. These calculations were based on previously measured percentages of 
each cell type at a resting state and  the total white cell counts (WCCs) provided by the 
clinicians (Table 13), as the total number of cells in each sample was not recorded at 
the time of the cell count. The total WCCs used for the healthy controls were taken 
from published values normally seen in healthy adults (Longmore, 2010) (Table 12) as 
white cell counts were not performed on the healthy control blood samples taken. 
The total WCCs fell within the normal range for all subjects, although the majority of 
PMR patients (71%) and RA patients (80%) had WCCs which fall in the top half of the 
normal expected range for a healthy adult (Table 13). One RA patient, SP7, had a 
particularly high WCC, at 10.5x 10
6 
per ml, which is very close to the top end of the 
normal range for a healthy adult. 
 
Table 12: Published ‘normal’ ranges for a white cell count (WCC) in a healthy adult (Longmore, 
2010). 
Normal range for healthy adult (x10
6
/ml): 
Total white cell count: 4-11 
Lymphocytes (T and B cells): 1.5-4.5 
Monocytes: 0.2-0.8 
 
Two subjects (SP9 and SP14) had very high T cell counts, outside of the normal range 
for a total lymphocyte count (Table 13). One of these subjects was a healthy control 
and the other was an RA patient. The monocyte counts were high for the majority of 
subjects (14 out of 19), and of the 5 subjects which fell within the normal range, 4 
were healthy controls and one was a PMR patient (Table 13). No published values for 
normal dendritic cell counts were found. 
Using the total WCC and the percentage of each cell type determined by flow 
cytometry, the number of IL-6 producing cells for each cell type could be calculated 
(Table 14). Unpaired T tests were performed to determine whether the mean number 
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of IL-6-producing cells was different for healthy controls, RA patients and PMR 
patients in each of the five cell types, using the Bonferroni test to correct for multiple 
comparisons (meaning that any value equal to or below 0.01 was taken to be 
significant) (Bland, 1995). Using unpaired T tests, the mean number of IL-6-producing 
CD14+ monocytes was significantly higher (P= 0.01) for PMR and RA patients 
compared to healthy controls (Table 15). None of the other cell types were 
significantly different between the groups. Overall monocyte numbers were elevated in 
both disease patients but because they were not different between RA and PMR it 
suggests this may be a consequence of elevated circulating IL-6. It cannot account for 
the elevated circulatory IL-6 in PMR.
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Table 13: The absolute number of each cell type in each participant (x10
6
/ml). The number of each cell type (resting) in each participant was calculated 
using the percentages of each cell type measured by flow cytometry. The values in red are based on the median of the normal expected range for a healthy 
adult as WCCs were not performed on these subjects. 
 
Study participant Diagnosis CD3+ CD14+ CD19+ CD123+ CD11c+
Total white cell count 
(x106cells/ml) CD3+ CD14+ CD19+ CD123+ CD11c+
SP1 PMR 43 16 5 15 21 8.9 3.8 1.4 0.4 1.3 1.9
SP2 PMR 47 15 4 12 22 7.8 3.7 1.1 0.3 0.9 1.7
SP3 HC 50 12 4 14 21 7.5 3.7 0.9 0.3 1.0 1.6
SP4 RA 38 18 4 19 21 8.9 3.4 1.7 0.3 1.7 1.9
SP5 HC 54 6 21 5 14 7.5 4.1 0.4 1.5 0.4 1.1
SP6 RA 34 17 11 15 24 8.9 3.0 1.5 1.0 1.3 2.1
SP7 RA 32 15 9 19 25 10.5 3.4 1.6 1.0 2.0 2.6
SP8 PMR 49 13 3 14 21 5.4 2.6 0.7 0.2 0.8 1.1
SP9 HC 70 5 5 8 12 7.5 5.3 0.4 0.4 0.6 0.9
SP10 HC 56 11 4 14 15 7.5 4.2 0.8 0.3 1.1 1.1
SP11 RA 42 14 11 16 16 7.0 3.0 1.0 0.7 1.1 1.1
SP12 HC 59 10 5 11 14 7.5 4.4 0.8 0.4 0.8 1.1
SP13 HC 37 21 5 19 18 7.5 2.8 1.6 0.4 1.4 1.4
SP14 RA 59 11 6 11 14 9.0 5.3 1.0 0.5 0.9 1.2
SP15 PMR 43 16 3 18 20 7.1 3.0 1.1 0.2 1.3 1.4
SP16 HC 47 16 5 14 17 7.5 3.5 1.2 0.4 1.0 1.3
SP17 PMR 31 20 4 16 28 9.3 2.9 1.9 0.4 1.4 2.6
SP18 PMR 36 22 4 14 24 8.2 2.9 1.8 0.3 1.1 2.0
SP19 PMR 38 19 7 12 23 8.5 3.3 1.6 0.6 1.1 2.0
% of each cell type in PBMC sample
Absolute no. of each cell type in participant 
(x106 cells/ml)
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Table 15: The mean number of IL-6 producing cells (x10
6
/ml) in healthy controls, RA patients and 
PMR patients. Unpaired student T tests were used to determine the statistical difference between 
the mean of the groups for each cell type. Values highlighted in yellow have a P-value that is less 
than or equal to 0.01, and are thus taken to be significant. 
Statistical testing CD3+ CD14+ CD19+ CD123+ CD11c+ 
Mean no. of IL-6 producing 
cells in healthy controls 1.02 0.65 0.33 0.74 0.90 
Mean no. of IL-6 producing 
cells in RA patients 1.12 1.24 0.46 1.14 1.15 
Mean no. of IL-6 producing 
cells in PMR patients 1.53 1.32 0.25 1.05 1.59 
T test RA vs HC 0.86 0.01 0.61 0.06 0.21 
T test PMR vs HC 0.39 0.01 0.64 0.08 0.02 
T test: PMR vs RA 0.55 0.73 0.20 0.65 0.19 
 
 
 
Actual number of IL-6 producing cells (x10
6
 
per ml) 
Study participant CD3+ CD14+ CD19+ CD123+ CD11c+ 
1 3.6 1.4 0.4 1.2 1.8 
2 1.0 1.1 0.1 0.9 1.3 
3 1.1 0.9 0.3 1.0 1.4 
4 0.8 1.6 0.2 1.7 1.7 
5 3.1 0.4 1.3 0.4 0.9 
6 2.9 1.5 0.9 0.9 1.3 
7 0.7 1.2 0.2 1.3 1.0 
8 0.1 0.5 0.0 0.5 0.5 
9 0.8 0.3 0.2 0.5 0.5 
10 0.4 0.7 0.1 0.9 0.9 
11 0.8 0.9 0.7 1.1 0.9 
12 3.2 0.7 0.3 0.8 0.8 
13 2.0 1.5 0.3 1.4 1.2 
14 0.4 0.9 0.3 0.8 0.9 
15 1.2 1.1 0.2 1.2 1.3 
16 0.6 1.2 0.1 1.0 1.2 
17 1.5 1.9 0.3 1.4 2.4 
18 0.6 1.7 0.1 1.0 1.9 
19 2.6 1.6 0.6 1.1 1.9 
Table 14: The actual number of IL-6 producing cells (x10
6
/ml) for each of the 5 cell types in 
resting PBMC. The values given for the healthy control patients are based on the median of the 
normal WCC count expected for a healthy adult. 
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3.2.2.4 Measuring the intensity of IL-6 staining within unstimulated cells 
The mean fluorescence intensity (MFI) of the IL-6 antibody staining inside the 
unstimulated PBMCs was measured by flow cytometry in order to identify an 
individual cell type which may be producing greater amounts of IL-6 in patients with 
PMR, but not in RA patients or in healthy controls. 
The MFI of IL-6 staining in CD3+ T cells was very low in all subjects in all groups 
(2,450- 17,020) except for one RA subject (SP11) in which CD3+ T cells had a higher 
MFI of 44,568 (Figure 32). There were no significant differences between the means 
of the three groups. The MFI of IL-6 staining was also relatively low in CD14+ 
monocytes in the majority of subjects (4,611- 40,494). There were, however, two 
subjects with significantly higher MFI values; one healthy control patient (SP9) with 
an MFI of 72, 397 and one RA subject with an MFI of 151,313. Again there was no 
significant difference between the means of the groups. 
The range of MFI in CD19+ B cells was greater in subjects with RA (2,391- 114,817) 
and PMR (2,926- 69,814) compared to healthy controls (4,443- 41,420), however, 
there was no significant difference between the means of the groups. In the CD123+ 
pDCs and CD11C+ mDCs there was a greater range in MFI in the subjects with RA 
(3,033- 43,990) and PMR (3,772- 62,428) compared to healthy controls (7,516- 
26,096), but again, there were no statistically significant differences between the 
means of the diseased groups compared to healthy controls.  
Based on these results, no single cell type was found to be constitutively producing 
high levels of IL-6 in PMR participants. Taken together, all cell types in all individuals 
were able to produce intracellular IL-6 but mostly at low or very modest levels. CD3+ 
T cells and CD19+ B cells were the most heterogeneous whilst DC and monocytes 
were homogeneous in their expression of IL-6, which demonstrated no elevation in 
PMR patients.  
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Figure 32: The mean fluorescence intensity (MFI) of intracellular IL-6 staining in the resting 
PBMCs of (a) healthy controls of a similar age (b) RA patients and (c) PMR patients. Blood 
samples were dual stained for cell type and IL-6. Samples were analysed by flow cytometry, with 
10,000 events collected per sample. Each symbol represents one subject. 
Constitutive Intracellular IL-6 (Mean Fluorescence Intensity) 
(a) 
(c) 
(b) 
Cell type 
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3.2.2.5 IL-6 in the culture supernatant of resting PBMC  
In order to determine if intracellular IL-6 staining reflected the secretory capacity of 
the cells, the supernatants from resting (i.e. unstimulated) PBMC were collected after 
24 hours in culture and stored at -80°C before being analysed by CBA. The 
concentration of secreted IL-6 in the supernatants was measured. 
Low levels of IL-6 were detected in the unstimulated PBMC culture supernatant of one 
PMR patient (SP1: 8.5 pg/ml) and one RA patient (SP4: 2.8 pg/ml) but not in the 
supernatant of any other subjects. This confirms that unstimulated PBMC from PMR 
patients do not constitutively produce higher quantities of IL-6 and thus are not 
responsible for the elevated levels of IL-6 in the circulation of these patients. 
Furthermore, the results suggest that despite the presence of low concentrations of 
intracellular IL-6 detectable within the PBMC, they do not seem to necessarily secrete 
it. 
 
3.2.3 Measuring inducible IL-6 in PBMC 
In order to determine if PBMC from PMR patients showed a greater responsiveness to 
stimulation, the PBMC were also cultured with LPS (1 μg/ml) for 24 hours and IFNγ 
(100 ng/ml) for the final four hours. This had been previously shown to stimulate 
cellular responses in all cell types in young healthy control PBMC. 
3.2.3.1 The change in the percentage of IL-6 positive cells following stimulation 
The actual percentage of IL-6 positive cells following stimulation is shown in Figure 
33. The change in the percentage of IL-6-positive cells between unstimulated and 
stimulated PBMC are shown in Figure 34. For the majority of subjects in all groups 
(healthy controls, RA patients and PMR patients) the percentage of IL-6-positive 
CD14+ monocytes and CD123+ pDCs changed very little (<13%) following 
stimulation (Figure 34a-c). For most of these subjects the percentage of IL-6 positive 
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CD14+ and CD123+ cells was between 85% and 100% prior to stimulation, thus 
making further stimulation difficult to assess. There were only minor increases and 
decreases in the percentage of IL-6 positive CD14+ monocytes and CD123+ pDCs for 
most subjects. One subject, SP6 (RA) experienced a relatively large increase in IL-6 
positive CD123+ pDCs following stimulation, going from 67% to 99% IL-6 positive 
cells, a percentage change of 48% (Figure 34) and study participant 8 (PMR) 
experienced a percentage change of 27%. For these two cell types, only one subject, 
SP12 (HC) experienced a percentage decrease in the percentage of IL-6 positive cells 
of over 10% (Figure 34). There was no significant difference between the responses of 
the PMR patients, RA patients and healthy controls. 
The responses of CD11c+ mDCs to stimulation were more varied than the responses of 
the CD14+ monocytes and the CD123+ pDCs (Figure 34a-c). Subjects experienced up 
to 24% change (increase or decrease) in the percentage of IL-6 positive cells. RA 
subject SP6 was most responsive to stimulation, with an increase of 57% following 
stimulation. There were no significant differences between the responses of the 
different groups in the CD11c+ mDCs. 
The responses of the CD19+ B cells to stimulation were much more variable than in 
the monocytes and dendritic cells. There were a few ‘non-responders’ in all three 
groups (including healthy controls, RA patients and PMR patients); some of these 
were the subjects who already had a high percentage of IL-6 positive cells and thus 
were already responding at a maximum level so a large increase was not possible. 
Some subjects, however, had a low percentage of IL-6 positive CD19+ cells prior to 
stimulation and did not appear to respond at all to the stimulation (SP2, SP7 and SP18) 
(Figure 34a-c). In all three groups there were very high responders (SP4, SP8, SP10 
and SP16 percentage increase by 91%, 102%, 77% and 176% respectively) (Figure 
34a-c). In all groups there were subjects who experienced a large decrease in the 
percentage of IL-6 positive cells (SP1, SP7, SP11 and SP12, percentage decrease by 
33%, 27%, 46% and 52% respectively). The responses were therefore much more 
variable in the CD19+ B cells than the other antigen presenting cells. Again, however, 
there were no significant differences between the IL-6 responses of the B cells in the 
different groups. 
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The responses to stimulation in the CD3+ T cells were even more variable for all 
groups. Three healthy control subjects (SP3, SP9 and SP16) experienced very large 
percentage increases (up to 445%) in the percentage of IL-6 positive cells from 
unstimulated to stimulated T cells (Figure 34). Three RA subjects (SP4, SP11 and 
SP14) also experienced a very large increase (up to 1013%) in the percentage of IL-6 
positive cells (Figure 34b). One PMR patient experienced a relatively large increase of 
63% (Figure 34c) with other PMR subjects showing increases of up to 21%. Subjects 
in all three groups had large decreases (up to 82%) in the percentage of IL-6 positive 
CD3+ T cells following stimulation (Figure 34a-c). Again, some subjects in all groups 
had CD3+ T cells which were not very responsive to stimulation. There was a great 
deal of variation in the responses of CD3+ T cells to stimulation in all the groups, and 
some of the responses to stimulation were very extreme compared to the other cell 
types, perhaps due to the larger variation in percentage IL-6 positive cells prior to 
stimulation. There were no significant differences between the responses of the 
different groups. 
In conclusion, there appears to be variable responses in all the cell types and in all the 
groups. The biggest changes appear to be in the CD3+ T cells and CD19+ B cells, 
however there was a greater capacity for change in these cells as the percentage of IL-6 
positive cells in these cell types was more variable prior to stimulation. Many of the 
CD14+ monocytes, CD123+ pDCs and CD11c+ myeloid dendritic cells were already 
stimulated to their maximum capacity (i.e. approximately 80%- 100% of cells were 
positive for IL-6) prior to stimulation and thus there was less capacity for change. 
There were also some cell types in some subjects which did not appear to be 
responsive at all, despite not being stimulated to maximum capacity prior to 
stimulation. The percentage of IL-6 positive cells decreased quite dramatically in some 
cell types (namely the CD3+ and CD19+ cells) after stimulation, suggesting that the 
stimulatory technique may be detrimental to IL-6 production in these cells.  
Having tested the cellular responses to stimulation, i.e. the percentage change from 
unstimulated to stimulated values in each patient or control group, it was found that 
there were no significant differences between the mean percentage change in the 
percentage of IL-6 positive cells in PMR patients, RA patients and healthy control 
patients.   
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Figure 33: The percentage of each cell type within the stimulated PBMC containing intracellular 
IL-6. The cells were stimulated for 24 hours with LPS (1 μg/ml) and IFNγ (100 ng/ml) for the final 
4 hours prior to antibody staining. Values were determined by flow cytometry, with 10,000 events 
collected per participant. Graph (a) illustrates the percentage of IL-6 positive cells in healthy 
controls of a similar age, (b) in RA patients and (c) in PMR patients. Each symbol represents one 
participant.  
% IL-6 positive cells 
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Figure 34: The percentage of cells which were stained for intracellular IL-6 in unstimulated and 
stimulated PBMCs (joined by black line) in (a) healthy controls (b) RA patients and (c) PMR 
patients. Cells were stimulated with LPS (1 μg/ml) for 24 hours and IFNγ (100 ng/ml) for the final 
four hours.
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3.2.3.2 Changes in intensity of intracellular IL-6 staining following PBMC 
stimulation 
There were no significant differences between the mean intracellular IL-6 levels in 
stimulated PBMC between any of the groups (HC, RA and PMR). Thus the percentage 
change in the MFI between unstimulated and stimulated PBMC was examined 
(Figures 36a-c). Figure 35 shows the MFI of stimulated PBMC.   
There was very little change in MFI from unstimulated to stimulated CD3+ T cells in 
all three groups (Figure 36), except for one RA subject (SP4) in which the MFI 
increased by a 1205%, one healthy control patient (SP16) which showed an increase of 
240% and one PMR patient (SP17) which showed an increase of 110%. Ten out of the 
nineteen subjects displayed a decrease in MFI after stimulation, and three did not 
change, suggesting that these cells did not respond to LPS or IFNγ by producing IL-6 
and the stimulation may have caused a down regulation in IL-6 production. 
CD14+ monocytes displayed variable responses to stimulation in all three groups. In 
some subjects in all the groups the MFI increased dramatically, namely SP4 (988%), 
SP8 (258%), SP13 (370%), SP16 (230%) and SP18 (102%) (Figure 36). The MFI 
decreased in only 3 subjects and some did not respond at all to the stimulation, again 
this was in all the groups and therefore was not disease specific. 
The responses of CD19+ B cells were variable in all groups. Again, SP4 (RA) showed 
a significant increase in MFI by 5033%, significantly greater than any other subject. 
SP10 and SP13 (healthy controls) also displayed large increases in MFI (1243% and 
800% respectively). As with the CD3+ T cells and CD14+ monocytes, there were 
some subjects who experienced a decrease in MFI from unstimulated to stimulated 
cells and some subjects with non-responsive CD19+ B cells. 
CD123+ pDCs and CD11c+ mDCs also displayed variable responses to stimulation in 
all groups. Generally there were smaller percentage increases or decreases in MFI 
(<100%) compared to the responses seen in the other cell types, suggesting that DCs 
were not stimulated by LPS and IFNγ to produce IL-6. The MFI, however, in RA 
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subjects SP4, SP6 and SP11 and healthy control subjects SP12 and SP13 were 
significantly increased (>180%) following stimulation in both CD123+ pDCs and 
CD11c+ mDCs, and the MFI of healthy control subject SP16 was also significantly 
increased in the mDCs. 
Overall, there were a group of subjects with highly responsive PBMCs in all three 
groups. There were, however, also subjects which responded negatively or did not 
respond at all to the stimulation in terms of IL-6 production in all three groups. Having 
tested the cellular responses to stimulation, i.e. the percentage change from 
unstimulated to stimulated values in each patient or control group, it was found that 
there were no significant differences between the mean percentage change in MFI in 
PMR patients, RA patients and healthy control patients.   
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Figure 35: The mean fluorescence intensity (MFI) of intracellular IL-6 staining in the stimulated 
PBMCs of (a) healthy controls (b) RA patients and (c) PMR patients. The cells were stimulated 
for 24 hours with LPS (1μg/ml) and IFNγ (100 ng/ml) for the final 4 hours Blood samples were 
dual stained for cell type and IL-6. Samples were analysed by flow cytometry, with 10,000 events 
collected per sample. Each symbol represents one subject. 
Intracellular IL-6 in stimulated PBMC (Mean Fluorescence Intensity) 
Cell Type 
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Figure 36: The mean fluorescence intensity of IL-6 staining in unstimulated and stimulated 
PBMCs (joined by a black line) in (a) healthy controls (b) RA patients and (c) PMR patients. Cells 
were stimulated with LPS (1 μg/ml) for 24 hours and IFNγ (100 ng/ml) for the final four hours. 
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3.2.3.3 IL-6 secreted in the supernatant of stimulated PBMC cultures 
The supernatants from the stimulated PBMC were also collected after 24 hours in 
culture and stored at -80°C before being analysed by CBA as previously described. IL-
6 was measured in these supernatant samples. 
Concentrations of IL-6 were significantly higher in the stimulated supernatants 
compared to unstimulated PBMC in all the groups (Figure 37). In healthy controls the 
mean concentration of IL-6 measured in stimulated supernatants was 3926.1 pg/ml, 
compared to 8182.3 pg/ml in RA patients, and 5301.2 pg/ml in PMR patients. In the 
unstimulated PBMC supernatants, only two subjects (one PMR and one RA) had 
concentrations of IL-6 which were detectable above the sensitivity threshold for the 
CBA kit (above 2.5 pg/ml).  
These results suggest that at least one cell type in every participant sample was 
stimulated to secrete very high concentrations of IL-6 (>1000 pg/ml) when stimulated 
by LPS and IFNγ over 24 hours. There was, however, no significant difference 
between the mean of the IL-6 concentration measured in the stimulated PBMC 
supernatants between RA patients, PMR patients and healthy controls with these 
sample sizes. 
Secreted IL-6 values did not reflect the results observed in the flow cytometry assays 
following cell stimulation. None of the cell types measured by flow cytometry were 
found to have particularly high MFI stains suggestive of large amounts of IL-6 in any 
of the participant groups, and responses to stimulation were very variable. Reasons for 
this discrepancy are considered in the discussion. 
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Figure 37: The IL-6 concentration measured in the supernatants taken from PBMC cultured for 
24 hours with LPS (1 µg/ml) and IFNγ (100 ng/ml) for the final 4 hours. Each symbol represents 
an individual study participant. The red line represents the mean for the group. NS= not 
significant. 
 
 
3.2.4 Summary 
CD3+, CD14+, CD19+, CD123+ and CD11c+ PBMC in all subjects constitutively 
produced low to modest levels of intracellular IL-6. This corresponded with very low 
concentrations of secreted IL-6 in parallel cultures (<8.5 pg/ml). Stimulation of PBMC 
with IFNγ/LPS induced strong intracellular IL-6 responses in all cell types of some 
samples. Overall, however, responses were highly variable and no significant 
differences in cell responsiveness were observed between PMR, RA and control 
samples. In contrast, secreted IL-6 increased dramatically following stimulation of all 
cultures (>1000 pg/ml) with LPS and IFNγ, suggesting intracellular staining may not 
reflect the secretory capacity of these cells, but also confirming no differences between 
PBMC responses of PMR RA and control groups. 
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3.3 The cytokine profile of PMR patients, RA patients and healthy 
controls (refer to Aim 6 in Section 1.16) 
3.3.1 Measurements of other inflammatory cytokines in the plasma 
A panel of other cytokines (IL-10, TNFα, IL-12p70, IL-1β, IL-2, IL-4, IL-8, 1L-17A 
and IFNγ) were measured in the plasma of the PMR patients, RA patients and healthy 
controls in order to examine the disease pathologies more broadly (Figure 38).  
All of the cytokines measured in healthy controls fell below the sensitivity threshold 
for the CBA assay and were therefore not detectable, except for IL-8 in all subjects, 
and IL-12p70 in one subject (Figure 38a). Concentrations of IL-8 in healthy controls 
ranged from 3.6 to 7.1 pg/ml, with a mean of 5.2 pg/ml (Figure 39) 
The same cytokine panel was measured in the plasma of RA patients by CBA (Figure 
38b). Concentrations of IL-17A, IFNγ and IL-1β were not detectable in any 
participants as they fell under the sensitivity threshold of the CBA kit. Two out of six 
RA patients, however, had significantly elevated concentrations of five other 
cytokines, IL-10, TNFα, IL-12p70, IL-2 and IL-4 (Figure 38b). This suggests a 
potential difference in disease pathology in these RA patients. Plasma IL-8 was 
detectable in all RA subjects (range; 6.3-32.0 pg/ml, mean; 12.1 pg/ml) (Figure 39), 
however, the mean was not statistically different to the mean of the IL-8 concentration 
in healthy controls (P= 0.100). 
This panel of cytokines was also measured in the plasma of PMR patients by CBA 
(Figure 38c). In contrast to RA and similarly to the healthy controls, all cytokines 
were below the lower threshold of detection, except for IL-6 and IL-8 (range; 6.3-32.0 
pg/ml, mean; 8.1 pg/ml). Again, although the mean concentration of IL-8 was visibly 
higher than the mean IL-8 concentration in healthy controls, the P value was not 
significant (P= 0.103) (Figure 39).  
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Figure 38: The concentration of ten cytokines measured in the plasma of RA (b) and PMR (c) 
patients and healthy controls (a) of a similar age. Each symbol represents the geometric mean of 
n=4 repeats for IL-6, IL-10 and TNFα and n=2 repeats for all other cytokines for each participant. 
The dotted red line represents the lowest threshold level of detection as stated on the CBA kits.  
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Figure 39: The concentration of IL-8 in the plasma of RA and PMR patients and healthy controls 
of a similar age. IL-8 concentrations were measured in the plasma by CBA. Each data point 
represents the geometric mean of n=2 results for each patient. The red line represents the mean 
for the group. NS= not significant. 
 
3.3.2 Measurements of other inflammatory cytokines in the serum 
The concentrations of these cytokines were also measured in the serum by CBA 
(Figure 41), which demonstrated similar results but perhaps greater sensitivity. For 
example, in healthy control patients and PMR patients only IL-8 was detectable above 
the threshold limit of the kits, except for one control subject who had raised IL-4 and 
IL-2 levels. In the serum of the same two RA patients (SP7 and SP14), levels of IL-10, 
TNFα, IL-12p70, IL-2, IL-4 and IL-8 were raised to a detectable level, with a third RA 
subject (SP11) also having detectable levels of TNFα, IL-2 and IL-4 (Figure 41b).  
A Bland-Altman plot comparing IL-8 concentrations in the plasma and serum showed 
a cluster of patients with a very small difference in the mean measurements (close to 
zero) at the lower end, suggesting that the measurements for plasma and serum were 
agreeable (Figure 40). As with IL-6, there is, however, a clear bias in favour of the 
serum measurements particularly at the higher end (mean IL-8 concentration 10 pg/ml 
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and above), also evidenced by the fact that nearly all data points are below zero. This 
suggests that the concentrations of both cytokines are higher in the serum than in the 
plasma, particularly at the higher end of the measurements where there is more 
variation.  
 
Figure 40: Bland Altman plot comparing IL-8 concentrations measured in the plasma and serum 
of RA and PMR patients and healthy controls of a similar age. Each data point represents one 
participant. 
 
3.3.3 Summary 
Looking more broadly at cytokine responses in the serum and plasma of our 
participants, a small number of RA patients (2 out of 6) were found to have raised 
levels of several cytokines together including IL-4, TNFα, IL-10, IL-12p70 and IL-2. 
This was not observed in PMR patients or healthy controls, and may indicate that 
different disease pathologies exist within RA that are not present in PMR, although has 
to be applied in interpretation due to the small sample numbers. 
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 Figure 41: The concentration of ten cytokines measured in the serum of RA (b) and PMR (c) 
patients and healthy controls (a) of a similar age. Cytokines were measured by CBA. Each 
symbol represents the geometric mean of n=2 repeats for IL-6, IL-10 and TNF and n=1 repeat 
for all other cytokines for each participant. The dotted red lines represent the threshold levels 
of detection for the CBA kits. 
(c) 
(a) 
(b) 
Cytokine 
Cytokine concentration in serum (pg/ml) 
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3.3.4 Cytokines in the culture supernatant of resting (unstimulated) PBMC  
The same panel of nine cytokines (as well as IL-6) were measured in the PBMC 
culture supernatants of unstimulated PBMC (Figure 42a-c). Only secreted IL-8 was 
detectable in all three patient groups. The concentration of secreted IL-8 in the culture 
supernatants was around 100 times greater than the concentration of IL-8 measured in 
the serum. Results suggest that a high concentration of IL-8 is constitutively secreted 
by one, a few, or all of the PBMC types when in a resting state in all the subjects, 
including the healthy controls. There was no significant difference between the mean 
IL-8 concentration of the healthy controls (1082.4 pg/ml (range: 515.3-2274.0)), RA 
patients (2116.6 pg/ml (range: 410.8-2269.0)) and PMR patients (1946.4 pg/ml (range: 
622.5-4577.7) (Figure 43), although the range for PMR was notably higher. 
TNF was detected in the unstimulated PBMC culture supernatants of three healthy 
controls, three RA patients, and one PMR patient only, at a maximum concentration of 
26.1 pg/ml. IL-1β was measured at a concentration of 181.7 pg/ml in one PMR patient. 
One other PMR patient, one RA patient and one healthy control also had detectable 
levels of IL-1β, however the maximum concentration for these other subjects was 14.2 
pg/ml. IL-17A was measured in one healthy control at a concentration of 21.5 pg/ml. 
The concentration of IL-17A in all other subjects fell below the high sensitivity 
threshold for the CBA assay (18.9 pg/ml). IL-12p70, IFNγ, IL-10, IL-4 and IL-2 were 
not detectable in the unstimulated PBMC culture supernatants in any of the subjects. 
Taken together, the culture supernatants from unstimulated PBMC do not reflect the 
cytokine profiles shown in the participants’ serum or plasma. It is possible that 
substances in their own serum or in vivo which are not present in the culture are 
required to stimulate the cells, or alternatively, the PBMC are not the predominant 
source of these cytokines.  
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Figure 42: The concentration of ten cytokines measured in the culture supernatants of 
unstimulated PBMC from RA (b) and PMR (c) patients and healthy controls of a similar age 
(a). Cytokines were measured in the culture supernatants using CBA kits. Each symbol 
represents one participant. The red dotted lines represent the lowest threshold limit of 
detection for the kit. 
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Figure 43: The concentration of IL-8 in the unstimulated PBMC culture supernatants taken from 
RA and PMR patients and healthy controls of a similar age. The concentration of IL-8 was 
measured using a CBA kit. Each symbol represents one participant. The red line represents the 
mean of each group. NS= not significant. 
 
3.3.5 Cytokines secreted in the supernatant of stimulated PBMC cultures 
The supernatants from the stimulated PBMC were also collected after 24 hours in 
culture and stored at -80°C before being analysed by CBA as previously described. 
The same panel of cytokines were measured in these supernatant samples. 
As with the unstimulated PBMC supernatants, IL-8 was present at the highest 
concentrations of all the measured cytokines in stimulated culture supernatants. 
Significantly greater (100-500 fold) concentrations were detected in stimulated PBMC 
culture supernatants (39,190-126,529 pg/ml) compared with unstimulated PBMC 
culture supernatants (229-6,534 pg/ml) (Figure 44a). This indicates that there are one 
or more PBMC cell types which are strongly stimulated by LPS and/or IFNγ to 
produce IL-8. The mean concentration of IL-8 in stimulated PBMC supernatants was 
greater for PMR than RA, and for RA than healthy controls, but this was not found to 
be significant using unpaired T tests (Figure 44a) for these sample sizes. 
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The IL-1β concentration in the supernatants of stimulated PBMC was significantly 
higher than the concentration in the unstimulated PBMC supernatants for all subjects. 
The concentration of IL-1β in stimulated PBMC supernatants ranged from 192.1 pg/ml 
to 4802.9 pg/ml, compared to the concentration in unstimulated PBMC supernatants; 
in which only 4 subjects had detectable levels of IL-1β (i.e. only 4 subjects had levels 
of IL-1β over 7.2 pg/ml). Again, as with IL-6 and IL-8, there was no significant 
difference between the mean IL-1β concentrations in the 3 groups (Figure 44b) 
indicating that PBMC secretion of IL-1β is not linked to PMR or RA disease, but is a 
typical inflammatory reaction to LPS and IFNγ stimulation. 
The concentration of TNF in the stimulated PBMC supernatants was also significantly 
increased above the measured concentration in the unstimulated PBMC supernatants. 
TNF was only detectable in the unstimulated PBMC supernatant of seven subjects (3 
HC, 3 RA and 1 PMR), where TNF levels ranged from 3.8 pg/ml (the threshold of 
detection) to 14.5 pg/ml. TNF levels were detectable in the stimulated PBMC 
supernatants in all subjects, with levels ranging from 11.7 pg/ml up to 479.7 pg/ml 
(Figure 44c). Again, no statistically significant difference between the means of the 
three groups was observed for these sample sizes, indicating that this is the ‘normal’ 
PBMC response to LPS and IFNγ stimulation. 
IL-10 was not detectable in any of the unstimulated PBMC culture supernatants, 
however when stimulated with LPS and IFNγ, three RA patients (SP4, SP6 and SP14) 
and two healthy controls (SP5 and SP16) had detectable levels of IL-10. The 
maximum IL-10 concentration in the healthy controls was 9.8 pg/ml whereas the 
maximum concentration in RA subjects was 32.6 pg/ml. There was no detectable IL-
10 in PMR subjects.  
IL-12p70 was not detectable in the unstimulated PBMC supernatants in any subjects, 
however it was detectable at very low levels in one RA patient (SP7) and one healthy 
control subject (SP16). IL-12p70 was not detectable in the stimulated PBMC 
supernatants in any of the PMR patients.  
IL-17 was only detectable in the unstimulated PBMC supernatant of one healthy 
control subject (SP12) and no RA or PMR subjects. When stimulated with LPS and 
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IFNγ, however, one healthy control subject had a raised concentration of IL-17 (SP5-
57.5 pg/ml) in the PBMC supernatant, and two RA patients had elevated IL-17 
concentrations (SP4-85.7 and SP6-104.9 pg/ml). No PMR patients had raised levels of 
IL-17 in the stimulated PBMC supernatant, this time suggesting that IL-17 may be 
linked to RA but not to PMR. A larger patient cohort would be required to confirm 
this. 
IL-2 was only detectable in the stimulated PBMC supernatant of two RA patients (SP4 
and SP6) and no other subjects. IL-4 was detectable in the stimulated PBMC 
supernatant of only one RA patient (SP4) and no other subjects. IFNγ was added to the 
stimulated PBMC for the final four hours of culture in order to stimulate certain cell 
types, thus analysing the levels of secretory IFNγ in these samples was not possible. 
 
3.3.6 Summary  
 
When left unstimulated, PBMC did not consistently secrete significant concentrations 
of any cytokine, except IL-8. No significant differences between the IL-8 secreted by 
disease groups and control group were observed. Upon stimulation with IFNγ/LPS, 
increased secretion of IL-8, TNFα and IL-1β from PBMC was observed. Nonetheless, 
there were no significant differences between cytokines secreted by PBMC in disease 
groups and the control group. 
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Figure 44: The concentration of secreted (a) IL-8 (b) IL-1β (c) TNF in culture supernatants taken 
from PBMC stimulated for 24 hours with LPS (1 μg/ml) and IFNγ (100 ng/ml) for the final 4 
hours. Each symbol represents one participant. Concentrations were measured using CBA kits. 
The red lines represent the mean for the group. NS= not significant.
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Previous studies have looked for the source of IL-6 specifically in peripheral blood 
monocytes in PMR, with varying results and no clear-cut answers. Roche and 
colleagues suggested that monocytes were the source, using PCR methods to 
determine that monocytes contained IL-6 mRNA, whereas T cells did not (Roche et 
al., 1993). There was, however, no difference between PMR patients and healthy 
controls, and just because the monocytes contained IL-6 mRNA did not prove that they 
secrete it or are the major source. Alvarez-Rodriguez and co-workers, however, 
concluded that monocytes were not the major source of IL-6 in PMR, using 
intracellular staining and flow cytometry methods (Alvarez-Rodriguez et al., 2010). 
They did not, however, present a complete set of data, only taking into account the 
percentage of IL-6 positive cells and not the MFI of IL-6 staining. Moreover, almost 
100% of monocytes were stimulated in both PMR patients and controls, making it 
difficult to observe increases in IL-6 production in the patients with PMR. 
Furthermore, this study did not include a disease control, thus it was not possible to 
control for the effects of raised circulating IL-6 concentrations on IL-6 responses in the 
monocytes.  
This study aimed to resolve these issues, ensuring that laboratory work was completed 
with appropriate controls and an exhaustive approach to explore the PBMC as a 
possible source of IL-6 in PMR. Two types of negative control were included in the 
present study, one group had no sign of inflammatory disease and were thus deemed 
the ‘healthy controls’, and the other group were patients with active RA and thus had 
raised circulating concentrations of IL-6. This meant that any general effects caused by 
this circulating IL-6 had been controlled for, and any differences seen in PMR PBMCs 
were related specifically to PMR disease pathogenesis.  
This section will discuss the findings, limitations, and implications of the present 
study, answering some of the questions relating to the pathogenesis of PMR in the 
same order as the methods and results. Secondary findings relating to RA are also 
discussed here, with an emphasis on comparing the pathogenesis of these two 
inflammatory diseases.  
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4.1 The significance of IL-6 in PMR disease pathogenesis 
 
4.1.1 Circulating IL-6 in PMR and RA (refer to Hypothesis 1 in Section 1.15, Aim 
1 in Section 1.16) 
In agreement with previous studies (Straub et al., 2000, Cutolo et al., 2006), it was 
confirmed that mean IL-6 concentrations are significantly elevated in the plasma and 
serum of PMR and RA patients compared to healthy controls of a similar age and 
gender distribution (Section 3.1.2). Unlike previous studies, the timing of the blood 
sampling and processing was strict, in order to account for the circadian variation 
associated with IL-6 (Crofford et al., 1997, Perry et al., 2009). Age and gender 
boundaries were also adhered to with regards to recruitment of the patients, confirming 
that the differences seen here are relevant to PMR and RA, not due to natural 
immunosenescence or hormonal differences. 
As IL-6 concentrations are consistently and significantly raised in PMR and RA 
patients compared to healthy controls, IL-6 could potentially be a good bio-marker for 
these diseases. If a quick and economically viable method of measurement became 
available then measuring circulating IL-6 could become an important tool for 
clinicians in terms of diagnosing both PMR and RA. Nevertheless, serum and plasma 
IL-6 is raised in other inflammatory conditions so existing disease criteria would also 
need to be used alongside the measurement of this clinical disease marker. 
 
4.1.2 IL-6 measurement: plasma vs serum (refer to Hypothesis 2 in Section 1.15, 
Aim 2 in Section 1.16) 
According to the literature, there is no agreement as to whether plasma or serum 
should be used to analyse cytokine profiles. Thus in this study, IL-6 was measured in 
both the plasma and the serum in order to observe if there were any major differences 
in IL-6 concentrations observed. The serum was separated from the rest of the blood 
constituents at the clinic within one hour of being extracted and the plasma was 
separated within two hours, after whole blood was transported from the clinic to the 
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UWE laboratories (30-40 minute journey), meaning that the timing of the separation of 
plasma and serum from other blood constituents, and the conditions of storage varied 
slightly between plasma and serum. Therefore this needs to be taken into consideration 
when comparing cytokine concentrations in these two blood components. The 
composition of plasma and serum also varies considerably. Serum is separated from 
fibrin in clotted blood, as well as blood cells and related coagulation factors by 
centrifugation, whereas plasma is separated from blood cells only, due to the addition 
of an anticoagulant prior to centrifugation (Yu et al., 2011). This means plasma still 
contains clotting factors which could affect cytokine measurement. Serum on the other 
hand is reported to contain RF, which may also interfere with cytokine measurement 
(Bartels et al., 2011, Churchman et al., 2012, Bartels and Madsen, 2013). 
A correlation between the concentration of IL-6 measured in the plasma and serum of 
participants was observed (Section 3.1.3). Plasma and serum IL-6 concentrations 
correlated very well with a high correlation coefficient of 0.961 (P< 0.0001), however, 
there was a clear bias towards the serum measurements highlighted by the >45° angle 
of the regression line (Figure 14). A Bland and Altman plot confirmed this bias 
towards the serum measurements. This bias towards the serum measurements was 
similar for IL-8, which was also measured in the plasma and serum by CBA (Figure 
38). This indicates that although the values correlated well and thus were roughly 
equivalent, the values were not exactly the same. Serum values were consistently 
higher than the plasma values, which could mean that the preparation method for 
serum may be more suitable for cytokine measurement, however, it could alternatively 
mean the shorter time to freezing of the serum preserves the higher concentrations of 
cytokines, which appear to be more quickly degraded in plasma. 
 Future studies should therefore consider carefully which blood component to use 
when studying cytokine profiles and also how to prepare and store samples in order to 
reduce degradation of cytokines. There are a number of factors which may have 
affected cytokine concentrations in the plasma and serum and these are discussed in 
the following section.  
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4.1.3 Biological activity of raised IL-6 (refer to Hypothesis 3 in Section 1.15, Aim 
3 in Section 1.16) 
Having confirmed that IL-6 was elevated in the circulation of PMR patients, it was 
then necessary to determine whether this IL-6 was active and thus capable of causing 
the pathological symptoms experienced by PMR patients. Results showed for the first 
time, that the IL-6 present in the plasma of PMR patients is biologically active, 
determined by the proliferation of IL-6-dependent B9 cells following incubation with 
the participant plasma samples (Section 3.1.5). It was confirmed that the IL-6 
measured in the plasma of RA patients (most likely to be derived from the synovium) 
was also biologically active. This confirms a crucial role for IL-6 in the pathogenesis 
of these diseases. 
Biologically active concentrations of IL-6 in the plasma measured by the B9 bioassay 
were actually higher than the IL-6 concentrations measured by CBA, at the higher 
values. According to Mire-Sluis and colleagues, immunoassays (such as ELISA and 
CBA) provide very ‘variable estimates’ of cytokine concentration in the sample, 
whereas bioassays may provide a more accurate estimate of the concentration of active 
cytokine in the sample (Mire-Sluis et al., 1995). Therefore the results from bioassays 
provide a more accurate representation of the action of IL-6 in vivo. The B9 bioassay, 
for example, takes into account the action of the IL-6 when free and when bound to its 
soluble receptor. The IL-6 soluble receptor has also been shown to enhance the 
sensitivity of B9 cells in a dose-dependent manner (Diamant et al., 1994).  
Concentrations of the soluble IL-6 receptor have been shown to be increased in RA 
patients compared to healthy controls (Robak et al., 1998), which may have enhanced 
the B9 cell proliferation and could explain the higher concentrations of IL-6 measured 
in the B9 bioassays compared to the CBA assays. The concentration of soluble IL-6 
receptor has not yet been quantified in PMR patients. Jones and colleagues suggest that 
the soluble IL-6 receptor itself may actually contribute to the pathology of diseases 
such as RA, where it has such a crucial role in controlling IL-6-mediated events (Jones 
et al., 2001). 
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4.1.4 IL-6 and fatigue (refer to Hypothesis 4 in Section 1.15, Aim 4 in Section 
1.16) 
Until recently, researchers have looked for correlation between fatigue and IL-6 in 
PMR but found unexpectedly poor correlation, despite a clear temporal correlation in 
early morning IL-6 levels and fatigue symptoms. Thus, the following step was to 
determine whether IL-6 was directly associated with this major and highly debilitating 
symptom of PMR and RA. The recently devised BRAF-MDQ has given clinicians a 
deeper insight into the different aspects associated with fatigue (Hewlett et al., 2005). 
With the development of this questionnaire, it was possible to separate fatigue into 
four different groupings, two with a more somatic aspect: physical fatigue and living 
fatigue, and two with a more psychological aspect: cognitive fatigue and emotional 
fatigue. Other researchers have considered a potential link between IL-6 and fatigue as 
a whole in RA, with one study recently using the BRAF-MDQ to find a correlation 
between serum IL-6 and total fatigue (Helal et al., 2012). Until now, however, no 
study has looked at the individual aspects of fatigue to see whether IL-6 has a 
particular association with certain aspects, and no study has included PMR patients, 
who also suffer from fatigue. 
Here, it is shown for the first time using the BRAF-MDQ, that IL-6 concentrations in 
the plasma of PMR and RA patients and total fatigue score demonstrate an 
unequivocal positive correlation (r= 0.487, P= 0.030), indicating a significant 
association between IL-6 and fatigue (Section 3.1.6.1). Furthermore, when individual 
aspects of fatigue were plotted against plasma IL-6 concentrations, physical fatigue (r= 
0.479) and living fatigue (r= 0.499) correlated well. Cognitive fatigue (r= 0.067) and 
emotional fatigue (r= 0.311), in contrast, showed no correlation. Overall this suggests 
that the more physiological aspects of fatigue are linked to IL-6, whereas the 
psychological aspects of fatigue are not directly related to IL-6, but may be a 
consequence of the physical aspects.    
Studies have shown that there is a strong relationship between the circadian fluctuation 
of IL-6, activity of the HPA axis, and production of adrenocorticotrophic hormone 
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(ACTH) and cortisol, with cortisol acting to suppress inflammation and cytokine 
secretion in a negative feedback control loop under normal circumstances (Figure 45) 
(Crofford et al., 1997, Morand and Leech, 2001, Perry et al., 2009). In RA, with 
known circadian fluctuation of IL-6, synovial fluid IL-6 concentrations were shown to 
increase around 5.75 hours before increasing in the blood, with plasma cortisol 
concentrations rising 3 hours later in order to suppress and resolve inflammation 
(Perry, 2008). There are, however, reports suggesting that the HPA-axis response is 
defective in PMR and RA patients, resulting in inadequate cortisol and ACTH levels in 
relation to the high circulating levels of cytokines such as IL-6 (Gudbjӧrnsson et al., 
1996, Straub et al., 2000, Straub et al., 2002). Furthermore, increased circulating pro-
inflammatory cytokine concentrations (mainly IL-6) are believed to play a direct role 
in the dysfunction of the HPA-axis (Choy, 2012).  
  
 
 
 
 
 
 
Figure 45: Illustration adapted from Perry (2008), showing the regular HPA axis control loop 
(dotted line on left) and the hypothesised cortisol/IL-6 negative feedback loop (dotted line on 
right). In RA and PMR inadequate HPA axis mechanisms (red arrow) in relation to circulating 
IL-6 levels may lead to fatigue symptoms. Narrow solid lines indicate positive feedback and 
narrow dotted lines indicate negative feedback. 
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This malfunction of the HPA-axis has been linked to the development of fatigue 
(Tsigos and Chrousos, 2002 and Sriringan and Choy, 2010), although the exact 
mechanisms involved are yet to be resolved (Figure 45).  Nonetheless, this link is 
apparent in the results of the present study, where increased concentrations of IL-6 in 
both RA and PMR patients correlated well with the physical aspects of fatigue. Thus, 
the existence of a relationship between circulating IL-6 concentrations and fatigue 
seems very likely, and should form the basis for new research into the physiological 
mechanisms behind this relationship.  
Moreover, a link between the CRP levels of PMR and RA patients and fatigue was 
explored. As expected, a significant correlation was observed between this secondary 
measure of inflammation and fatigue when using Spearman’s rank correlation 
coefficient (rs= 0.661). Furthermore, the quality of IL-6 assays was confirmed by 
testing the strength of the correlation between plasma IL-6 concentrations and CRP 
levels. CRP is raised in response to raised circulating IL-6 levels. When tested using 
Spearman’s rank correlation coefficient, a strong correlation between CRP and IL-6 
levels was found at the 0.5% probability level, suggesting that the results from the IL-6 
assays were accurate as they corresponded well with this secondary measure of 
inflammation. 
 
 
4.2 Exploring the cellular source of IL-6 in PMR (refer to Hypothesis 
5 in Section 1.15, Aim 5 in Section 1.16) 
With IL-6 confirmed as having a role in the pathogenesis of PMR, and in particular 
having a potential role in the onset of fatigue, the crucial next step was to explore the 
cellular source of the elevated circulating concentrations of IL-6. It was hypothesised 
that one of the PBMC types (T cells, monocytes, B cells or DCs) may be responsible 
for the significant quantities of IL-6 measured in the plasma and serum of PMR 
patients. RA patients whose circulating IL-6 is derived from synovium in the joints, 
were used as an independent control for the downstream activation of peripheral blood 
cells by high levels of circulating IL-6. 
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4.2.1 IL-6 production by PBMC in ‘a resting state’ 
It was demonstrated that all cell types in all participants were capable of producing IL-
6 in ‘a resting state’, but mostly at low or very modest levels (Section 3.2.2). Some 
cell types constitutively produced IL-6; with nearly all monocytes in all subjects 
(disease and controls) staining positively for IL-6 (70-100%), and a high percentage of 
the two types of dendritic cells staining positively for IL-6 (35-100%) in all subjects. 
The percentage of lymphocytes (CD3+ T cells and CD19+ B cells) which were 
positive for IL-6 was more varied (4-99% and 13-100% respectively). When looking at 
the MFI of IL-6 staining in the same cells, however, it became clear that only low or 
modest concentrations of IL-6 were present in all of the cells.  
Crucially, there were no significant differences between the percentage of IL-6 
positive cells or MFI in the PMR patients, RA patients and healthy controls in the 
unstimulated PBMC. This was confirmed in parallel cultures, where very low 
concentrations of secreted IL-6 were measured in culture supernatants from resting 
PBMC (<9 pg/ml), with no difference between the patient groups and healthy control 
group. Thus without additional stimulation, the PBMC from patients with active 
disease (and no treatment at the time of sampling) were not the source of elevated 
concentrations of circulating IL-6 in PMR patients. 
When calculating the absolute number of IL-6 producing cells for each PBMC cell 
type using data from the flow cytometry assays (i.e. the percentage of IL-6 positive 
cells) and the WCCs provided by the clinicians (Section 3.2.2.3), it was found that the 
mean number of IL-6 producing CD14+ monocytes was significantly higher (P< 0.05) 
in PMR patients and RA patients compared to healthy controls. This may suggest that 
monocytes produce large quantities of IL-6 in inflammatory diseases. There was, 
however, no significant difference between PMR and RA samples, and no single cell 
type which produced elevated concentrations of IL-6 in PMR patients alone, 
confirming that the PBMC are not the source of IL-6 in PMR patients. Actual WCCs 
were not performed on healthy control samples, so published ‘normal’ values were 
used to calculate absolute numbers of IL-6 producing cells in healthy controls. With 
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the values for healthy controls based entirely on estimated total white cell counts, these 
results must be interpreted with caution, but they do substantiate the previous findings. 
 
4.2.2 Evidence to support findings 
There is strong evidence in the literature which demonstrates that the five cell types 
under study are capable of producing IL-6 (Section 1.11). Furthermore, a study by 
Kashipaz and colleagues demonstrates that PBMC in normal subjects constitutively 
produce low levels of IL-6 when in a resting state (Kashipaz et al., 2003), confirming 
observations in this study. Kashipaz and colleagues also found that there were a higher 
percentage of IL-6 positive CD14+ cells than CD14- cells, i.e. monocytes produce 
more IL-6 than the other PBMC (Kashipaz et al., 2003), again corroborating the 
findings from the present study, where almost all monocytes in all patients were found 
to constitutively produce IL-6.  
In contrast to the present study, Alvarez-Rodriguez and colleagues measured the 
percentage of unstimulated monocytes containing intracellular IL-6 in PMR patients 
and healthy controls, and found that a mean of approximately 30% were positive for 
IL-6 in both groups (Alvarez-Rodriguez et al., 2010). This was much lower than the 
percentage of IL-6 positive monocytes measured in this study. The PBMC were, 
however, treated very differently. In the study by Alvarez-Rodriguez and colleagues, 
whole blood samples were cultured for four hours prior to surface staining (Alvarez-
Rodriguez et al., 2010).  PBMC were subsequently separated by lysing the red blood 
cells (RBCs) and the PBMC were then fixed, permeabilised and intracellularly stained 
(Alvarez-Rodriguez et al., 2010). In the present study PBMC were separated on 
Histopaque 1077 and cultured for 24 hours both of which may have stimulated further 
IL-6 production from the monocytes.  
In summary, PBMC from RA, PMR and HC groups all constitutively contain low 
levels of IL-6, including the majority of monocytes and DC, and a proportion of T and 
B cells. No significant differences were observed between patient samples and controls 
that could account for elevated IL-6 in PMR, despite the fact that samples were taken 
from patients with currently active and untreated disease at the time of sampling. 
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4.2.3 PBMC response to in vitro stimulation  
Having demonstrated that PBMC from PMR patients do not constitutively contain or 
produce IL-6, it was hypothesised that PBMC in the PMR patients may have an altered 
or enhanced IL-6 response to factors present in vivo, causing an overproduction of IL-
6. To test this theory, the PBMC were subjected to stimulation with LPS and IFNγ 
which was shown to stimulate all cell types in pilot studies using PBMC from healthy 
controls.  
Despite good responses to LPS/IFNγ in healthy controls, the overall responses to 
stimulation in vitro were hugely variable, with some cells responding strongly, some 
proving unresponsive and some being negatively affected by stimulation in all groups 
(whether examining intensity or percentage of IL-6 positive cells). The type of 
response to stimulation appears to be person-specific. Overall PBMC from PMR 
patients were not found to differ in their responsiveness to stimulation in vitro 
compared to RA or healthy controls, with both responders and non-responders evident 
in all groups. 
 
4.2.4 Secreted IL-6 in PBMC culture supernatants 
In contrast, stimulation of PBMCs with LPS/IFNγ induced dramatic secretion of IL-6 
in all samples as quantities greater than 1019 pg/ml were measured in PBMC culture 
supernatants, compared to less than 9 pg/ml in unstimulated PBMC culture 
supernatants (Section 3.2.3.3). There were, however, no significant differences 
between the mean concentrations of secreted IL-6 in PMR patients, RA patients and 
healthy controls. This confirms that although all these cell types are capable of IL-6 
production (specifically in response to 24 hour LPS/ 4 hour IFNγ stimulation), the 
PBMC cell types in PMR patients were not behaving any differently to those in RA 
patients and healthy controls, and one, a few, or all cell types secreted large quantities 
of IL-6 in response to stimulation. This substantiates the previous evidence that the 
PBMC are not the source of the significantly raised serum/plasma IL-6 in PMR.  
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4.2.5 Evidence to support findings 
Roche and colleagues similarly found that there was no difference in IL-6 secretion by 
PBMC cultured from PMR patients, GCA patients and normal healthy controls in 
response to anti-CD3 stimulation (Roche et al., 1993).  After 24 hours in culture, IL-6 
was produced by the PBMC from PMR patients (mean 42 pg/ml), GCA patients (mean 
99 pg/ml), and normal healthy controls (mean 74 pg/ml) at ten-fold lower levels than 
this study, which may reflect the use of different stimulants. Roche and colleagues 
provided weak evidence that the monocytes may be the source of the spontaneous IL-6 
secretion in PMR, and attribute the fact that there was no difference in responsiveness 
between the groups to the fact that they did not use a monocyte-specific stimulus 
(Roche et al., 1993). LPS, used in the present study, has the ability to stimulate IL-6-
production in monocytes (Rossol et al., 2011) alongside IFNγ (Delneste et al., 2003). 
Thus, even when a monocyte-specific stimulant was applied, there was no evidence to 
suggest that monocytes are the source of elevated IL-6 in PMR. This concurs with the 
findings of Alvarez-Rodriguez and colleagues who also examined ex vivo CD14+ cell 
responses to LPS stimulation (Alvarez-Rodriguez et al., 2010). This study extends 
their work by examining the intensity of staining within the monocyte population, and 
concludes that monocytes are not the source of elevated circulating IL-6 in PMR 
patients.  
For the first time other cells within the PBMC population, namely T cells, B cells and 
DCs, were examined as the potential source of IL-6 in PMR. Using IFNγ and LPS 
stimulants capable of triggering IL-6 production from monocytes and all of the other 
PBMC, no differences were observed between the mean concentrations of IL-6 
produced by PMR patients, RA patients and healthy controls in the present study. 
These PBMC are thus not the likely source of spontaneous IL-6 production in PMR. 
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4.2.6 Another cell type within PBMC cultures responsible for IL-6 production? 
It is possible that that there may be other cell types, like natural killer (NK) cells, 
within the PBMC cultures that may be capable of secreting high levels of IL-6, but 
which were not identified by flow cytometry due to it not expressing one of the five 
surface markers which the cells were stained for (CD3, CD14, CD19, CD123 or 
CD11c).  
NK cells are a potent source of IL-6 (Al-Tae, 2012) and are stimulated by LPS (Conti 
et al., 1991). NK cells are likely to have been present in the cultures and they do not 
possess surface CD3 (Anderson et al., 1989) or any of the other surface markers which 
were stained for, meaning that they would not have been identified by flow cytometry. 
Distinguishing NK cells is problematic as they lack an NK-specific cell surface marker 
(Milush et al., 2009), but with NK cells making up approximately 10- 20% of the 
PBMC (Zamai et al., 2007), this does make them a potential source of the IL-6 found 
in the stimulated PBMC culture supernatant samples. Research, however, has 
suggested that patients with active untreated PMR have significantly lower numbers 
and relative percentages of lymphocytes with natural killer cell activity than healthy 
controls (Uddhammer et al., 1995), meaning that they would be an unlikely source of 
the IL-6 in PMR patients. Furthermore, even if NK cells are capable of producing IL-6, 
there were no significant differences between the IL-6 concentrations measured in the 
PBMC supernatants of PMR patients, RA patients and healthy controls, indicating that 
NK cells are not likely to be critically involved in the pathogenesis of PMR. 
Alternatively, some peripheral blood cell types may have been excluded, like 
neutrophils, due to the PBMC isolation process. Neutrophils are polymorphonuclear 
rather than mononuclear and were therefore not isolated alongside the other cells types, 
so could not account for the elevated IL-6 in the stimulated PBMC culture 
supernatants. They could, however, be the source of elevated circulating IL-6 in PMR 
patients, as they are known to be capable of producing IL-6 (Kaplanski et al., 2003). 
Alvarez-Rodriguez and colleagues recently showed that effector functions of 
phagocytes, are deregulated in PMR, GCA and elderly onset RA patients and have 
suggested that that neutrophils may have a pathogenic role in these inflammatory 
diseases (Alvarez-Rodriguez et al., 2013); however, they did not look specifically at 
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IL-6 production in these cells. Hence, this requires further exploration in order to 
confirm whether neutrophils may be the source of IL-6 in PMR. 
 
4.2.7 Summary 
Taken together, using different methods to test the hypothesis, PBMC were 
consistently found not to be the source of elevated plasma/serum IL-6 in PMR patients. 
Using a highly sensitive method to look at intracellular IL-6 production at a single cell 
level in PMR patients, RA patients and healthy controls, as well as measuring 
secretory IL-6 concentrations in the serum and plasma and in parallel PBMC 
supernatant cultures, it has been confirmed that there is no difference in the production 
or secretion of IL-6 between unstimulated and stimulated PBMC of PMR patients, RA 
patients and healthy controls. Thus, it is concluded that PBMCs are not the source of 
raised IL-6 in PMR. 
 
 
4.3 Other circulating cytokines in PMR and RA (refer to Hypothesis 6 
in Section 1.15, Aim 6 in Section 1.16) 
A panel of nine cytokines (excluding IL-6) were quantified in the plasma and serum of 
the PMR and RA patients alongside the healthy controls in order to determine whether 
any other cytokines play a role in the pathogenesis of PMR and to examine the 
cytokine profile of RA more broadly (Section 2.4). 
 
4.3.1 IL-8  
The proinflammatory chemokine, IL-8 was detectable in the plasma and serum of 
almost all RA patients (plasma: 6- 32 pg/ml, serum: 11- 36 pg/ml), all PMR patients 
(plasma: 5- 16 pg/ml, serum: 6- 18 pg/ml) and all healthy controls (plasma: 4- 7 pg/ml, 
serum: 4- 23 pg/ml) (Section 3.3). Visually there appears to be a trend towards higher 
Chapter 4 - Discussion 
154 
 
IL-8 concentrations in the plasma and serum of RA patients and PMR patients than the 
healthy controls. There were, however, no significant differences between the mean 
plasma and serum IL-8 concentrations of the three groups. This indicates that 
circulating concentrations of IL-8 are naturally higher than the other cytokines 
measured in the plasma and serum, however, based on this data, IL-8 is not likely to 
have a role in the pathogenesis of RA or PMR.  
In contrast, in a much larger study, Alvarez-Rodriguez and colleagues found that 
circulating serum IL-8 concentrations were significantly elevated in patients with 
elderly-onset RA (EORA) (40 subjects) and active PMR (95 subjects) compared to 
healthy controls (25 subjects), even after GC treatment (Alvarez-Rodriguez et al., 
2013). No difference was observed between PMR and EORA serum IL-8 
concentrations (Alvarez-Rodriguez et al., 2013). Reasons for elevated serum 
concentrations of IL-8 in these conditions were considered. Circulating neutrophils in 
patients with EORA demonstrated an ‘increased migratory capacity’, possibly linked 
to increased circulating IL-8 concentrations; however this was only apparent in EORA 
patients. Reasons for increased circulating IL-8 in PMR were unclear, however it was 
suggested that again there may be a link between IL-8 and dysfunctioning neutrophils. 
As there was no significant difference between the mean serum concentration of IL-8 
in RA patients, PMR patients and healthy controls in the present study, it seems that 
the role of IL-8 in the pathogenesis of these diseases may not be as important as the 
role of IL-6, which was significantly raised in the disease groups even with the small 
patient sample numbers. 
 
4.3.2 IL-17 
Previous studies have indicated a key role for IL-17 in the pathogenesis of RA (Hwang 
et al., 2004, Oukka, 2008). Thus, it was predicted that IL-17 would be raised in the 
serum and plasma of the RA patients in this study. IL-17 concentrations in the serum 
and plasma were, however, undetectable in all RA subjects. Evidence suggests that IL-
17 acts locally at the site of the inflammation (the synovium), with high levels 
expressed in the SF of RA patients (Chabaud et al., 1999, Harrington et al., 2005) and 
a direct involvement in the destruction of joint tissue (Oukka, 2008). With such a 
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specific site of action, this could be why elevated levels of IL-17 were not detected in 
the blood. 
A recent study showed that Th17 cell numbers are increased in PMR patients, 
suggesting that IL-17 might be elevated and may, therefore, be contributing to PMR 
disease (Samson et al., 2012). As IL-17 was not raised in the serum and plasma of 
PMR patients, and these patients do not exhibit symptoms of joint inflammation and 
destruction, it does not seem likely that IL-17 has a critical role in PMR disease 
pathogenesis. 
 
4.3.3 Other circulating cytokines in PMR and RA- current knowledge and new 
evidence 
In a previous study by Clarke and colleagues, it was demonstrated that the cytokines 
TNFα, IL-1β and IL-4 were elevated in the plasma of a sub group of RA patients (3 
out of 9 individuals), which they proposed may be linked to the fact that these patients 
were also unresponsive to GC therapy (Clarke et al., 2011). This was, however, only a 
small-scale study and the real significance of this finding was unclear. To add weight 
to this finding, in the present study it was also found that cytokines TNFα and IL-4 
were raised in the serum and plasma of a sub-group (2 out of 6) of RA patients, but not 
PMR patients or healthy controls (Figure 37 and 40). In contrast to the study by 
Clarke and co-workers, plasma and serum IL-1β concentrations were not detectable in 
any of the participants. The detection limit of the CBA kit for IL-1β (7.2 pg/ml), 
however, was higher than that for TNFα (3.8 pg/ml) and IL-4 (4.9 pg/ml), so the kit 
may not have had ‘sufficiently robust’ sensitivity (Churchman et al., 2012) to detect 
low levels of IL-1β that may have been present in the samples.  
Knowing the key role of TNFα in inducing synovitis and inflammatory cytokine 
production in RA (Section 1.5.1), it was not surprising that this cytokine was elevated 
in the serum and plasma of some RA patients in this study. In line with the present 
study, Cicuttini and colleagues demonstrated that IL-4 was raised in a sub group of 
patients with RA (12 out of 140 patients), as well as sub-groups of patients with 
systemic lupus erythematosus (2 out of 19 patients), psoriatic arthritis (2 out of 24 
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patients) and Behҫet’s syndrome (1 out of 5 patients), whilst no IL-4 was detected in 
any PMR patients tested (6 patients) (Cicuttini et al., 1995). It remains unclear as to 
why this cytokine is raised in only a subset of these patients, but it seems that it may 
not be crucial to the onset of these diseases; otherwise all patients would be exhibiting 
high levels of the cytokine. Hence, it seems that IL-4 is likely to be elevated as a 
consequence of the disease process, as opposed to being a direct contributor to RA 
pathogenesis.  
 
4.3.4 Further raised cytokines in same RA sub-group 
As well as confirming that cytokines TNFα and IL-4 were raised in the serum and 
plasma of a subset of RA patients, it has been shown for the first time that there are a 
range of other cytokines, namely IL-2, IL-12p70 and IL-10 which are also elevated in 
the same subset of RA patients (Figure 37 and 40). As with TNFα, IL-4 and IL-1β, 
these cytokines were not raised in PMR patients compared to healthy controls. 
Furthermore, using data taken from the MD thesis of Dr Mark Perry, where a range of 
cytokines were measured in the plasma of 16 RA patients using a Luminex100®, it is 
possible to demonstrate that these same cytokines are also raised in a sub-group (50%) 
of RA patients (Perry, 2008) (Table 16). This finding was not identified or discussed 
by the author. 
Using the data from Perry, in order to prove that statistically two sub groups exist 
within RA, with either 5 raised cytokines or no raised cytokines, a system was 
developed whereby the median concentration for each group of cytokines was 
identified, and then the cytokine concentrations for each patient examined to see 
whether it fell above or below the median value (Perry, 2008, Kirwan, J., personal 
communication, 2013). The number of cytokines which were above the median for the 
group was recorded (Table 17) and a Chi-Square test used to determine whether the 
distribution of the number of cytokines above the median was different from what 
would normally be expected (Table 17) in a Gaussian distribution. 
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Table 16: Mean concentrations of cytokines IL-6, TNFα, IL-1β, IL-4 and IL-10 (pg/ml) measured 
in the plasma over a 13-hour period (9pm- 10am) in 16 RA patients.  The median concentration 
for each cytokine for the 16 patients is shown, as well as the number of cytokines above the 
median for each patient. Mean cytokine concentrations that are above the median are highlighted 
in yellow. * indicates below limit of assay detection (<2.4 pg/ml for IL-1β and <0.01 pg/ml for IL-4 
and IL-10) (original data from Perry, 2008).  
 
 
Mean plasma cytokine concentration 
(pg/ml) over a period of 13 hours   
  
No. of 
cytokines 
above median 
Patient 
number IL-6 TNFα IL-1β IL-4 IL-10 
 1 80 15 * * * 
 
1 
2 62 130 10 83 159 
 
3 
3 29 23 * 3 62 
 
0 
4 99 393 40 378 7222 
 
5 
5 45 9 8 27 * 
 
0 
6 30 24 7 250 115 
 
1 
7 66 97 * 53 1155 
 
3 
8 15 8 * * * 
 
0 
9 97 81 7 84 1019 
 
3 
10 53 281 33 209 2206 
 
4 
11 113 77 3 * 301 
 
3 
12 19 24 * * 24 
 
0 
13 184 485 34 574 796 
 
5 
14 23 27 * * * 
 
0 
15 63 62 8 45 40 
 
0 
16 105 452 16 460 3600 
 
5 
        Median 63 69 9 84 549 
   
 
In agreement with the present study, there was a sub-group of RA patients (8 out of 16 
patients) who had raised concentrations of several cytokines namely; TNFα, IL-4, IL-
2, IL-10 and IL-6 (Table 16). There are two distinct groups of patients, those with no 
or one cytokine raised above the median concentration, and those with 3, 4 or all 5 
cytokines above the median concentration. The distribution was statistically different 
from the expected Gaussian distribution (P< 0.0001), confirming the findings from the 
present study, which indicate that there are two sub-groups of RA patients with very 
different cytokine profiles.  
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Table 17: Chi-Square test to confirm the existence of two sub-groups of RA patients: one with low 
concentrations of circulating cytokines, and one with high concentrations of several circulating 
cytokines. 
No. of cytokines above median 0 1 2 3 4 5 
Observed 6 2 0 4 1 3 
Expected 0.5 2.5 5 5 2.5 0.5 
Deviation (O-E) 5.5 -0.5 -5 -1 -1.5 2.5 
Deviation squared (O-E)
2
 30.25 0.25 25 1 2.25 6.25 
(O-E)
2
/E 60.5 0.1 5 0.2 0.9 12.5 
       
Degrees of freedom 5   
Chi-square value higher than critical 
value- therefore statistically there is a 
difference between observed and expected 
values (P< 0.0001) 
   
Chi-square 79.2  
Critical value 11.07  
Chi-squared P 1.234E-
15 
     
 
 
4.3.5 What are the implications of this finding? 
The Th1 immune response is predominant in RA, thus, finding increased 
concentrations of Th1 cytokines such as IL-12p70 in the serum and plasma of some 
RA patients was not overly surprising, especially in the subset of patients who have 
raised levels of a number of other predominantly Th1 cytokines. IL-4, however, 
strongly promotes a Th2 response (Trinchieri, 1995). Studies have shown that IL-4 
suppresses IL-12-induced IFNγ production (D’Andrea et al., 1993), which is why IL-4 
may have been raised in these RA patients alongside IL-12p70. IL-10 was raised in the 
plasma and serum of the same sub-group of RA patients, thus reinforcing the theory 
that IL-10 is over-produced in order to down-regulate the production of pro-
inflammatory cytokines such as TNFα.  
As there are only 2 RA patients out of 6 with increased cytokine concentrations in the 
present study it is difficult to make any proper assumptions about what might be 
happening with these patients. Nonetheless, these two patients do stand out from the 
others, and these results confirm what has been shown in other studies (Cicuttini et al., 
1995, Perry, 2008, Clarke et al., 2011), thus it is reasonable to consider that there 
could be a specific disease mechanism involved. If this were true, there might be 
clinical implications for RA patients. Overall, there is compelling evidence for the 
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existence of two pathologies within RA (and possibly in other immune-mediated 
inflammatory diseases with a synovitis component) with very different cytokine 
profiles, which may require differential diagnosis and treatment. A study with a much 
larger cohort of RA patients (100+) would be necessary to confirm this finding. 
 
4.3.6 Secreted cytokines in the PBMC culture supernatants  
Contrary to what was observed in the serum and plasma, where a subset of RA patients 
were found to have raised concentrations of IL-2, IL-4, IL-10, and IL-12p70, these 
same cytokines were not secreted at detectable levels by PBMC in any of the 
supernatants after 24 hours culture without stimulation (Section 3.3.4). Thus the 
increased concentrations of these cytokines in the serum and plasma must have come 
from an alternative, more localised source, such as the synovial cells, not the PBMC. 
Secreted TNF was detectable in 5 participants, but there were no significant 
differences between RA patients, PMR patients and healthy controls. Secreted IL-1β 
was detected in only 4 participants, with no significant differences between groups, 
and secreted IL-17 was detectable in one healthy control participant. These results 
confirm the idea that in RA, these cytokines are predominantly produced locally by 
cells at the site of inflammation, not by circulating PBMC.  
IL-8 was measured in the unstimulated PBMC culture supernatants of nearly all study 
participants, and was secreted at 200-2000 fold higher quantities (229 pg/ml- 2456 
pg/ml) than the other cytokines measured. IL-8 concentrations in the culture 
supernatants were approximately 100 times greater than the concentration of IL-8 
measured in the serum, suggesting that the PBMC are a major source of IL-8 and that 
the culture conditions may have strongly stimulated the cells responsible. There were, 
however, no significant differences between the unstimulated mean IL-8 
concentrations for the three groups (PMR, RA and healthy controls); again suggesting 
that IL-8 does not play a major role in the pathogenesis of these diseases (Figure 42).  
Stimulation with LPS and IFNγ increased secretory IL-8 concentrations by 100-500 
fold, and as with the plasma and serum data, there is a visible trend towards higher 
secretory IL-8 concentrations in the disease groups, however the means are not 
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significantly different. A larger patient sample would need to be tested in order to 
confirm any role for IL-8 in PMR. As mentioned, Alvarez-Rodriguez and others have 
suggested that circulating IL-8 is raised in RA and PMR patients and may be due to 
dysfunctioning neutrophils (Kreiner et al., 2010, Alvarez-Rodriguez et al., 2013).  
Following stimulation with LPS and IFNγ, secretory IL-1β and TNF concentrations 
also increased in all participants (100- 5000 fold and 10- 200 fold respectively) 
(Figure 43). Again, there were no significant differences between disease and control 
groups, thus suggesting that these are ‘normal’ PBMC responses and thus are not 
related to PMR or RA disease.  
 
4.4 Overall discussion of findings 
Having determined that there is a sub-group of RA patients with raised cytokines in the 
plasma and serum, and provided speculative reasons as to why biologically they might 
be raised, reasons why these cytokines are raised in only a small sub-group of RA 
patients but not all patients were considered, as well as what this tells us about RA and 
PMR, which have previously been considered as diseases with similar pathologies. 
Clarke and colleagues suggested a link between the subgroup with raised cytokines 
and a lack of responsiveness to GC therapy. This has not been tested here but is an idea 
which requires further exploration. There is some weak evidence to suggest that the 
cytokine profile reflects the different stages of disease. According to a study by Raza 
and colleagues, cytokines IL-2, IL-4, IL-13, IL-17 and IL-15 were significantly raised 
only in the sub-group of patients in the very early stages of RA disease, which they 
demonstrated was no longer present in patients with long-term, established disease 
(Raza et al., 2005). Within the data in the present study and the data taken from Perry’s 
thesis there is no evidence of a link between the cytokine profile of the patient and the 
different disease ‘stages’ in RA or PMR patients (Perry, 2008). For example, of the 8 
patients with raised cytokines in Perry’s study, the disease duration spans from 4 years 
to 30 years, and those with all 5 cytokines raised have disease durations of 7, 18 and 5 
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years. Despite the small sample of patients, this does not concur with the theory that 
the cytokines might be raised in the patients only in the very early stages of RA.  
It was also considered that the sub group of RA patients with raised cytokine 
concentrations may display different symptoms or levels of clinical markers. This did 
not appear to be the case based on the data from Perry’s thesis (Perry, 2008). As with 
the present study, all patients were selected because they had clinically active disease. 
Concentrations of clinical markers such as PV and CRP did not correlate with the 
number of cytokines above the median. Notably, however, all patients in the sub-group 
with raised cytokines were positive for RF, whereas those without raised cytokines 
were not all positive for RF. The significance of this finding is unclear at this stage. 
The fact that there are two such different and distinctive cytokine profiles within RA 
patients could indicate that there are two different pathologies within RA disease. This 
also raises the question as to whether the circulating cytokine profile of RA patients is 
acquired or inherent. Only a subset of RA patients displayed these elevated levels of 
particular cytokines, yet all RA patients displayed similar symptoms, thus it could be 
that this cytokine profile may be a consequence of the disease process as opposed to 
being the cause of the disease. One theory is that there may be two types of RA, one 
more immunologically aggressive, which requires higher titres of cytokines in order to 
reduce the inflammation. 
The fact that there was no sub-group with raised cytokines in PMR suggests that RA 
and PMR have very different pathologies. The symptoms of PMR appear to be 
associated entirely with IL-6, of which the source is still unknown, despite these 
extensive investigations. RA patients, on the other hand, are associated with having a 
cascade of different inflammatory cytokines, produced predominantly in the synovium, 
perhaps as a result of the disease process. Thus, despite presenting similar symptoms 
of inflammation and fatigue, there may be two very different underlying causes for 
these diseases.  
Despite demonstrating very similar results, all three studies (Perry, 2008, Clarke et al., 
2011, and the present study) only have very limited patient numbers. A larger scale 
study with a greater number of patients, looking at a larger panel of cytokines, and 
Chapter 4 - Discussion 
162 
 
looking further in depth at the clinical symptoms and clinical markers of disease would 
be required to test these theories and to find out more about the underlying pathologies 
of PMR and RA. 
This brings about the question as to whether PMR may even be called an 
‘inflammatory disease’. This label has been applied to PMR, and perhaps rightly so, as 
increased IL-6 in the blood brings about an APR in all PMR patients (if an APR is not 
present then the diagnosis of PMR is considered incorrect) (Kirwan, J., personal 
communication, 2013), which is a key feature of an inflammatory response. In spite of 
this, with no clear and isolated site of inflammation, the other features of chronic 
inflammation appear to be absent. Inflammation is usually brought about in response 
to tissue damage or infection, with appropriate leukocytes recruited to a specific and 
localised area (Punchard et al., 2004). With no known site of inflammation, however, 
this typical inflammatory response is not observed. The classic signs of inflammation 
are made up of four components; pain (dolor), heat (calor), redness (rubor) and 
swelling (tumour) (Punchard et al., 2004); all of which are present in affected joints in 
RA, but appear to be absent in PMR (but may be manifesting as more systemic 
symptoms). There is a wealth of evidence pointing to the fact that IL-6 is the main 
cause of the symptoms of PMR, however it appears to have a very solitary role in the 
disease, with the other signs of inflammation lacking. This is unless, however, there is 
an inflammatory site that is yet to be discovered. 
 
4.5 Discussion of methodologies 
4.5.1 Limitations of the study 
4.5.1.1 Difficulties with participant recruitment 
Although the target sample numbers for the three participant groups were reached (the 
aim was to recruit 6-10 per group), the number of participants involved in this study 
was still relatively small (7 PMR patients, 6 RA patients and 7 healthy controls). The 
sample number reflected the aim of finding large and obvious differences between 
PMR patients, RA patients and controls, which could then be confirmed later in a 
larger more comprehensive study. If differences between diseased patients and healthy 
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controls were not significant, then it was considered unlikely that they would be 
relevant to our understanding of the pathology of the diseases.  
Other studies in the field have tended toward relatively small to modest sample 
numbers, for example Roche and colleagues included 13 PMR patients and 20 healthy 
controls in a similar study and Alvarez-Rodriguez and colleagues included 34 PMR 
patients and 17 healthy controls in their study into circulating cytokines in PMR 
(Roche et al., 1993, Alvarez-Rodriguez et al., 2010). It suggests that other research 
groups may have struggled with the recruitment of participants, where the inclusion 
criteria for participants are very specific (requiring no current treatment) and a certain 
level of commitment is involved for all parties. 
 
4.5.1.2 Difficulties finding patients to fit study criteria 
 
Difficulties were encountered in getting general practitioners to recruit patients for the 
study, and further difficulties were experienced in the recruitment of patients who had 
not already been put on GC treatment. As a consequence, collecting enough participant 
samples to reach the initial targets took much longer than expected. 
 
4.5.1.3 Commitment for participant 
Although not a huge commitment, patients were required to return to the clinic for 
9am, 48 hours after their initial appointment, and thus were asked to delay their 
treatment for a further two days. This may have been off-putting for those in pain and 
discomfort looking for immediate relief from symptoms. 
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4.5.2 Sample handling 
4.5.2.1 Timing and transportation of blood samples  
The way in which the plasma and serum were separated and handled prior to testing 
may have affected the concentration of IL-6 present in the sample. The serum was 
usually separated from the cellular elements within an hour of being taken from the 
participant, and this sample was subsequently frozen at -80°C as soon as possible 
(Section 2.1.2). This protocol, however, was not always adhered to as the research 
doctors involved were often busy seeing other patients in the rheumatology clinic and 
the process was delayed by variable lengths of time (exact times not recorded). The 
plasma, conversely, was transported from the rheumatology clinic to the UWE 
laboratories (a journey of approximately 30- 40 minutes), and then separated from the 
cellular constituents approximately 1- 1.5 hours after the blood sample was extracted 
from the study participant. The timing of this was relatively consistent from sample to 
sample.   
De Jager and colleagues recommend that serum or plasma are separated from whole 
blood immediately in order to maintain ‘optimal analyte stability’, or within one hour 
if immediate separation is not possible (de Jager et al., 2009). It has also been 
suggested that a delay in sample processing could lead to altered cytokine expression 
as a result of degradation, absorption or increased cellular production of cytokines by 
the blood cells present in the sample (Duvigneau et al., 2003).  
The conditions within the blood collection tube have also been shown to trigger the 
release of cytokines from blood cells, as well as the anticoagulant (sodium  heparin in 
this study), lack of nutrients, cell death and external temperature (Jackman et al., 
2011). Duvigneau and colleagues reported that in porcine blood samples, a delay in 
sample processing (of over an hour) and storing the sample either at RT or at 4°C 
resulted in increases of IL-6, IL-10 and IL-1α production, indicating that monocytes in 
particular may be particularly susceptible to environmental changes (Duvigneau et al., 
2003).  Furthermore, Exley and colleagues recommend that blood samples are stored at 
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4°C for a maximum of 30 minutes prior to separation to ensure the optimal 
measurement of TNFα (Exley et al., 1990). 
Thus the delay in serum and plasma separation (due to busy schedules in the clinic and 
transportation respectively) meant that these samples were not always frozen down 
immediately or within the hour, therefore cytokine concentrations may have been 
affected. The time delay in separating plasma from the whole blood sample was 
consistent for each sample, thus controlling for these effects to some extent. 
Nonetheless, direct comparisons with other studies where the time delay before 
processing is not stated would not be appropriate. External temperatures would have 
differed for each sample as the blood samples were kept at atmospheric temperature 
during the journey- and as the samples were collected over the period of a year, the 
temperature conditions would have varied dramatically from the winter months to the 
summer months.  
 
4.5.2.2 The blood separation process 
The separation processes involved in extracting plasma and serum may in fact trigger 
cytokine production in blood cells. According to Whiteside and colleagues, the clotting 
process involved in separating serum from the blood activates leukocytes within the 
sample to produce cytokines, so for this reason it may be better to quantitate cytokines 
in the plasma instead to avoid this clotting process and thus avoid leukocyte activation 
(Whiteside et al., 1994). This could explain the higher cytokine titres in the serum, 
which contrary to previous assumptions, may not be the ideal outcome. 
 
4.5.2.3 Sample storage 
Long-term storage is also known to affect cytokine stability. According to a study by 
de Jager and co-workers, however, within the short time frame that the samples were 
stored for in this study (<1.5 years), out of the ten cytokines measured, only 
degradation of IL-17 may have occurred (de Jager et al., 2009). As IL-17 was not 
detected in any of the plasma and serum samples and was detected in only one 
unstimulated culture supernatant sample and three stimulated culture supernatant 
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samples, this could be a valid reason. The exact half-life of many cytokines, however, 
has not yet been elucidated, and may vary between cytokines (Bartels and Madsen, 
2013). In the de Jager study IL-6, IL-1β and IL-10 degraded up to 50% of their original 
concentration within 2-3 years in storage, and IL-2, IL-4 and IL-12 began to degrade 
within 3 years in storage (de Jager et al., 2009). This should not have been an issue 
with the short time frame that the samples were stored for, however the lower study 
participant numbers were stored for longer than the higher participant numbers (up to 
1.5 years compared to 1 month) prior to laboratory analysis. 
 
4.5.2.4 Anticoagulant 
Sodium heparin coated the glass blood collection tubes in order to stop the blood 
coagulating. According to a study by de Jager and colleagues, out of three 
anticoagulants tested (sodium heparin, ethylenediaminetetraacetic acid (EDTA) and 
sodium citrate), plasma collected in sodium heparin coated tubes demonstrated the 
most consistent recovery for the range of cytokines that they looked at, including IL-
1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17, TNF and IFNγ (de Jager et al., 2009). 
Consequently they concluded that sodium heparin is the ‘preferred anticoagulant’ for 
measuring cytokines in multiplex assays (de Jager et al., 2009) and endorses its use in 
this study. Alternatively, Riches and colleagues suggest that in order to reflect in vivo 
cytokine measurements, it does not matter which anticoagulant is used, as long as it is 
endotoxin-free (Riches et al., 1992).  
 
4.5.2.5 Sample freeze-thawing 
The process of freeze-thawing a plasma or serum sample is believed to affect the 
stability of cytokines. Each test (ELISA, CBA, IL-6 bioassay) was performed using a 
fresh aliquot, with any repeats performed on the same sample which had been re-
frozen and re-thawed. Out of interest, the IL-6 in the same plasma samples was tested 
three times by ELISA, re-freezing the sample between each test, in order to determine 
whether the freeze-thawing process made any significant difference to the stability of 
the cytokine (data not shown). No significant differences between the repeats were 
observed, and thus it was accepted that the freeze-thawing process was not detrimental 
Chapter 4 - Discussion 
167 
 
to the stability of IL-6. This is corroborated by de Jager and co-workers who found that 
IL-6 was particularly stable throughout multiple freeze-thawing cycles and during 
short-term storage (de Jager et al., 2009).  
In contrast, in this same study by de Jager and co-workers, the stability of cytokines 
IL-4, IL-17, TNFα and IFNγ were particularly affected by multiple freeze-thawing 
cycles (de Jager et al., 2009).  There was no evidence of cytokine degradation within 
the CBA results of the current study, where only very low concentrations of these 
cytokines were measured in the serum and plasma of some participants, and there were 
no significant differences between repeats using the same CBA kits.  
 
4.5.3 The B9 bioassay 
4.5.3.1 B9 sensitivity 
B9 cells are very sensitive to IL-6 (Guerne et al., 1989); however, a crucial problem 
with cell lines is that they are increasingly being shown to be able to respond to a range 
of other cytokines (Mire-Sluis et al., 1995).  Studies have demonstrated that B9 cells 
may proliferate in response to IL-4 (Helle et al., 1988), IL-11 and IL-2 (Diamant et al., 
1994). Hence IL-6-neutralising antibodies were used in this study to be able to confirm 
that the B9 cell proliferation was specifically due to IL-6 present in the samples. 
 
4.5.3.2 MTS assay vs DNA tritiated thymidine incorporation assay  
The incorporation of [
3
H] thymidine into cell DNA is a routine method used to 
measure DNA synthesis and hence cell proliferation in B9 cells (and other cell lines) in 
response to IL-6 (Guerne et al., 1989, de Benedetti et al., 1991, Rosenbaum et al., 
1992, Diamant et al., 1994). Nonetheless, a colorimetric assay based on the reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to MTS was 
used in this study due its speed and low-cost compared to the [
3
H] thymidine 
incorporation assay. According to Gieni and colleagues, the MTS assay may be a more 
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sensitive method than [
3
H] thymidine incorporation as MTS assays were capable of 
detecting ‘2-16 fold’ lower cytokine concentrations in their study (Gieni et al., 1995).  
 
4.5.4 ELISA and CBA 
4.5.4.1 Problems associated with cytokine assays 
There is large variation between the IL-6 concentrations measured in the serum and 
plasma in different studies, largely because there is no standard method for the 
measurement of cytokines in clinical material. The majority of studies which have 
quoted values for serum and plasma IL-6 have measured the cytokine by ELISA, 
which is thought to be the most commonly used and ‘best validated’ method of 
cytokine measurement (Leng et al., 2008). Multiplex cytokine assays such as 
cytometric bead array (CBA) have become a more widely used technique as they have 
the advantage of being able to detect multiple cytokines in a smaller volume of sample, 
however, according to Breen and colleagues, they may not provide sufficiently 
reproducible results when carrying out repeat testing (Breen et al., 2011). This was not 
observed here. CBA trends were highly reproducible, but actual values did vary greatly 
between the CBA kits, necessitating the use of geometric means to normalise the data. 
In contrast, the ELISA was found more likely to produce false positive results and 
inconsistent results. The reasons for this are not clear, although RF (discussed below) 
may be a factor. 
 
4.5.4.2 Endogenous plasma proteins 
Concerns have been raised about the suitability of cytokine assays for use in 
rheumatology. Endogenous plasma proteins, in particular RF, are believed to interfere 
with binding by providing competition for binding sites, giving false positive results 
(Bartels et al., 2011, Churchman et al., 2012, Bartels and Madsen, 2013). RFs are 
human autoantibodies (normally of IgM class, but can be IgA, IgD, IgE or IgG) which 
target the Fc region of IgG antibodies, and are present in 70-80% of RA patients, and 
up to 10% of healthy individuals (Mewar and Wilson, 2006). Bartels and colleagues 
suggest that RFs interfere particularly with ELISAs and multiplex assays such as CBA, 
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but can be removed by precipitating the sample prior to conducting the assay (Bartels 
et al., 2011). In a recent study, however, it was found that cytokine concentrations 
(including IL-6) in the serum samples from RA patients were not largely affected by 
the removal of RF when measured by CBA, which indicated that there was no 
interference from RF or false positivity when using CBA to measure cytokines in 
individuals with inflammatory diseases such as RA (Churchman et al., 2012). 
Cytokine measurement by Luminex bead assays, on the other hand, was particularly 
affected by interference with RF (Churchman et al., 2012), suggesting that CBA was 
the better choice of multiplex assay for the measurement of cytokines in rheumatoid 
arthritis patients in this study. Nevertheless, cytokine results from the Perry study may 
have been affected by this, as a Luminex 100® was used to measure cytokines in RA 
patient plasma (Perry, 2008).  
 
4.5.4.3 Should cytokine measurement methods be standardised? 
There is accumulating evidence which highlights a need to standardise the way 
cytokines are measured in order to be able to draw direct comparisons between and 
within studies. This issue was raised over 20 years ago at the European workshop for 
Rheumatology Research, when several European research groups conducted 
immunoassays (and bioassays) to detect a range of inflammatory cytokines in human 
synovial fluid and serum in different laboratories and compared the results (Roux-
Lombard and Steiner, 1992). Laboratories testing the same samples with the same 
ELISA kits produced similar results, but different ELISA kits produced different 
values, albeit with similar patterns (Roux-Lombard and Steiner, 1992). Another study 
showed contrasting results from different lots of ELISA kits from the same 
manufacturer- with some results differing by up to 50% (Aziz et al., 1999). Based on 
the current study, other aspects of these assays require standardising in order for direct 
comparisons between studies to be drawn, including standardisation of the use of 
serum or plasma, storage conditions, use of controls, use of terminology (i.e. quoting 
means, medians, range, SEM or standard deviation) and methods used to normalise 
data. 
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4.5.4.4 Threshold limits of CBA kit 
The CBA kit may not have been sufficiently sensitive to measure serum/plasma IL-17. 
The lowest threshold limit of detection was 18.9 pg/ml. Thus, a more sensitive 
approach to measuring this cytokine may be required in order to determine whether IL-
17 is raised in PMR and thus important to its pathogenesis. For future studies a highly 
sensitive ELISA might be more effective. The lowest threshold limit of detection for 
IL-1β was also relatively high (7.2 pg/ml), so again, this lack of sensitivity may have 
resulted in IL-1β being undetected in any of the samples, and thus differences between 
the disease groups and control group could not be observed. 
 
4.5.4.5 Serum/plasma- an indirect way of measuring cytokine production  
The advantage of looking at the cytokine profile in blood samples is that they are far 
easier to obtain than synovial fluid, or biopsies. Bartels and Madsen (2013), however, 
recently made the point that only a very substantial cytokine concentration would be 
reflected in the blood, which could be why so many cytokines were ‘undetectable’ in 
this study. Cytokines function at a local or ‘microenvironment level’ (Alvarez-
Rodriguez et al., 2010), meaning that cytokines involved in the pathogenesis of RA 
would most likely be functioning at the site of inflammation, and would therefore not 
be detectable in the circulation in any great concentrations. The cytokine profile of the 
plasma or serum therefore may not be the most accurate representation of what is 
happening in vivo.  
 
4.5.5 Flow cytometry 
4.5.5.1 Background stimulation 
One concern with measuring intracellular IL-6 in the PBMC by immunostaining and 
flow cytometry was that the cells may have been subjected to some background 
stimulation, causing the cells to produce low levels of IL-6, and thus not showing an 
accurate representation of the cell behaviour in vivo. This has been noted in another 
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study by Kashipaz and co-workers, where a low percentage of unstimulated PBMC 
were found to produce IL-6 in the absence of additional stimulation (Kashipaz et al., 
2003). IL-6 production was considerably reduced in the presence of polymyxin B 
(Kashipaz et al., 2003), indicating that bacterial endotoxin may have been present in 
the samples causing low-level background stimulation.  
There are also a number of other ways by which the PBMC may have been 
unintentionally stimulated to produce IL-6, including the invasive process involved in 
collecting the blood sample (Bartels and Madsen, 2013), a delay in sample processing 
or sample storage (Duvigneau et al., 2003), the process involved in the blood 
separation (Whiteside et al., 1994), or even just the action of gently pipetting the 
sample (Mcleod, J., personal communication, 2011). This prompts the question as to 
whether the cells were ever actually in ‘a resting state’. The cells would have been 
under constant stress during the collection, separation and staining process, so again, 
perhaps the results here may not be indicative of what is happening in vivo. Steps were 
taken to reduce background stimulation, including not culturing the PBMC in FCS, a 
process which has previously been shown to increase IL-6 mRNA expression in 
synoviocytes (Rosenbaum et al., 1992); however some potentially stimulatory actions 
(such as pipetting) could not be avoided. 
 
4.5.5.2 Do the flow cytometry results reflect the CBA data? 
The dramatic differences in the IL-6 concentrations measured in the supernatants of 
unstimulated and stimulated PBMC do not reflect the minor and variable changes seen 
in the flow cytometry data from unstimulated to stimulated cells. Reasons for this are 
considered here. 
 
Timing of IL-6 release from cells 
Firstly, the timing of IL-6 release from cells may explain why generally only small 
changes in intracellular IL-6 quantities from unstimulated to stimulated PBMC were 
observed by flow cytometry. The staining process was started after the PBMC had 
been in culture for 24 hours, with a golgi-blocker (monensin) added for the last 4 hours 
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of this period. Research suggests that some cells (leukocytes, glial cells and a 
macrophage cell line) secrete large quantities of IL-6 between 4 and 6 hours post LPS 
stimulation, which then decreases dramatically and subsequently plateaus (De Forge 
and Remick, 1991, Minogue et al., 2012). This could explain why large quantities of 
IL-6 were measured in the stimulated PBMC supernatants at 24 hours but no longer 
intracellularly.  
DeForge and Remick found that following LPS stimulation (10 µg/ml) of whole blood, 
leukocyte IL-6 mRNA induction occurred after 1 hour with levels peaking at 4 hours 
and then plateauing again at approximately 6 hours to less than 10% of the maximum 
mRNA up until 24 hours when they stopped the assay (DeForge and Remick, 1991). 
The presence of IL-6 mRNA obviously does not confirm its production or release from 
these cells, however, IL-6 concentrations were also measured in the plasma taken from 
these stimulated cultures at time points 4, 6 and 24 hours. It was found that the mean 
IL-6 concentration in the plasma increased by 1900 pg/ml from 4 to 6 hours, and by 
only 1300 pg/ml from 6 to 24 hours (DeForge and Remick, 1991). This strongly 
suggests that the majority of IL-6 was released from cells long before the 20 hour time 
point where, in the present study, monensin was added to the cells in order to block the 
golgi from releasing IL-6. Minogue and colleagues demonstrated that following LPS-
stimulation (100 ng/ml)  IL-6 mRNA expression in glial cells increased at 2 hours but 
IL-6 was released from cells at 4 hours, which they concluded after measuring IL-6 in 
the supernatants from the stimulated glial cultures (Minogue et al., 2012). They also 
suggested that the slight delay in the induction of IL-6 mRNA in glial cells is due to 
the requirement of TNFα (which is released at 1 hour post LPS stimulation) to activate 
JAK2/STAT1 signalling pathways, triggering the transcription of IL-6 mRNA 
(Minogue et al., 2012). A study by Manderson and co-workers demonstrated that in 
the macrophage RAW264.7 cell line, following stimulation with 100 ng/ml LPS and 
500 pg/ml IFNγ, IL-6 was detected in the supernatant at 4 hours post stimulation 
(approx. 900 pg/ml), and concentrations dramatically increased in the supernatant at 6 
hours post stimulation (approx.. 2500 pg/ml) (Manderson et al., 2007). Using 
fluorescence imaging techniques, at 6 hours, IL-6 was visible in the golgi complex 
where it was accumulating prior to release via recycling endosomes through the 
constitutive secretory pathway (Manderson et al., 2007).  
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Thus, there is a large body of evidence to suggest that PBMC begin synthesising IL-6 
at around 1 hour post-stimulation, and subsequently release the IL-6 from the cell at 
approximately 6 hours post stimulation (De Forge and Remick, 1991, Manderson et 
al., 2007). So, in this study, at the time the PBMC were stained (following 24 hours in 
culture with the golgi-blocker added for the final 4 hours) intracellular IL-6 
concentrations may have been as low as 10% of what they would have been after 6 
hours in culture. Thus, although large quantities of IL-6 were released by the PBMC 
into the culture supernatant in all participants, only minimal quantities were measured 
intracellularly by flow cytometry. Prior to the study, healthy control PBMCs taken 
from donors at UWE, Bristol were tested for intracellular IL-6 after 4 and 24 hours 
stimulation with LPS and IFNγ, however it was found that both were similar with 
respect to intracellular IL-6 (MFI) values and the percentage of IL-6 positive cells. 
Again, the peak time for IL-6 production and secretion is most likely to have been 
approximately 4-6 hours post stimulation, so peak timing for IL-6 production and 
accumulation within the cells may have been missed.  In future studies, if this were to 
be repeated, or IL-6 was to be measured intracellularly, then cells should be stained 
approximately 6 hours post LPS-stimulation in order to be able to measure intracellular 
IL-6 effectively.  
Nonetheless, in the present study there were no significant differences between the 
secreted concentrations of IL-6 in the PBMC culture supernatants of PMR patients, 
RA patients and healthy controls. Thus, even if the peak time for antibody staining had 
been missed, the PBMC of PMR patients were not secreting greater quantities of IL-6 
than the PBMC of RA patients or healthy controls. This demonstrates the power of 
measuring IL-6 production using different methods. 
 
Understanding IL-6 trafficking and release from cells 
Using flow cytometry, low levels of intracellular IL-6 were measured in a percentage 
of every PBMC type in every participant in the absence of stimulation. This, however, 
did not reflect the results of the CBA measurement of IL-6 in the unstimulated PBMC 
culture supernatants, where IL-6 was barely detectable (<9 pg/ml). Reasons for this are 
considered. 
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According to various studies, low levels of cytokines may be produced constitutively 
and stored within cells, meaning additional stimulation is not required to trigger 
production of the cytokine, although receptor-mediated stimulation may be required to 
trigger release of the cytokine into the extracellular environment (Stow et al., 2009, 
Lacy and Stow, 2011). It seems that flow cytometry was a sensitive enough technique 
to detect these low levels of stored IL-6 within the PBMC. In particular, it has been 
shown that neutrophils and macrophages store IL-6 within secretory granules and 
lysosome-related organelles (respectively) which they continuously release in very 
small quantities through a process known as ‘constitutive exocytosis’, which can then 
be up-regulated in response to stimulation (Stow et al., 2009, Lacy and Stow, 2011). 
According to Lacy and Stow, the advantage of storing pre-formed cytokines in 
granules inside the cell is that they can be released within minutes following receptor-
mediated cell stimulation (Lacy and Stow, 2011). If this was the case, and IL-6 was 
produced constitutively at low levels and stored within the cells, then detecting 
differences between unstimulated and stimulated IL-6 production within cell types 
using flow cytometry would have been extremely difficult- as demonstrated in the 
results of the present study.  
This question of whether intracellular staining accurately represents the secretory 
ability of cells has been raised in other studies (Alvarez-Rodriguez et al., 2010). The 
results of the present study confirm that the intracellular levels and secretory levels 
may not necessarily correspond. The processes involved in cytokine secretion appear 
to be very complex and the trafficking pathways involved and timing of release are 
dependent on the type of cell. Thus further research into the way IL-6 is trafficked and 
released from the different PBMC types would be necessary to gain a deeper 
understanding of the flow cytometry results. 
In conclusion, both the timing and mechanisms of cytokine release are crucially 
important to the measurement of intracellular IL-6. Having seen the biological 
variability between responses to stimulation, it is also clear that not every person or 
every cell will respond in the same way with regards to cytokine production and 
release, so perhaps this method is not ideal for detecting differences between IL-6 
production in PMR, RA and healthy control PBMCs. 
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4.6  Implications and future considerations 
4.6.1. Standardise methodologies and data reporting 
One of the main issues to stand out from this study is the need for many of the 
techniques to be standardised, in order to achieve some sort of consistency within the 
reporting of data. This is vital for studies measuring cytokines in order to be able to 
draw direct comparisons between and within studies. In cytokine-based assays such as 
this, future studies should carefully consider whether to use serum or plasma, as there 
are unequivocal differences between the results obtained from these two blood 
components. 
 
4.6.2 Find cytokine assay with sufficient accuracy and reproducibility 
Despite displaying similar trends, the results from different CBA kits gave very 
different values. Future studies should consider performing the assay in triplicate in 
order to gain a more accurate idea of the concentration of cytokines in a sample, if 
financially viable. Future studies should also move towards using assays which 
measure both free and bound cytokine to gain a more accurate estimation of the 
concentration of active cytokine in a sample. 
 
4.6.3 Sample collection, handling, processing and storage 
Future studies should strongly consider the optimal method to collect, separate, 
process and store blood samples when carrying out cytokine-based assays, taking into 
account which cytokines are to be analysed and their level of resilience to degradation, 
as well as the cells’ susceptibility to environmental and physical alterations. 
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4.6.4 Larger cytokine studies  
The results from three independent studies, including this one, have shown that there is 
a sub-group of RA patients (33-50%) with raised circulating concentrations of several 
cytokines (Clarke et al., 2011, Perry, 2008). Nonetheless, the sample sizes in all three 
studies were relatively small, and thus the significance of this finding is still unclear. 
A study looking at a larger panel of cytokines in a larger number of RA patients would 
confirm which cytokines are raised and what proportion of RA patients they are raised 
in. It would be useful to look at the cytokine profile of patients at all stages of the 
disease, and in those with active and non-active disease to see if any correlations or 
trends exist. Additionally, the usual clinical measures of RA should be tested (i.e. CRP 
and PV levels, presence or absence of RF), and questionnaires such as the BRAF-
MDQ performed, to see if a link exists between specific clinical symptoms and high 
levels of cytokines. Clarke and colleagues suggested that there may be a link between 
the patients with raised cytokines and the fact that they are resistant to glucocorticoid 
therapy (Clarke et al., 2011). This theory could also be tested using a much larger 
cohort of RA patients.  
 
4.6.5 Measuring intracellular cytokines by flow cytometry 
Research into the way individual cytokines are trafficked and released from different 
cell types would be highly valuable for future studies involving the measurement of 
intracellular cytokines, as well as time-course studies to detect when IL-6 is released 
from each cell type following stimulation. With this knowledge, it would be easier to 
ensure that cytokines are measured when concentrations are at their peak within the 
cell prior to release into the extracellular environment.  
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4.6.6 A relationship between IL-6 and fatigue 
The existence of a relationship between circulating IL-6 concentrations and fatigue 
seems extremely likely based on the results of the present study. Further investigations 
into the relationship between IL-6, the HPA-axis and the onset of the physical aspects 
of fatigue could be investigated in order to find a way to reduce this symptom.  
 
4.6.7 Exploring other potential sources of IL-6 in PMR 
PMR is considered an inflammatory disease purely due to increased concentrations of 
circulating IL-6. No other cytokines are raised in the circulation of PMR patients. At 
any other time you would consider inflammation to be an influx of cells and cascade of 
inflammatory cytokines at a particular site in the body, so with the original hypothesis 
disproved, there may be a specific site of inflammation that is yet to be discovered. 
This section suggests potential sources of IL-6 or inflammatory sites in PMR. 
 
Neutrophils? 
As mentioned previously, neutrophils were not isolated or tested in this study, however 
neutrophils are capable of producing large quantities of IL-6 (Kaplanski et al., 2003), 
and thus may be the source of circulating IL-6 in PMR patients. This requires further 
testing, using alternative density gradient centrifugation methods (sodium metrizoate 
and Dextran 500) to isolate the neutrophils (Oh et al., 2008, Axis-Shield, 2011), in 
order to identify whether these cells produce significantly greater quantities of IL-6 in 
PMR patients compared to RA patients and healthy controls. 
 
Vasculitis? 
Activated vascular endothelial cells are known to be capable of producing large 
quantities of IL-6 (Dasgupta and Panayi, 1990) over an extended period of time, in 
response to LPS stimulation (Loppnow et al., 1989). Thus, in future studies it may be 
beneficial to look at the vascular endothelium as a potential source of the elevated 
circulating IL-6 in PMR patients. This could be observed by taking biopsies of blood 
vessels from PMR patients and healthy controls and directly testing endothelial cells 
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for IL-6 production. Alternatively, as this procedure is highly invasive, there may be 
other less direct ways of finding out whether the endothelium might be involved prior 
to taking biopsies.  
Various biomarkers in the bloodstream may indicate that endothelial cells are 
activated, and hence more likely to be the source of elevated IL-6 in PMR. Soluble 
inter cellular adhesion molecule-1 (sICAM-1) is constitutively expressed on 
endothelial cells, but is upregulated by proinflammatory cytokines and is thought to 
have a direct contribution to inflammatory responses in the blood vessel wall (Lawson 
and Wolf, 2009). This soluble ICAM-1 is shed from the membrane during 
inflammation as a result of proteolysis (Newby, 2005). According to a study by 
Macchioni and colleagues, not only were levels of sICAM-1 significantly increased in 
the serum of patients with PMR vs healthy controls (measured by ELISA), these levels 
also corresponded to the level of disease activity in both PMR and GCA, based on 
complete clinical and laboratory investigations carried out before and after treatment 
(Macchioni et al., 1994).  
It has also been suggested that vascular endothelial growth factor (VEGF) causes 
endothelial cells to secrete IL-6 (Dankbar et al., 2000). Meliconi and co-workers 
postulate that this may occur as a result of a positive feedback loop, with mononuclear 
cells producing VEGF, which induces the release of IL-6 from endothelial cells, 
bringing about an inflammatory immune response (Meliconi et al., 2000). In PMR 
patients, serum concentrations of VEGF are significantly elevated compared to normal 
controls (Meliconi et al., 2000). If VEGF does induce IL-6 secretion from endothelial 
cells, then the endothelium could potentially be a major source of IL-6 in PMR. In RA, 
increased VEGF expression (as a result of elevated levels of IL-6/sIL-6R) has been 
found to stimulate pannus (fibrovascular tissue) development (Ballara et al., 2001). 
Thus it would be interesting to observe if there was a correlation between specific 
disease symptoms, IL-6 and VEGF concentrations in the blood of both PMR and RA 
patients. 
 
Aortitis?  
Although apparently uncommon in PMR, limited evidence suggests that PMR is 
associated with subclinical aortitis (Ashraf et al., 2013), i.e. inflammation of the aortic 
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wall (Gornik and Creager, 2008). GCA and Takayasu arteritis are the most common 
causes of aortitis but it is also associated with other rheumatic diseases such as RA, 
where rheumatoid nodules form in the aortic wall (Gornik and Creager, 2008). 
Previously, if PMR patients were found to have signs of vasculitis then the diagnosis 
would change to GCA (Weyand and Goronzy, 2003). A number of more recent 
reports, however, have suggested that aortitis may actually be a rare symptom of PMR.  
Narváez and colleagues discuss MRI as a useful, non-invasive technique for 
diagnosing aortitis in GCA and PMR patients (Narváez et al., 2005). Nevertheless, the 
GCA and PMR patients in their study presented with very similar symptoms so it 
seems highly likely that all the patients actually had co-existing GCA- where vasculitis 
is one of the key features. Katoake and colleagues also reported two incidences where 
supposed PMR patients had aortitis without stenosis (narrowing of the blood vessels) 
and no evidence of GCA, leading them to believe that aortitis might be a feature of 
PMR (Katoake et al., 2008). Again, the diagnoses are uncertain, and based on their 
description of patient symptoms it seems possible that these PMR patients had co-
existing GCA. Milchert and Brzosho agree that aortitis is ‘difficult to classify’ in 
patients with symptoms of PMR (Milchert and Brzosko, 2008). 
Furthermore, a case of ‘life-threatening PMR’ with aortitis in the absence of GCA 
symptoms has recently been reported (Ashraf et al., 2013). The patient did not respond 
to GC treatment, (a sign that perhaps this patient did not have PMR) however anti-IL-6 
monoclonal antibody therapy (tocilizumab) and aortic reconstruction was apparently 
successful, thus suggesting a link between PMR, vasculitis and IL-6. Again, the 
diagnosis of the patient is questionable, and it is likely that although not exhibiting all 
the symptoms of large vessel vasculitides, there may have been another underlying 
cause. 
Thus, there is weak evidence for the existence of aortic inflammation in PMR, 
suggesting that the aorta may be the source of raised IL-6 in PMR. The diagnoses of 
PMR in nearly all cases, however, are unconvincing. Moreover, this vasculitis/aortitis 
is apparent in only a small sub-group of PMR patients, yet all PMR patients exhibit 
high circulating concentrations of IL-6, making it unlikely that an inflammatory site 
within the aorta is the source of elevated concentrations of IL-6. To test this theory, 
non-invasive methods of testing for aortitis, such as MRI, could be adopted for a large 
sample of PMR patients, in order to see the exact prevalence of this symptom within a 
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PMR population and whether it could be the source of increased concentrations of IL-
6. 
 
Synovitis? 
There is also weak evidence to suggest that a synovitis component exists in PMR 
(Meliconi et al., 1996, Frediani et al., 2002) despite the lack of localised inflammation 
or swelling. Other studies have suggested that muscular tissue may be the source of 
elevated IL-6 in PMR (Kreiner et al., 2010), or the bursae (Salvarani et al., 1997) or 
even ligament attachment sites (Kotani et al., 2011) (refer to Section 1.12). Thus, 
future studies could consider that a tissue component may exist, and may require more 
invasive techniques, such as muscle biopsies of affected and unaffected sites within the 
same patient (internal controls) to further investigate this theory. 
 
4.7 Conclusions 
4.7.1 Circulating IL-6 in the plasma and serum is raised in the circulation of PMR 
and RA patients compared to healthy age and gender-matched controls (P<0.05) 
IL-6 appears to play a direct role in the pathogenesis of PMR and RA and may be a 
useful bio-marker for these diseases as it is consistently and significantly elevated in 
the blood of these patients above healthy controls. If a cheap, quick and reproducible 
test to measure this cytokine could be developed, this may give a more direct reflection 
on the patients’ disease state than measuring secondary disease events such as CRP or 
PV levels, which are used currently for diagnosis. 
 
4.7.2 Serum and plasma IL-6 concentrations correlated very well, but IL-6 
concentrations are higher in serum than in plasma 
Plasma and serum IL-6 concentrations correlated very well with a high correlation 
coefficient of 0.961 (P< 0.0001). There was, however, a clear bias towards the serum 
measurements, particularly at the higher concentrations of IL-6. This indicates that 
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there are significant differences between cytokine concentrations in the plasma and 
serum, thus deciding which blood component to test should be considered carefully. 
Sample collection, processing, handling and storage prior to analysis may be of upmost 
importance in reducing degradation of cytokines, although IL-6 is relatively stable. 
Further testing is required to determine the optimal conditions for cytokine analysis in 
blood samples. 
 
4.7.3 Raised circulating IL-6 in PMR and RA patients is biologically active 
For the first time IL-6 in the plasma of PMR (and RA patients) caused IL-6-dependent 
B9 cells to proliferate, which was largely neutralised in the presence of a neutralising 
IL-6 antibody. Deemed ‘biologically active’, this raised IL-6 is therefore highly likely 
to be involved in PMR and RA pathogenesis.  
 
4.7.4 Fatigue, and in particular the somatic aspects of fatigue (living fatigue and 
physical fatigue) strongly correlate with circulating concentrations of IL-6 
For the first time, using the BRAF-MDQ, plasma IL-6 levels in both PMR and RA 
patients have been shown to strongly correlate with fatigue (r= 0.487). Two individual 
aspects of fatigue namely ‘physical fatigue’ and ‘living fatigue’ in particular correlated 
very well with IL-6 concentrations in the plasma (r= 0.479 and r= 0.499 respectively), 
whereas ‘cognitive fatigue’ and ‘emotional fatigue’ did not (r= 0.067 and r= 0.311 
respectively). This indicates that there is a relationship between circulating 
concentrations of IL-6 and the physical aspects of fatigue. Thus, reducing circulating 
IL-6 concentrations could have a direct effect on a patient’s physical well-being and 
ability to cope with day-to-day life. Cognitive and emotional fatigue may not have a 
physiological trigger, but may occur as a consequence of the physical aspects.  
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4.7.5 The circulating lymphocytes and antigen-presenting cells are not the source 
of elevated plasma/serum IL-6 in PMR patients 
CD3+ T cells, CD14+ monocytes, CD19+ B cells, CD123+ pDCs and CD11c+ mDCs 
in all subjects constitutively produced low to modest levels of intracellular IL-6. This 
corresponded with very low concentrations of secreted IL-6 in parallel cultures (<9 
pg/ml), but there were no significant differences in secreted IL-6 concentrations in 
unstimulated cells from PMR, RA and HC samples. 
 
Stimulation of PBMC induced strong intracellular responses in all cell types of some 
samples. Overall, however, responses were highly variable and no significant 
difference in cell responsiveness was observed between PMR, RA and healthy control 
samples. In contrast, secreted IL-6 increased dramatically in all participants following 
stimulation (>1000 pg/ml) suggesting that intracellular staining may not reflect the 
secretory capability of these cells, but also confirming no differences between PBMC 
responses of PMR, RA and control groups. 
 
Taken together, using different methods to test the hypothesis, the PBMCs tested were 
not found to be the source of elevated concentrations of IL-6 in PMR, suggesting that 
the neutrophils, vascular endothelium, joints, muscular tissue or aorta could be 
potential sources. 
 
4.7.6 There may be a subset of RA patients with raised circulating concentrations 
of several cytokines  
Looking more broadly at the cytokine profiles in the serum and plasma of the 
participants, a subgroup of RA patients were found to have raised levels of several 
cytokines including IL-4, TNFα, IL-10, IL-12p70 and IL-2. This was not observed in 
PMR patients or healthy controls. This could be an indicator that different disease 
pathologies exist within RA, that are not present in PMR. As all RA patients exhibit 
similar symptoms, this could indicate that cytokines are raised in some patients as a 
consequence of a more immunologically aggressive form of the disease. 
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4.7.7 PMR is associated with raised circulating IL-6 only 
IL-6 is responsible for the symptoms observed in PMR and thus is a major part of the 
pathogenesis of the disease. No other cytokines measured were raised in the circulation 
of PMR patients and thus no other cytokines appear to be involved with the 
pathogenesis of the disease. This indicates that PMR and RA are very different in 
terms of disease pathology, despite sharing similar symptoms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 - Discussion 
184 
 
4.8 Overall summary & conclusions 
This study has confirmed that IL-6 concentrations in the serum and plasma are 
significantly raised in PMR and RA patients compared to healthy controls, whilst 
demonstrating that IL-6 concentrations were consistently higher in serum than in 
plasma. This IL-6 was found to be biologically active, thus capable of contributing to 
the pathogenesis of both these diseases. A significant correlation was observed 
between the total fatigue score and circulating IL-6 concentrations in the plasma of 
PMR and RA patients, with two individual aspects of fatigue; physical fatigue and 
living fatigue, correlating very well with plasma IL-6 concentrations.  
Furthermore, using a variety of methods to test the hypothesis, this study has ruled out 
the PBMCs as a potential source of IL-6 in PMR, increasing the likelihood that either 
the vascular endothelium or muscle tissue may be involved. Looking more broadly at 
the circulating cytokine profiles of PMR and RA patients, IL-6 was the only cytokine 
to be significantly raised in the circulation of PMR patients compared to healthy 
controls. A small sub-group of RA patients, however, had raised circulating 
concentrations of IL-4, TNFα, IL-10, IL-12p70 and IL-2, which may indicate that 
different disease pathologies exist within RA, that are not present in PMR. 
Methodologies involved in cytokine analysis and the reporting of this analysis requires 
standardisation, in order for researchers to be able to draw direct comparisons between 
studies, enabling research to move forward more quickly and efficiently. 
Future investigations should consider the clinical implications for raised IL-6, look 
deeper into the relationship between IL-6 and fatigue onset, carry out a larger more 
comprehensive study of the circulating cytokines in RA, establish a more standardised 
approach to cytokine analysis, and crucially, continue exploring the cellular source of 
IL-6 in polymyalgia rheumatica. 
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Appendix A: Questionnaires and case report forms (CRF) used for 
the recruitment of patients and controls 
 
Screening for recruitment of controls 
Date of Birth: ..................................... 
Gender: Male  Female 
Inclusion Criteria 
Is the patient above 55 but below 85 years old? Yes  □ No □ 
Is there any inflammatory rheumatological illness? Yes  □ No □ 
Is CRP < 5? Yes  □ No □ 
Is PV < 1.75? Yes  □ No □ 
 
Exclusion Criteria 
On glucocorticoids (oral or parenteral) or biologic treatment 
in the last month? 
Yes  □ No □ 
Inflammatory diseases such as inflammatory bowel disease, 
colitis, asthma? 
Yes  □ No □ 
Giant cell arteritis? Yes  □ No □ 
Other auto-immune diseases? Yes  □ No □ 
Cancer? Yes  □ No □ 
Infections, treatment with antibiotics within the past 6 weeks? Yes  □ No □ 
Significant renal disease (creatinine >150 μmol/L and/or 
eGFR < 30 ml/min)? 
Yes  □ No □ 
Significant hepatic impairment? Yes  □ No □ 
Participation in a clinical trial within the past 30 days? Yes  □ No □ 
Pregnancy and lactation?                                                         
NA     □ 
Yes  □ No □ 
Working shift employee? Yes  □ No □ 
Jet lag? Yes  □ No □ 
 
CRP =.............................  
PV=...............................  
Participant (control) consented on.............................  
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Screening for the recruitment of PMR patients 
Date of Birth: ..................................... 
Gender: Male  Female 
Inclusion Criteria 
Is the patient above 55 but below 85 years old? Yes  □ No □ 
Does the patient meet 3 or more of Bird criteria? Yes  □ No □ 
Bird Criteria: 
Bilateral shoulder pain/stiffness Yes  □ No □ 
Duration of symptoms <2 weeks Yes  □ No □ 
Initial ESR >40 mm/h (PV>1.72, CRP>5) Yes  □ No □ 
Stiffness >1 hour Yes  □ No □ 
Age >65 years    Yes  □ No □ 
Depression and/or weight loss    Yes  □ No □ 
Bilateral upper arm tenderness   Yes  □ No □ 
Number of Bird criteria met: ...........................
.. 
Currently active disease (CRP≥5, PV≥1.72 or ESR≥29)? Yes  □ No □ 
 
Exclusion Criteria 
On glucocorticoids (oral or parenteral) or biologic treatment in 
the last month? 
Yes  □ No □ 
Inflammatory diseases such as inflammatory bowel disease, 
colitis, asthma? 
Yes  □ No □ 
Giant cell arteritis? Yes  □ No □ 
Other auto-immune diseases? Yes  □ No □ 
Cancer? Yes  □ No □ 
Infections, treatment with antibiotics within the past 6 weeks? Yes  □ No □ 
Significant renal disease (creatinine >150 μmol/L and/or eGFR < 
30 ml/min)? 
Yes  □ No □ 
Significant hepatic impairment? Yes  □ No □ 
Participation in a clinical trial within the past 30 days? Yes  □ No □ 
Pregnancy and lactation?                                            NA     □ Yes  □ No □ 
Working shift employee? Yes  □ No □ 
Jet lag? Yes  □ No □ 
PMR diagnosis made on............................. 
Patient consented on.............................. 
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Screening for the recruitment of RA patients 
Date of Birth: ..................................... 
Gender: Male  Female 
Inclusion Criteria 
Is the patient above 55 but below 85 years old? Yes  □ No □ 
Does the patient meet 4 or more of the ACR criteria? Yes  □ No □ 
 
ACR Criteria: 
Morning stiffness (≥1 hour) Yes  □ No □ 
Swelling (soft tissue) of three or more joints Yes  □ No □ 
Swelling (soft tissue) of hand joints (PIP, MCP, or wrist) Yes  □ No □ 
Symmetrical swelling (soft tissue) Yes  □ No □ 
Subcutaneous nodules Yes  □ No □ 
Serum rheumatoid factor Yes  □ No □ 
Erosions and/or periarticular osteopenia in hand or wrist joints seen 
on radiograph 
Yes  □ No □ 
Number of ACR criteria met: ..........................
... 
Currently active disease (CRP≥5, PV≥1.72 or ESR≥29)? Yes  □ No □ 
Are there at least 3 tender AND swollen joints? Yes  □ No □ 
Is morning stiffness ≥ 45 minutes? Yes  □ No □ 
 
Exclusion Criteria 
On glucocorticoids (oral or parenteral) or biologic treatment in 
the last month? 
Yes  □ No □ 
Inflammatory diseases such as inflammatory bowel disease, 
colitis, asthma? 
Yes  □ No □ 
Co-existent giant cell arteritis? Yes  □ No □ 
Other auto-immune diseases? Yes  □ No □ 
Cancer? Yes  □ No □ 
Infections, treatment with antibiotics within the past 6 weeks? Yes  □ No □ 
Significant renal disease (creatinine >150 μmol/L and/or eGFR 
< 30 ml/min)? 
Yes  □ No □ 
Significant hepatic impairment? Yes  □ No □ 
Participation in a clinical trial within the past 30 days? Yes  □ No □ 
Pregnancy and lactation?                                                NA     □ Yes  □ No □ 
Working shift employee? Yes  □ No □ 
Jet lag? Yes  □ No □ 
 
Patient consented on............................. 
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Clinical Summary sheet 
 
Past Medical History 
..........................................................................................................................................
..........................................................................................................................................
..........................................................................................................................................
..........................................................................................................................................
..........................................................................................................................................
..........................................................................................................................................
........................................................................................................................ 
Allergies 
...........................................................................................................................................
...........................................................................................................................................
...................................... 
Social History 
...........................................................................................................................................
...........................................................................................................................................
...................................... 
Clinical Examination 
BP.................... Temp.................... Body Weight.................... 
Sats.................... Pulse.................... 
...........................................................................................................................................
...........................................................................................................................................
...........................................................................................................................................
...........................................................................................................................................
...........................................................................................................................................
...........................................................................................................................................
.................................................................................................................. 
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Bristol Rheumatoid Arthritis Fatigue- Multi Dimensional Questionnaire (BRAF- 
MDQ) 
 
We would like to know how fatigue has affected you in the 
past 7 days. 
Please answer all of the questions. Don’t think too long and 
hard, just give your first reaction – there are no right or 
wrong answers! 
 
1 Please circle the number that shows your average level of fatigue 
during the past 7 days. 
 
No Fatigue      0     1     2     3     4     5     6     7    8     9     10      Totally 
Exhausted    
*********** 
For each of the following questions, please tick one answer that best 
applies to you 
2 How many days did you experience fatigue during the past week (7 
days)?  
0 □ 4 □ 
1 □ 5 □ 
2 □ 6 □ 
3 □ Every day □ 
 
3 How long, on average, has each episode of fatigue lasted during the 
last 7 days? 
Less than one hour □ 
Several hours □ 
All day □ 
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 Health Assessment Questionnaire (HAQ) 
Please tick the one response which best describes your usual abilities over the past week. 
  PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE ACTIVITIES: 
Cane (W)                                      Walking frame (W)                 Built up or special utensils (E) 
Crutches (W)                                Wheelchair (W)                       Special or built up chair (A) 
Devices used for dressing (button hooks, zipper pull, shoe horn) 
Other (specify)………………………………………………………. 
PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM ANOTHER PERSON: 
Dressing and Grooming    Eating  
Rising      Walking 
 
1. DRESSING AND GROOMING 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE 
to do 
 
Are you able to:  
 
      a.  Dress yourself, including tying 
shoelaces     
            and doing buttons? 
 
      b. Shampoo your hair? 
 
2.RISING 
 
 
      ……… 
 
 
      ……… 
 
 
 
      ……… 
 
 
      ……… 
 
 
 
      ……… 
 
 
      ……… 
 
 
 
 
      ……… 
 
 
      ……… 
 
 
Are you able to: 
 
a. Stand up form an armless straight 
chair? 
 
b. Get in and out of bed? 
 
3.EATING 
 
 
      ……… 
 
      ……… 
 
 
 
      ……… 
 
      ……… 
 
 
 
      ……… 
 
      ……… 
 
 
 
      ……… 
 
      ……… 
 
 
Are you able to: 
 
a. Cut your meat? 
 
b. Lift a full cup or glass to your 
mouth? 
 
c. Open a new carton of milk (or 
soap powder)? 
 
4.WALKING 
 
 
      ……… 
 
      ……… 
 
 
      ……… 
 
 
 
      ……… 
 
      ……… 
 
 
      ……… 
 
   
 
      ……… 
 
      ……… 
 
 
      ……… 
 
    
 
      ……… 
 
      ……… 
 
 
      ……… 
 
 
 
 
 
 
Are you able to: 
 
a. Walk outdoors on the flat ground? 
 
b. Climb up five steps? 
   
  
      ……… 
 
      ……… 
 
     
 
      ……… 
 
      ……… 
 
        
 
      ……… 
 
      ……… 
 
     
 
      ……… 
 
      ……… 
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5. HYGEINE 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE 
to do 
 
Are you able to: 
 
       a.    Wash and dry your entire body? 
 
       b.    Take a bath 
 
       c.    Get on and off the toilet? 
 
6.REACH 
   
 
      ……… 
 
      ……… 
 
      ……… 
 
    
 
       ……… 
 
      ……… 
 
      ……… 
 
 
 
      ……… 
 
      ……… 
 
      ……… 
 
 
 
      ……… 
 
      ……… 
 
      ……… 
 
 
Are you able to? 
 
       a.    Reach and get down a 5 lb object 
(e.g. bag of potatoes) from just above your 
head? 
         
       b. Bend down to pick up clothing off 
the floor?  
 
7.GRIP 
 
 
      ……… 
 
 
      ……… 
 
 
 
      ……… 
 
 
      ……… 
 
 
 
      ……… 
 
 
      ……… 
 
 
 
      ……… 
 
 
      ……… 
 
 
Are you able to: 
 
        a.   Open car doors? 
 
        b.   Open jars which have been 
previously opened? 
 
        c.    Turn taps on and off? 
 
8.ACTIVITIES 
 
 
      ……… 
 
      ……… 
 
     
      ……… 
 
 
 
      ……… 
 
      ……… 
 
     
      ……… 
 
 
 
      ……… 
 
      ……… 
 
     
      ……… 
 
 
 
      ……… 
 
      ……… 
 
     
      ……… 
 
 
Are you able to: 
 
a. Run errands and shop? 
 
b. Get in and out of a car? 
 
c. Do chores such as vacuuming, 
housework or light gardening? 
 
 
      ……… 
 
      ……… 
 
     
      ……… 
 
 
      ……… 
 
      ……… 
 
     
      ……… 
 
 
      ……… 
 
      ……… 
 
     
      ……… 
 
 
      ……… 
 
      ……… 
 
     
      ……… 
 
 
      PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE ACTIVITIES: 
Raised toilet seat (H)                                Bath seat (H)                                 Bath rail (H) 
Long handles appliances for reach (R)                                   Jar opener (for jars previously opened) (G) 
Other (specify)……………………………………………………………………….. 
PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM ANOTHER PERSON: 
Hygiene       Gripping and opening things   
Reach Errands and housework   
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Rheumatoid Arthritis Disease Activity Score (DAS) 
 
  
 
No of swollen joints: .......... 
 
No of tender joints: .......... 
 
CRP =..........  
 
Patient’s global health:  
Considering all the ways your arthritis affects you, please mark 
on the line how well you think you are doing: 
 
Very well 
 
 
 
Very 
badly 
 
 
DAS-28 =.......... 
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Additional notes on blood sampling 
 
Whole Blood sample taken at: ............................................. 
Amount withdrawn: ............................................................. 
Further notes on blood sampling: 
..............................................................................................  
..............................................................................................   
..............................................................................................   
..............................................................................................   
 Notes on individual samples: 
 Small sample (4ml plasma) Large sample (35ml) 
Actual amount    
Sample Code   
Haemolysis   
Outcome   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  -: no haemolysis 
   ±: very minimal 
   +: minimal 
   ++: moderate 
   +++: severe 
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Score sheet for answers generated from questionnaires 
 
BRAF-MDQ 
Physical total (0-22), Q 1-4  
Living total (0-21), Q 5-11  
Cognition total (0-15), Q 12-16  
Emotion total (0-12), Q 17-20  
Total score (0-70)  
 
HAQ 
Score  
Conversion  
 
HAD 
Anxiety  
Depression  
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Appendix B: Patient information sheet and consent form 
   
  
 
  
   
   
 
 
   
 
 
Academic Rheumatology Unit 
The Courtyard 
Bristol Royal Infirmary 
Bristol BS2 8HW 
 
 
 
 
The cellular source of Interleukin-6 in Polymyalgia Rheumatica 
 
Patient Information Sheet 
(Version 1.3 Date 25 March 2012) 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends and relatives if you wish. Ask us if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish to 
take part. 
 
What is the purpose of the study?   
 
Polymyalgia rheumatica causes pain and stiffness around shoulder and hip joints.  We 
think that these symptoms are related to various “chemical messengers” (also called 
cytokines). We are particularly interested in studying one of these cytokines which is 
called interleukin-6 or for short, IL-6. We already have some limited information 
about its role in polymyalgia rheumatica but we would like to know more and find out 
its source. In other words, we would like to know what cells are responsible for 
secreting it.  
 
We have also found out from our previous work in rheumatoid arthritis that IL-6 
levels are elevated in this disease. Rheumatoid arthritis is a disease that causes pain, 
swelling and stiffness of joints across the body. In both polymyalgia rheumatica and 
rheumatoid arthritis, patients wake up in the morning with profound stiffness. 
However in polymyalgia rheumatica, IL-6 levels are higher than those detected in 
rheumatoid arthritis.   
 
We aim towards recruiting 6-10 patients with polymyalgia rheumatica, 6-10 with 
rheumatoid arthritis and 6-10 controls who do not have any disease that causes 
inflammation. By doing so, we will be able to compare between the three groups and 
add more power to our study. 
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The information we are going to get from you and other participants will greatly help 
us set up a bigger study in the future. 
 
Why have I been chosen? 
 
You have been chosen to take part in this study because you fall into one of the 
following groups: 
 
1) You have recently been diagnosed with polymyalgia rheumatica  
2) You have recently been diagnosed with rheumatoid arthritis  
3) You belong to the control group* 
 
*The control group gives us a comparison for these other inflammatory conditions.  
 
What will I be asked to do if I take part?   
 
One or two days after reading this leaflet, the research doctor will telephone you to 
know about your decision. If you have agreed to take part, we will be sending you a 
taxi to bring you to our Rheumatology Centre where we first saw you and talked to 
you about the study. 
 
The doctor will ask you to read and sign a consent form. You will get a copy of the 
signed consent form to take with you as well.  The doctor will then perform clinical 
assessment on you and ask you to complete a few questionnaires. Next, one blood 
sample will be taken from you through a needle prick. We would like to take 35mls of 
blood. This amount of blood equates to 3-4 tablespoons approximately. 
 
After giving blood, you will be free to go home through our transport. Please feel free 
to help yourself with any coffee or tea whilst in the department. The taxi will pick you 
up back home at your convenience. We estimate the total duration of your stay in the 
department for the study will be around one hour. 
 
Blood taken from you will be processed immediately and then transported in a special 
container without any personal identifiers to the University of the West of England 
where further analysis will take place. Your confidentiality will be highly respected 
and secured throughout the study. After performing the required tests on your 
sample, all blood materials left will be destroyed. 
 
You will be later invited to attend a short meeting with the other patients in the 
study.  You do not have to attend this meeting.  If you do come it will give you the 
chance to tell us about any ideas that you have, so we can improve future studies. We 
welcome your suggestions to help us to improve how we look after patients involved 
in research at any time.  
 
 
Do I have to take part?   
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No, taking part is voluntary.  It is up to you to decide whether or not to take part.  If 
you decide to take part, you are still free to withdraw at any time.  If you decide not 
to take part, you do not have to give a reason, nobody will be upset and the standard 
of care you receive will not be affected in any way. 
 
 
What are the possible risks of taking part?   
 
There are hardly any real risks from taking part in this study. However, and as you 
may be aware of, this study involves taking one blood sample from you. This means 
that you may experience some pain at the site of needle prick. A bruise may also 
appear on this site later. This bruise does not last for long and normally fades away 
within a few days. 
 
What are the possible benefits of taking part?   
 
You will not be paid for taking part.  The information that we get from this study may 
help us understand polymyalgia rheumatica better and therefore, improve the way 
this disease is managed in the future.  
 
Is my doctor being paid for including me in the study?   
 
No.  
 
Are there any restrictions on what I might eat or do?   
 
No. 
 
What if something goes wrong?   
 
Considering how our study is conducted, we believe that this is very unlikely to 
happen. However, if anything goes wrong for any reason, our research team will stay 
with you and try to help and sort out any problem. 
 
After you have gone home, if you still have a question, you can always contact the 
research doctor at work on 0117 342 2515 or 0117 342 2902. During out of hours, the 
doctor will be happy to take your call on his own mobile phone which is 0753 320 
4380. In the unlikely event of an emergency, you will need to go through the normal 
route by contacting the Accident and Emergency Department. 
 
If you have concerns about any aspect of the way you have been approached during 
the course of this study you may wish to contact the hospital’s Patient Advice and 
Liaison Service (PALS) on 0117 928 3571, Mincom number 0117 934 9261, or write to 
PALS, Bristol Royal Infirmary, Main BRI Front Entrance, Queens Building, Bristol, BS2 
8HW. If you wish to make a formal complaint please write to Dr, Chief Executive U.H. 
Bristol Headquarters, Marlborough Street, Bristol, BS1 3NU or telephone Patient 
Complaints Manager on 0117 928 3604. 
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Confidentiality - who will know I am taking part in the study?   
 
All information we collect about you during the course of the research will be kept 
strictly confidential.  Any information about you that leaves the hospital (including 
any samples sent to the University of West of England) will be made anonymous so 
that it cannot be used to identify you.  Your medical records may be looked at by 
people from the hospital’s Research Office or the regulatory authorities to check that 
the study is being carried out correctly.  Your name, however, will not be disclosed 
outside the hospital.  
 
Do I need to inform my GP about my participation in the study? 
 
As our study does not involve any new treatments or changes to your medical plans, 
there is no need to inform your GP. However if you would like to discuss it with your 
GP, then feel free to do so. 
 
Who has reviewed the study? 
 
This research study has been reviewed and approved by the Ethics Committee. 
 
 
Contact Information: 
 
University of Bristol University of the West of England 
Professor John Kirwan 
Consultant Rheumatologist and Professor 
of Rheumatic Diseases 
0117 342 2904  
Miss Hannah Bazzard 
PhD Student 
0117 328 3812 
Dr Vanessa Quick and Dr Matt Roy 
Clinical Research Fellows 
 
Dr Victoria Davenport 
Academic Supervisor 
0117 928 2178 
 
 
A copy of this Patient Information Sheet and the signed Informed Consent Form will be 
provided to the patient to keep. 
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Academic Rheumatology Unit 
The Courtyard 
Bristol Royal Infirmary 
Bristol BS2 8HW 
 
 
CONSENT FORM 
 
 
Title of project: The cellular source of Interleukin-6 in Polymyalgia 
Rheumatica 
 
Name of Researchers:  Professor John Kirwan, Consultant 
Rheumatologist                    
                                              and Professor of Rheumatic Diseases 
                                              Dr Vanessa Quick, Clinical Research Fellow 
                                              Dr Matt Roy, Clinical Research Fellow 
Miss Hannah Bazzard, PhD student 
Dr Victoria Davenport, Academic Supervisor 
 
 
Please initial box 
 
1. I confirm that I have read and understand the information sheet 
dated 25 March 2012 (version 1.3) for the above study and have 
had the opportunity to ask questions. 
 
 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time; without giving any reason, without my 
medical care or legal rights being affected. 
 
 
3. I understand that my medical notes will be looked at by 
responsible individuals from regulatory authorities where it is 
relevant to my taking part in research.  I give permission for these 
individuals to have access to my records. 
 
 
4. I understand that the samples may be transferred to another place 
for the research to be performed, and that any samples that leave 
the hospital will be coded so that it is not possible to use them to 
identify me. 
 
 
Appendices 
229 
 
5. I understand that my samples will be destroyed after performing 
the required analyses on them. 
 
 
6. I understand that the University of Bristol and the University of the 
West of England will have ownership of the research results and 
may file patents or otherwise protect and commercialise research 
results.  I understand that there will be no financial benefit or 
direct personal benefit to me, either as a result of 
commercialisation of the research results or in respect of the 
original samples donated. 
 
 
 
7. I agree to take part in the above study. 
                                                                                   
 
 
 
 
After you have initialled all the above boxes, please complete below by printing your 
name, today’s date and your signature. 
 
 
 
 
________________________ ________________
 ____________________ 
Name of Patient Date Signature 
 
 
 
 
_________________________ ________________
 ____________________ 
Name of Person taking consent Date Signature 
(If different from researcher) 
 
 
 
_________________________ ________________
 ____________________ 
Researcher Date Signature 
 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes  
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Appendix C: Raw data 
 
Patient demographics 
 
 
Fatigue scores 
 
 
ELISA data 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Gender F F F F M F M F F F M F M F M F F F F F
Age (years) 75 72 63 55 62 72 73 79 59 65 68 60 71 60 73 60 88 76 65 75
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
C-Reactive Protein (mg/L) 11 15 2 4 5 29 11 15 1 1 11 2 1 7 38 2 25 28 102 19
RA DAS-28 (score) 5.86 5.65 4.79 5.51 6.64 4.84
PMR-AS (score) 23.2 34.2 43.2 57 72.9 69.8 132.1
Disability (HAQ) 0.375 1.5 0.25 2 0 1.63 2.13 1.75 0 0.875 1.25 0 0 2.125 1.143 0 1.75 2 1.75 1.25
Participant number
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
Fatigue- Physical subscale 13 16 9 16 0 17 16 18 5 9 19 1 2 18 21 12 18 16 17 15
Fatigue- Living subscale 3 10 2 17 0 12 10 10 0 7 4 0 0 9 15 0 10 16 13 10
Fatigue- Cognition subscale 0 5 6 12 0 4 3 2 2 9 0 0 0 4 3 0 0 5 0 6
Fatigue- Emotion subscale 0 4 1 10 0 3 10 6 0 8 0 0 0 2 5 0 5 4 7 6
Fatigue (BRAF-MDQ) (total) 16 35 18 55 0 36 39 36 7 33 23 1 2 33 44 12 33 41 37 37
Participant number
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
Mean plasma IL-6 (pg/ml) 10.9 18.6 11.6 6.2 * 28.3 * * * * * 10.4 * * * * 19.6 8.3 11.1 8.4
Mean serum IL-6 (pg/ml) * 14.5 11.7 * * 24.2 * 5.1 * * 6.0 21.5 * 7.6 5.7 * 28.8 * 26.2 6.4
Participant number
Appendix 
231 
 
 
B9 bioassay data 
 
 
CBA cytokine data 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
Bioactive IL-6 in sample (pg/ml) * 7.6 * * * 72.4 111.9 * * * 16.0 * * 11.2 * * 27.9 * 19.2
Plasma
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
IL-12p70 (pg/ml) * * * * * * 5.2 * * * * * * 8.3 * * * * * *
TNFα (pg/ml) * * * * * * 17.7 * * * * * * 14.5 * * * * * *
IL-10 (pg/ml) * * * * * * 5.7 * * * * * * 6.8 * * * * * *
IL-6 (pg/ml) 3.3 20.1 * * * 41.2 27.1 8.7 * * 4.5 * * 15.7 4.8 * 24.2 19.4 9.3 13.8
IL-1β (pg/ml) * * * * * * * * * * * * * 7.3 * * * * * *
IL-8 (pg/ml) 5.8 5.7 6.0 9.9 3.9 6.6 32.0 6.7 4.6 * 6.3 5.0 6.3 6.5 15.8 7.1 11.3 4.8 6.2 11.2
IL-17A (pg/ml) * * * * * * * * * * * * * * * * * * * *
IFNγ (pg/ml) * * * * * * * * * * * * * * * * * * * *
IL-4 (pg/ml) * * * * * * 13.1 * * * * * * 10.2 * * * * * *
IL-2 (pg/ml) * * * * * * 16.3 * * * 3.0 * * 11.5 * * * * * *
Participant number
Serum
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
IL-12p70 (pg/ml) * * * * * * 7.3 * * * * * * 7.1 * * * * * *
TNFα (pg/ml) * * * * * * 82.4 * * * 8.5 * * 34.1 * * * * * *
IL-10 (pg/ml) * * * * * * 22.5 * * * * * * 15.0 * * * * * *
IL-6 (pg/ml) 4.7 35.2 * * * 56.5 37.1 11.4 * * 8.1 * * 34.3 8.1 * 33.9 * 9.9 15.8
IL-1β (pg/ml) * * * * * * * * * * * * * 6.9 * * * * * *
IL-8 (pg/ml) 14.3 10.1 8.5 11.5 7.9 18.9 35.9 6.9 4.0 * 11.3 6.4 9.0 10.7 18.2 23.4 14.6 5.6 14.3 11.0
IL-17A (pg/ml) * * * * * * * * * * * * * * * * * * * *
IFNγ (pg/ml) * * * * * * * * * * * * * * * * * * * *
IL-4 (pg/ml) * * * 12.5 * * 163.5 * * 21.1 9.2 * * 69.9 * * * * * *
IL-2 (pg/ml) * * * 13.3 * * 237.1 * * 9.8 21.9 * * 63.4 * * * * * *
Participant number
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Unstimulated PBMC 
culture supernatant
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
IL-12p70 (pg/ml) * * * * * * * * * * * * * * * * * * * *
TNFα (pg/ml) * * 9.7 11.4 * * 6.1 * * * * 5.6 26.1 9.8 19.2 * * * * *
IL-10 (pg/ml) * * * * * * * * * * * * * * * * * * * *
IL-6 (pg/ml) 8.5 * * 2.8 * * * * * * * * * * * * * * * *
IL-1β (pg/ml) 181.7 * * 14.2 * * * * * * * 13.3 * * 13.7 * * * * *
IL-8 (pg/ml) 4577.7 1652.3 2274.0 6534.1 723.1 2269.0 1789.1 2405.7 515.3 229.2 410.8 1546.6 555.4 987.0 2456.1 1733.1 713.3 1196.8 622.5 709.4
IL-17A (pg/ml) * * * * * * * * * 21.5 * * * * * * * *
IFNγ (pg/ml) * * * * * * * * * * * * * * * * * *
IL-4 (pg/ml) * * * * * * * * * * * * * * * * * *
IL-2 (pg/ml) * * * * * * * * * * * * * * * * * *
Participant number
Stimulated PBMC 
culture supernatant
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
IL-12p70 (pg/ml) * * * * 1.7 * 2.1 * * * * 1.6 * * * 3.3 * * * *
TNFα (pg/ml) 60.4 67.8 41.3 479.7 11.7 46.1 73.7 94.6 22.0 65.1 45.7 71.2 180.6 46.6 43.6 108.9 43.9 29.5 22.1 25.0
IL-10 (pg/ml) * * * 32.6 5.1 8.4 * * * * * * * 22.1 * 9.7 * * * *
IL-6 (pg/ml) 2553.9 2404.8 3614.8 18126.5 3585.9 13007.7 6026.8 6029.6 2162.3 3059.6 2194.0 1019.1 6904.4 6081.9 7705.1 7136.7 7451.5 4100.5 6863.0 3656.9
IL-1β (pg/ml) 1272.5 1247.4 465.2 4802.9 192.1 2646.9 892.7 1298.5 434.4 908.4 1099.1 1394.4 2313.1 1191.7 1638.8 2628.7 1864.9 892.1 1102.8 961.1
IL-8 (pg/ml) 104414.3 72779.4 45149.4 124817.6 49911.9 90457.8 70304.4 106215.9 68036.1 92296.9 59735.3 39190.2 115095.9 87766.7 111671.2 117809.5 104100.1 97253.1 126529.3 86827.4
IL-17A (pg/ml) * * * 85.7 57.5 104.9 * * * * * * * * * * * * * *
IFNγ (pg/ml) 41.8 83.3 968.8 1533.5 849.4 632.3 1851.7 121.5 56.7 47.2 97.9 34.8 47.5 211.3 87.2 80.2 17.3 38.0 205.8 122.8
IL-4 (pg/ml) * * * 5.3 * * * * * * * * * * * * * * * *
IL-2 (pg/ml) * * * 4.8 * 2.6 * * * * * * * * * * * * * *
Participant number
Appendix 
233 
 
 
Flow cytometry data 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
% IL-6 positive cells
Unstimulated or 
Stimulated
Cell type/ 
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
%IL-6 pos Unstimulated T cells 94 28 30 23 75 96 22 4 15 10 27 72 70 7 41 18 51 22 81
%IL-6 pos Unstimulated Monocytes 97 93 99 98 93 99 77 76 88 90 95 95 99 93 98 98 98 94 100
%IL-6 pos Unstimulated B cells 93 40 100 52 85 94 18 16 51 26 94 72 95 63 100 34 66 26 100
%IL-6 pos Unstimulated pDC 89 97 100 98 93 67 67 63 88 87 93 97 97 81 99 94 99 90 99
%IL-6 pos Unstimulated mDC 95 76 89 91 88 61 39 41 61 77 74 79 86 73 94 90 93 95 97
%IL-6 pos Stimulated T cells 24 5 70 99 51 90 4 5 40 10 67 16 76 82 49 97 83 14 68
%IL-6 pos Stimulated Monocytes 99 94 100 100 94 99 70 85 93 99 90 72 100 96 98 98 96 92 92
%IL-6 pos Stimulated B cells 63 34 93 100 87 94 13 33 52 47 51 35 100 68 98 93 81 27 100
%IL-6 pos Stimulated pDC 86 98 100 99 92 99 64 80 91 98 94 89 100 92 100 90 97 88 100
%IL-6 pos Stimulated mDC 89 69 68 100 93 96 35 50 73 93 62 70 100 84 96 95 85 90 98
Participant number
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pilot
Mean fluorescence 
intensity (MFI)
Unstimulated or 
Stimulated
Cell type/ 
Diagnosis PMR PMR Control RA Control RA RA PMR Control Control RA Control Control RA PMR Control PMR PMR PMR RA
MFI Unstimulated T cells 5617 3383 5954 3477 5270 13840 2791 2450 5030 10945 44568 5894 9962 5068 9100 4202 4478 15648 17020
MFI Unstimulated Monocytes 9672 13252 19455 8567 15505 23186 4611 5268 72397 8498 151313 29346 13443 16199 22680 11785 10684 10150 40494
MFI Unstimulated B cells 8663 4979 33998 4514 9668 56067 2391 2926 36305 4443 114817 41420 13685 38000 48339 6570 12707 69814 66495
MFI Unstimulated pDC 5783 15732 27079 8369 15604 5420 3887 4858 17896 27085 43990 13341 9290 27724 26712 8549 12033 18613 52462
MFI Unstimulated mDC 9426 5482 14049 6703 12041 4703 3033 3772 18795 26096 13231 10058 14621 34560 20724 7516 10072 39443 62428
MFI Stimulated T cells 2730 2382 8543 45359 3884 10924 1983 2537 3879 5971 35264 5772 10191 5268 10536 14302 9418 5225 20373
MFI Stimulated Monocytes 13816 7889 25128 93187 15905 41788 4808 18842 7859 15621 288804 9375 63203 23491 37355 38918 20636 20508 42814
MFI Stimulated B cells 8654 27751 24954 231699 9421 26590 2454 4187 8024 59651 128455 8975 123171 39128 66129 24780 22831 14369 89423
MFI Stimulated pDC 6398 11951 18946 87081 22486 38883 4967 6420 9102 40474 123918 79458 44000 22347 50581 11628 18091 15106 84431
MFI Stimulated mDC 6818 6653 10879 137693 12234 26420 3370 4948 14965 17126 124793 57746 44759 28758 41194 33958 13533 17525 59612
Participant number
